Subject Index

A

ABDOMEN
isolated perfused rat
tolbutamide-stimulated somatostatin release from, 119–121
rat aortas
prostacyclin production, insulin and, 454–458
from streptozotocin diabetic rats, ^{35}S-glycosaminoglycan and ^{35}S-glycopeptide metabolism in, 418–424

ABORTIONS
prostaglandin-induced
and cryopreservation of human fetal pancreas, 238–240
as source of fetal pancreas tissue, 24‡

ACARBOSE
-inhibition of α-glycosidase in diabetic mice
effects on diabetic nephropathy, 249–253

ACETALDEHYDE
and hemoglobin
in alcoholics, 15–20†

ACETONE
metabolism
in diabetic ketoacidosis, 242–248

ACETYLSALICYLIC ACID. *See* Aspirin

ACID
acetylsalicylic
and inhibition of nonenzymatic glycosylation of serum and plasma proteins, 55†
aminoisobuturic
uptake by cultured rat hepatocytes, in insulin binding and action studies, 145–148
aminophenylboronic, affinity chromatography with and glycosylated hemoglobin measurement, 701–705
arachidonic
and prostacyclin production in diabetic nephropathy, 75–76*
glycohydrolases
in diabetic chinese hamsters, 18*
hexuronic
analyses of diabetic basement membranes, 735–740

ACID-ETHANOL EXTRACTION
of IM-9 lymphocytes
evidence against insulin synthesis by, 182–184

ACTINOMYCIN D
and measurement of time course of glucose induction of proinsulin mRNA in starved rats, 627, 628

ADDUCT FORMATION
and formaldehyde and glyceraldehyde reactions with proteins, 15–16†
glucose and galactose lysine
and cataract formation in rats, 59–60†
and reactions of biologic aldehydes with proteins
in alcoholics, 15–20†

ADIPOCYTES
in fatty Zucker rat, 25*
isolated
role of glucose transport in postreceptor defect of non-insulin-dependent diabetes, 1016–1021
isolated rat
biologic activity and labeling properties of photoreactive insulin derivatives in, 1068–1075
in obese mice, 3*, 24*
rat
insulin resistance in, 589–591

ADIPOSE TISSUE. *See also* Adipocytes
insulin-like activity
and inhibitor in diabetic rat serum, 98, 99–103
insulin receptors in
aging and, 210
lipogenesis
in obese mice, 3*

ADRENAL GLANDS
dehydroepiandrosterone
therapeutic effects in diabetic mice, 830–833

α-ADRENERGIC BLOCKING AGENTS
and inhibition of insulin release by diazoxide and epinephrine, 779

ADRENERGIC STIMULATION
and electrical activity of mouse perifused islets, 985–989

α-ADRENERGIC SYSTEM
stimulation and blockage
and evaluation of parasympathetic nervous system in diabetic and non-diabetic subjects, 341–344
and evaluation of sympathetic nervous system in diabetics and normal subjects, 341–344

β-ADRENORECEPTORS
and acute glucose counterregulation following insulin-induced hypoglycemia in insulin-dependent diabetes, 641–646
and serum potassium during insulin-induced hypoglycemia, 616–617

AGE
and cause of death in UGDP study, 42–43§, 46–47§, 50–51§
and diabetes detection in BB rats, 7*
of diabetes diagnosis
and cytoplasmic islet cell antibodies, 586
and risk to siblings, 138–143, 1115–1117
and diabetes-obesity syndrome in mice, 5*
of diabetics in comparative study of continuous subcutaneous insulin infusion vs. multiple insulin injections, 256

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

* This index covers all reading matter in Volume 31 of DIABETES except the abstracts of papers presented at the 42nd Annual Meeting of the American Diabetes Association. The following symbols are used to indicate material that appeared in the Supplements: *Supplement 1, Proceedings of a Task Force on Animals Appropriate for Studying Diabetes Mellitus and its Complications; †Supplement 3, Proceedings of a Conference on Nonenzymatic Glycosylation and Browning Reactions: Their Relevance to Diabetes Mellitus; ‡Supplement 4, Proceedings of a Workshop on Preventing the Rejection of Transplanted Pancreas or Islets; §Supplement 5, The University Group Diabetes Program. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VII. Evaluation of Insulin Therapy: Final Report.

Subject Index

A

ABDOMEN
isolated perfused rat
tolbutamide-stimulated somatostatin release from, 119–121
rat aortas
prostacyclin production, insulin and, 454–458
from streptozotocin diabetic rats, ^{35}S-glycosaminoglycan and ^{35}S-glycopeptide metabolism in, 418–424

ABORTIONS
prostaglandin-induced
and cryopreservation of human fetal pancreas, 238–240
as source of fetal pancreas tissue, 24‡

ACARBOSE
-inhibition of α-glycosidase in diabetic mice
effects on diabetic nephropathy, 249–253

ACETALDEHYDE
and hemoglobin
in alcoholics, 15–20†

ACETONE
metabolism
in diabetic ketoacidosis, 242–248

ACETYLSALICYLIC ACID. *See* Aspirin

ACID
acetylsalicylic
and inhibition of nonenzymatic glycosylation of serum and plasma proteins, 55†
aminoisobuturic
uptake by cultured rat hepatocytes, in insulin binding and action studies, 145–148
aminophenylboronic, affinity chromatography with and glycosylated hemoglobin measurement, 701–705
arachidonic
and prostacyclin production in diabetic nephropathy, 75–76*
glycohydrolases
in diabetic chinese hamsters, 18*
hexuronic
analyses of diabetic basement membranes, 735–740

ACID-ETHANOL EXTRACTION
of IM-9 lymphocytes
evidence against insulin synthesis by, 182–184

ACTINOMYCIN D
and measurement of time course of glucose induction of proinsulin mRNA in starved rats, 627, 628

ADDUCT FORMATION
and formaldehyde and glyceraldehyde reactions with proteins, 15–16†
glucose and galactose lysine
and cataract formation in rats, 59–60†
and reactions of biologic aldehydes with proteins
in alcoholics, 15–20†

ADIPOCYTES
in fatty Zucker rat, 25*
isolated
role of glucose transport in postreceptor defect of non-insulin-dependent diabetes, 1016–1021
isolated rat
biologic activity and labeling properties of photoreactive insulin derivatives in, 1068–1075
in obese mice, 3*, 24*
rat
insulin resistance in, 589–591

ADIPOSE TISSUE. *See also* Adipocytes
insulin-like activity
and inhibitor in diabetic rat serum, 98, 99–103
insulin receptors in
aging and, 210
lipogenesis
in obese mice, 3*

ADRENAL GLANDS
dehydroepiandrosterone
therapeutic effects in diabetic mice, 830–833

α-ADRENERGIC BLOCKING AGENTS
and inhibition of insulin release by diazoxide and epinephrine, 779

ADRENERGIC STIMULATION
and electrical activity of mouse perifused islets, 985–989

α-ADRENERGIC SYSTEM
stimulation and blockage
and evaluation of parasympathetic nervous system in diabetic and non-diabetic subjects, 341–344
and evaluation of sympathetic nervous system in diabetics and normal subjects, 341–344

β-ADRENORECEPTORS
and acute glucose counterregulation following insulin-induced hypoglycemia in insulin-dependent diabetes, 641–646
and serum potassium during insulin-induced hypoglycemia, 616–617

AGE
and cause of death in UGDP study, 42–43§, 46–47§, 50–51§
and diabetes detection in BB rats, 7*
of diabetes diagnosis
and cytoplasmic islet cell antibodies, 586
and risk to siblings, 138–143, 1115–1117
and diabetes-obesity syndrome in mice, 5*
of diabetics in comparative study of continuous subcutaneous insulin infusion vs. multiple insulin injections, 256

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

* This index covers all reading matter in Volume 31 of DIABETES except the abstracts of papers presented at the 42nd Annual Meeting of the American Diabetes Association. The following symbols are used to indicate material that appeared in the Supplements: *Supplement 1, Proceedings of a Task Force on Animals Appropriate for Studying Diabetes Mellitus and its Complications; †Supplement 3, Proceedings of a Conference on Nonenzymatic Glycosylation and Browning Reactions: Their Relevance to Diabetes Mellitus; ‡Supplement 4, Proceedings of a Workshop on Preventing the Rejection of Transplanted Pancreas or Islets; §Supplement 5, The University Group Diabetes Program. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VII. Evaluation of Insulin Therapy: Final Report.

of diabetics with microangiopathy in immune complexes study, 8, 9
and glucose production and metabolism, 203–210
and implantation of peritonial access device in diabetics, 471
and insulin clearance in man, 851–854
and insulin removal rate from plasma in rat and man, 670–673
and mortality in UGDP study, 12§
of non-insulin-dependent diabetics in high density lipoprotein composition study, 127, 128
in pancreas endocrine cell content study in nondiabetics and diabetics, 695, 696, 697
of pancreatogenic and type I diabetics in insulin metabolism study, 348
of patients in chlorpropamide therapy in insulin-dependent diabetics study, 891
of Pima Indian and Caucasian subjects in insulin-resistance study, 953
and retinopathy in juvenile-onset type I diabetes of short duration, 874–882
and streptozotocin effects in animals, 47–48*
of surviving patients in UGDP study, and baseline characteristics, 54–71§
and viral sensitivity of beta cells, 47*

AGING SYNDROME
and glucosylation of human collagen in diabetics and nondiabetics, 47–51†
and Maillard reaction, 27†
and nonenzymatic glycosylation and browning
and cataract formation, 57–62†

AGGLUTINATION TEST
urinary
for detection of potentially reversible diabetic albuminuria, 973–975

ALANINE NITROGEN
branched-chain amino acids as major source of, 86–89

ALBUMIN
urinary
agglutination test for low concentrations in diabetics, 973–975

^{125}I-ALBUMIN
microaggregates
reticuloendothelial system phagocytosis of, in streptozotocin-diabetic rats, 110–117

ALBUMINURIA
detection by agglutination test for urinary albumin at low concentration, 973–975
and diabetes duration, 72–73*

ALCOHOLISM
as etiology of pancreatogenic diabetes and insulin metabolism, 348
lesions common to
compared with lesions in diabetics, 17†
and reactions of biologic aldehydes with proteins, 15–20†

ALDEHYDES
biologic
reactions with proteins in alcoholics, 15–20†
and nonenzymatic glycosylation of proteins, 1–2†

ALDOSE REDUCTASE
inhibition in diabetic rats
and motor nerve conduction velocity, 789–793

ALLERGY
to insulin
and HLA alloantigens in diabetics, 719–720
to protein
and Maillard reaction, 26†

ALLOGRAFT REJECTION. *See also* Rejection phenomena
and passenger cells, 23‡
and pretreatment of islet cells, 11–13‡, 15–16‡
susceptibility of, 36–37‡
theory of, 30–32‡

ALLOXAN
metabolic events after administration in animal models, 47*
in neonatal lambs
and myocardial function, 61*

ALLOXAN DIABETES
and diabetic neuropathy in animal models, 67–68*
in dogs, 26–27*
and comparison of peripheral and portal venous insulin administration on postprandial metabolic responses, 579–583
and prolonged hypoglycemic effect of subcutaneous administration of insulin in liposomes, 506–510
and sodium 2 chlorpropionate administration, 484–488
in mice
and reversal of hyperglycemia by intrasplenic transplantation of cultured allogeneic mouse islets, 55–59‡
in nonhuman primates, 40*, 60*
in rabbits
and cardiomyopathy, 61*
and macrovascular disease research, 58*
in rats
and cardiomyopathy, 60–61*
and extensor muscle contractile and electrical characteristics in vitro, 194–201
and macrovascular disease research, 57*
in squirrel monkeys
and atherosclerosis, 59*

AMADORI COMPOUNDS
and addition of amine to sugar carbonyl group, 2†
formation during Maillard reaction, 22–23†
assays for, 58†
fructosyl-L-tryptophan
mutagenicity of, 44–45†
physiologic effects, 26†
and reaction of Schiff base to hemoglobin A_{1c}, 52†

AMERICAN DIABETES ASSOCIATION
Annual Meetings and Scientific Sessions
Forty-second, **4**, vi; 742
audio cassettes of Scientific Sessions and Postgraduate courses, **7**, viii
Council on Epidemiology and Statistics, 282
Feasibility Grant Program, 94, 937–938

ADA
Future Meetings, **6**, xii, 840
Legislative Positions, 838–839
Lilly Award nominations, 838, 937
New Members, **2**, vi; **4**, vi; **7**, viii; 94, 282, 478, 571, 742, 838, 937
News of Affiliate Associations, 94
Organization Section, **2**, vi; **4**, vi; **7**, viii; 94, 282, 478, 571–572, 742, 838–839, 937–938, 1033–1034
Research and Development Award, 838, 937
Reviewers of Manuscripts, 95–96

AMES METHOD
and mutagenicity tests in Maillard browned fed animals, 43–45†

AMINES
addition to sugar carbonyl group
and Amadori-type rearrangement, 2†

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

AMINO ACIDS
absorption in rat gut
effects of glucose-amino acid browning products, 24†
analysis
of acetaldehyde hemoglobin adduct, 18–19†
branched chain
as source of alanine nitrogen in man, 86–89
branched chain, in alloxan-diabetic dogs
portal and peripheral venous insulin infusions and, 581
incorporation into glomeruli of diabetic animal models, 77*
loss of
and protein-sugar Maillard reaction, 25†
reaction of formaldehyde and glyceraldehyde with, 15–16†

p-AMINOBENZAMIDINE
and insulin action, 976–983
reductive alkylation of and assays for chemically and nutritionally available lysin, 10–11†

AMINOISOBUTYRIC ACID
uptake in cultured rat hepatocytes
and insulin-induced alterations in insulin binding and action, 145–148

^{14}C-AMINOISOBUTURIC ACID
and insulin-induced alterations in insulin binding and action
in primary cultures of rat hepatocytes, 145–148

ε-AMINO-LYSINE
-bound glucose
in tissues from diabetics, 1123-1126

AMINOPHENYLBORONIC ACID
affinity chromatography with
and glycosylated hemoglobin measurement, 701–705

AMPUTATION
in UGDP peripheral vascular follow-up examinations, 19§

AMYLASE
in diet supplementation after pancreatectomy in dogs, 27*

AMYLOID
islet
and spontaneous diabetes in nonhuman primates, 38*

ANDROGENS
and potentiation of streptozotocin diabetes in mice, 724–729

ANGINA PECTORIS
history of
and cause of death in UGDP study, 12§, 42–43§, 46–47§, 50–51§
in surviving patients in UGDP study, 54–56§, 60–62§, 66–68§

ANGIOTENSIN II
retinal vascular reactivity to in diabetics and nondiabetics,
with and without retinopathy, 1056–1060
vascular reactivity to
and diabetic nephropathy in animal models, 75*

ANIMAL MODELS. *See also* under specific animals, *i.e.*, Mouse; Nonhuman primates; Rats
Animal Resource Table, 43–44*
availability problems, 52*
and cardiovascular disease complications research, 54–62*
and cardiomyopathy, 60–61*
and diabetic control research, 62*
and microangiopathy of heart and arterial adventitia, 61–62*
recommendations, 62*
charge to Task Force, viii*
contributions to diabetes research, *v**
and diabetes etiology, 45–52*
recommendations for, 51–52*
and size of animal, 45–46*
and diabetic neuropathy, 66–70*
chemically induced and nutritionally induced models, 67–69*
genetic models, 66–67*
recommendations on, 69–70*
of diabetic nephropathy
and antibody to glomerular basement membranes, 77–78*
and antibody to tubular basement membrane, 78*
physiological studies of, 74–76*
recommendations, 78*
and diabetic pregnancy, 90–94*
and chronic hyperinsulinemia in primate fetus, 92–93*
and fetal lung development, 90–91*
and fetal malformations, 91–92*
recommendations, 93–94*
of insulin-dependent diabetes pathogenesis
and chemical agents, 47–48*
and genetics, 46*
and viruses, 46–47*
of macrovascular disease, 55–60*
of nondiabetic ocular complications, 85–86*
of ocular complications in diabetes, 83–87*
and cataracts, 83–84*
and corneal epithelium, 83*
recommendations, 86–87*
of spontaneously occurring diabetes, nonobese, 48–50*
obese, 50–51*
Task Force Participants, vi–vii*

ANIMAL RESOURCE TABLE, 43–44*

ANION EXCHANGE
glucose-induced electrical activity in islet B cells and, 653–655

ANTIBODIES
anti-DR
and localization of HLA-DR antibodies in human islets of Langerhans, 17–22‡
anti-insulin
and immunodetection of insulin in tissue extracts, 648–651
anti-insulin, anti-glucagon, anti-somatostatin, and anti-pancreatic polypeptide
and quantitation of endocrine cell content in pancreas of nondiabetics and diabetics, 694–699
cytoplasmic islet cell, and HLA antigens
and carbohydrate tolerance in families of children with insulin-dependent diabetes, 292–297
to glomerular basement membranes
in diabetic animal models, 77–78*
and HLA-DR antigens in human fetal pancreas tissue, 23–27‡, 29‡
to human albumin
and detection of potentially reversible diabetic albuminuria, 973–975
to insulin
and insulin resistance in diabetics, 798–799
islet cell
in insulin-dependent diabetics and first-degree relatives, 585–588
islet cell labeling with
in avidin binding studies in pancreas, 107–109
islet cell surface
preferential lysis of pancreas B-cells by, 459–462
islet cell surface and lymphocyte
in spontaneously diabetic rats, 278–280
monoclonal, recognizing T-cell antigens and DR-antigens in human fetal pancreas tissue, 26‡
mouse anti-rat Ia nonpolymorphic monoclonal
rat islets incubated with, and prolongation of allograft survival 48–54‡
testicular
in families of children with insulin-dependent diabetes, 294–295

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

thyroglobulin
in families of children with insulin-dependent diabetes, 294–295
tissue insulin receptor
in New Zealand obese (NZO) mouse, 24–25*

ANTIGENS. *See also* H-2 complex antigens; HLA antigens
and allogeneic reactivity theory, 30–32‡
and allograft rejection, 38‡
in cultured fetal mouse and human pancreas islets, 45‡
factor VIII-releated
in diabetic children without vascular disease, 1006–1008
HLA
distribution among Nigerian diabetics, 1119–1122
and immune response to insulin, 716–722
in insulin-dependent diabetics and first-degree relatives, 585–588
HLA-A, -B, and -DR
in maturity-onset insulin-using diabetics, 122–125
HLA-DR
in human fetal pancreas tissue, 23–27‡, 29
immunocytochemical localization in human islets of Langerhans, 17–22‡
in Japanese juvenile-onset diabetics and nondiabetics, 105–106
and influence of removal of passenger cells from skin and parathyroid allografts, 60–61‡
major histocompatibility complex
and allogeneic reactivity, 30–32‡
and organ culture, 32‡
and rat islet tissue cultures, 48–54‡
and stimulation of immune system
and susceptibility of established allografts to rejection, 36‡
viral
in islets of diabetic mice, 46*

ANTILYMPHOCYTE GLOBULIN
and cyclosporin A immunosuppression in kidney transplantation patients, 98–99‡
and reversal of insulitis in streptozotocin diabetic mice, 83‡

AORTAS
rat abdominal
^{35}S-glycosaminoglycan and ^{35}S-glycopeptide metabolism in, 418–420
rat abdominal
prostacyclin production, insulin and, 454–458

APOLIPOPROTEIN B
kinetics, and very-low-density lipoprotein triglyceride kinetics
in non-insulin-dependent diabetics, 217–224

^{14}C-ARACHIDONIC ACID
production of prostacyclin from
and diabetic nephropathy in animal models, 75–76*

ARGININE
acute insulin and glucagon responses in non-insulin-dependent diabetics
plasma glucose modulation of, 489–494
immunoreactive insulin response to
in HLA-identical nondiabetic siblings of insulin-dependent diabetics, 149–153
infusion, glucagon response to
in spontaneously diabetic dogs, 28*
insulin responses to
in non-insulin-dependent diabetics, 155, 156–157

ARGININE INFUSION TESTS
in pancreatogenic and type I diabetes, 349, 352, 353

ARTERIES
adventitia
microangiopathy in animal models, 41–42*
calcification
and cause of death in UGDP study, 42–43§, 46–47§, 50–51§
and mortality in UGDP study, 12§
in UGDP peripheral vascular follow-up examinations, 19§
in surviving patients in UGDP study, 54–56§, 60–62§, 66–68§
stenosis
and diabetic nephropathy, 72*

ARTIFICIAL PANCREAS
and restoration of glucose homeostasis in insulin-dependent diabetics, 46–52

ASPARAGINASE
E. coli
effects of reductive alkylation on biologic properties, 3†

ASPIRIN
and inhibition of nonenzymatic glycosylation of serum and plasma proteins, 55†

ATHEROSCLEROSIS
and abnormal composition of high-density lipoproteins in non-insulin-dependent diabetics, 126–131
animal models of, 55–60*
nonhuman primates, 38*, 58–60*
rabbits, 58*
swine, 58*
of coronary arteries
in diabetics, 60*
development
in alloxan diabetic nonhuman primates, 40*
and diabetes
and kinetics of very-low-density lipoprotein triglyceride and apolipoprotein-B, 217–224
in diabetics and nondiabetics, 54*
and nonenzymatic glucosylation of low-density lipoproteins, 283, 290
and prostacyclin, 454
and sterol synthesis in diabetic rats, 388–395

AUTOANTIBODIES
in Bio/Breeding/Worcester rat, 816–819
gastric parietal cell
in BB rats, 313–317
as marker for gastric and hematologic abnormalities associated with diabetes, 1051–1054

AUTOIMMUNE DISEASE
and diabetes in BB/W rat
autoantibody studies in, 816–819
and diabetes and gastric parietal cell autoantibodies in rats, 313–317
in families of children with insulin-dependent diabetes, 294–295
in spontaneously diabetic New Zealand obese mouse, 24–25*, 51*

AUTOIMMUNITY
gastric parietal cell
as marker for gastric and hematologic abnormalities associated with insulin-dependent diabetes, 1051–1054
and insulin-dependent diabetes, 45*
and microvascular disease in insulin-dependent diabetics, 70–73
in nonobese diabetic mouse, 24*
and spontaneous diabetes in BB rats, 9–12*

AUTOPSIES
in UGDP study, 42–43§, 46–47§, 50–55§

AUTORADIOGRAPHY
of fetal pancreatic B-cells, 755, 757
of rat fetal liver
insulin and, 61, 63–64

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

AVIDIN
fluoresceinated-
selective binding to A-cells of sectioned human and rat pancreas, 107–109

AZATHIOPRINE
and cyclosporin A
and heart allografts in rats, 95‡
and pancreas allografts in rats, 96‡
and immunosuppression, 93‡

B

BACTERIA
and antimicrobial function of avidin, 107
intercellular killing by granulocytes of diabetic and nondiabetic children, 1041–1043
sterilization by insulin, 36–38

BASEMENT MEMBRANES
glomerular
antibodies to, in diabetic animal models, 77–78*
in diabetic animal models, 76–77*
thickening, nutritional studies, 72*
thickening, proteinuria and, 73*
kidney
effect of diabetes on glycosaminoglycan component of, 735–740
synthesis in rat lens
glucose stimulation in vitro of, 1084–1086
thickening
and alterations in basement membrane proteoglycan of EHS tumors in normal and genetically diabetic mice, 185–188

BENZAMIDINE
and insulin action, 976–983

BIGUANIDES
in spontaneously diabetic Chinese hamsters, 17*

BILE ACIDS
metabolism in diabetes, 906–907, 908–909
secretion
in obese Zucker rat, 56*

BISULFITES
and Maillard reaction in foods, 32–33†

BLACKS. *See also* Nigerians
U.S. and African
evidence for genetic admixture as determinant in occurrence of insulin-dependent diabetes in, 532–536

BLADDER
dysfunction
in diabetic Chinese hamsters, 55*

BLINDNESS
and diabetic retinopathy, 82–83*

BLOOD
acetaldehyde
in alcoholics, and modification of hemoglobin, 15–20†
allogeneic elements, 2
cells, from insulin-dependent diabetics
insulin receptor binding and insulin action in, 706–714
cholesterol and low density lipoprotein
and dietary cholesterol in alloxan diabetic nonhuman primates, 40*
cholesterol and triglycerides
and continuous subcutaneous insulin vs. multiple insulin injections in diabetics, 258, 260
ertyhrocyte spectrin
glucosylation in diabetics, 64–68†
factor VIII activity and factor VIII-related antigen
in diabetic children without vascular disease, 1006–1008
glucagon levels, albumin/globulin ratio, cholesterol, free fatty acids, glycosylated hemoglobin, alkaline phosphatase, and branched-chain amino acids
and induced diabetes in dogs, 26*
hepatosplanchinic flow
and exercise in diabetics with autonomic neuropathy, 731–732
hypercoagulability
as cardiovascular disease risk factor, 54*
lactate levels
and sodium dichloroacetate in dogs, 328
lactate and pyruvate
and chronic administration of sodium 2 chlorpropionate in alloxan diabetic and normal dogs, 485–487
peripheral lymphocytes
trapping in pancreases of acute-onset insulin-dependent diabetics, 463–465
platelet aggregation
and prostacyclin, 454
platelet thromboxane A_2 synthesis
in streptozotocin diabetic rats, dietary vitamin E and, 947–950
red cells
deformability in diabetics, 62*
red cells in humans and animals
glycosylated hemoglobin in, 743–747
samples
from alloxan diabetic rats,195
in first- and second-stage insulin secretion and action of glucagon on glucose turnover in dogs, 964–971
and hemoglobin A_{1c} studies in monkeys, 1105
triglycerides, cholesterol, and phospholipids
after pancreatectomy in nonhuman primates, 40*

BLOOD GLUCOSE
control
with continuous subcutaneous insulin and multiple injections of insulin, 255–263
control in UGDP study
and cause of death, 44–45§, 48–49§, 52–53§
definitions, 7§
and genetic susceptibility to development of retinopathy by insulin-dependent diabetics, 226–230
mortality by, 14§
and physical training of diabetics, 1044–1049
of surviving patients, 57–59§, 63–65§, 69–71§
and vascular disease in non-insulin-dependent maturity-onset diabetics, 3§, 7–8§
and diabetes diagnostic criteria in UGDP study, 4–6§
fasting
and mortality in UGDP study, 12§
in spontaneously diabetic inbred Chinese hamsters, 15*
and human vs. porcine regular insulins in subcutaneous replacement therapy, 600–602
and hypoglycemic episodes in UGDP final report, 9–10§
levels in UGDP, 8–9§, 22§
means and standard errors of, 34§, 36§
prevention of nephropathy by 2-tetradecylglycidate in diabetic mice, 12, 14, 15
and sulfonylureas in insulin-dependent diabetes, 890–895

BLOOD PRESSURE. *See also* Hypertension
during exercise
and diabetics with autonomic neuropathy, 731
in UGDP study
and cause of death, 42–43§, 46–47§, 50–51§
diastolic, mean values and standard errors at baseline and follow-up examinations, 38§
in follow-up examination, 17§
of surviving patients, 54–56§, 60–62§, 66–68§

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

systolic, means and standard errors at baseline and follow-up examinations, 37§

BLOOD SUGAR
fasting
of diabetics with microangiopathy in immune complexes study, 7

BODY
height and weight
of diabetics in comparative study of continuous subcutaneous insulin infusion vs. multiple insulin injections, 256
postural changes
and autonomic diabetic neuropathy, 733–735
weight, *see* Weight

BONE MARROW CELLS
infusion in rats
and survival of islet cell allografts across major histocompatibility barriers, 63–67‡
neonatal inoculation in rats
and islet cell transplantation effects on immune insulitis, 84–88‡, 90–91‡
and total lymphoid irradiation transplantation and, 75–77‡

BONES
congenital malformations in offspring of diabetic rats
and maternal insulin therapy, 1–6

BRAIN
capillary basement membrane thickening
in spontaneously diabetic Chinese hamsters, 20*

BREATH
acetone concentrations
in diabetic ketoacidosis, 244, 245, 246, 247

BROWNING REACTION. *See* Maillard nonenzymatic browning reaction

C

CALCIUM
in culture mediums for islet cells, 57–58‡
and cyclic AMP interactions in pancreatic islets
mathematical modeling of, 170–176
-dependent ionophore A23187
and basal and insulin-stimulated sugar transport by rat soleus muscle, 846–849
influx into pancreatic B-cell in rat islets
gliclazide-induced, 1010–1015
and insulin regulation of sugar transport in pancreatic acini from streptozotocin-diabetic mice, 676
and myosin phosphorylation by pancreas islets, 566–569
and phenytoin-induced insulin release in isolated rat islets, 265–269
and regulation of 1,25-dihydroxy-vitamin D formation
in streptozotocin-diabetic rats, 401–405
uptake by islet cells
diazoxide and D600 and, 779
uptake by mouse islets of Langerhans, 985–989

CALCIUM CARBONATE
in diet supplementation after pancreatectomy in dogs, 27*

CALMODULIN
and myosin phosphorylation by pancreas islets, 566–569

CALORIES
intake
in spontaneously diabetic Chinese hamsters, 19*
regulation
and insulin therapy in diabetic dogs, 28*
restriction
in spontaneously diabetic Chinese hamster, 49*

CALORIMETRY, INDIRECT
in insulin-dependent diabetics with conventional therapy and artificial B-cells,46–52

CANCER
hospitalizations and mortality in UGDP follow-up examinations, 20§
life table of, 76§
and patient baseline characteristics, 42–51§
phenformin treatment group, 29§
tolbutamide treatment group, 30§

CAPILLARIES
basement membrane thickening
in brain of spontaneously diabetic Chinese hamsters, 20*
in hearts of diabetics, 61–62*
and induced diabetes in dogs, 26*
and retina of animal models, 85*
in Yucatan miniature swine, 31*, 32*
blood glucose measurement
and patient self-care, 256, 257, 258

CARBOHYDRATE INTOLERANCE
spontaneous
in nonhuman primates, 41*

CARBOHYDRATE METABOLISM
impaired
in nonhuman primates, 40*
and spontaneous diabetes in obese mice, 50*

CARBOHYDRATE TOLERANCE
cytoplasmic islet cell antibodies, HLA antigens and
in families of children with insulin-dependent diabetes, 292–297

CARBOHYDRATES
and fluorodinitrobenzene procedure for available lysine assays, 8†
structure
and nonenzymatic glycosylation of protein, 1–3†

CARBON DIOXIDE
formation
and Maillard browning reaction, 38†
D-U-^{14}C-glucose conversion to
in fat cells from insulin-dependent diabetics, 708

CARDIOTHORACIC RATIO
in UGDP, 17§
mean values and standard error at baseline and follow-up examinations, 38§

CARDIOVASCULAR DISEASE. *See also* Arteriosclerosis
animal models, 54–62*
and cardiomyopathy, 60–61*
and macrovascular disease, 55–60*
and microangiopathy of heart and arterial adventitia, 61–62*
in pigs, 34*
recommendations, 62*
and morbidity and mortality in diabetes, 54*
mortality in UGDP study life table of, 75§
phenformin treatment group, 29§
tolbutamide treatment group, 30§
risk factors
and cause of death in UGDP study, 12§, 42–43§, 46–47§, 50–51§
in surviving patients in UGDP study, 54–56§, 60–62§, 66–68§

CARDIOVASCULAR SYSTEM
response to hypoglycemia
in diabetics with autonomic neuropathy, 735

CARTILAGE
growth
diabetic serum inhibitor and, 97–103

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

-stimulating and inhibiting fractions of rat serum, 98–103

CASE REPORTS
diabetes mellitus following pentamidine-induced hypoglycemia, 40–42
glycosylated hemoglobin measurements and diabetes management, 76–78†
trapping of peripheral blood lymphocytes in pancreases of acute-onset insulin-dependent diabetics, 463–464

CASEIN
-glucose Maillard reactions, 25–26†

CASTRATION
and incidence of diabetes in male and female nonobese diabetic (NOD) mice, 24*

CATABOLISM
of collagen
streptozotocin diabetes in rats and, 426–430
insulin
age-related decrease in, 670–673
of nonenzymatic glucosylation of high-density lipoprotein
in guinea pigs, 1029–1032

CATARACTS
and diabetes, 82*
in diabetic animal models, 83–84*
and diet, 85*
formation in diabetes and aging
and nonenzymatic glycosylation and browning, 57–62†
and induced diabetes in dogs, 26*
in pancreatectomized nonhuman primates, 40*
in spontaneously diabetic dogs, 28*

CATECHOLAMINES
and hypoglycemia
and continuous subcutaneous insulin infusion, 481–482
and hypoglycemia in diabetics with autonomic neuropathy, 734
and hypoglycemia recovery, 773
and orthostatic hypotension in insulin-dependent diabetics, 733

CAUCASIANS
juvenile-onset diabetic
HLA antigens in, 106
nondiabetic
insulin resistance in, compared with Caucasians, 952–956

CELL SORTER
fluorescence-activated
and sorting of pancreatic islet cell subpopulations, 299–305

CELLS. *See also* Adipocytes
cultured bovine aortic endothelial
insulin binding, internalization and degradation in, 1077–1082
cultured and cloned from rat islet cell tumor
insulin, glucagon, and somatostatin receptors on, 521–530
DR-positive
in human fetal pancreas tissue, 26–27‡, 29‡
erythrocytes
glucose-containing fraction from membrane of, transferrence of glucose to hemoglobin in vitro, 371–374
fat and blood cells from insulin-dependent diabetics
insulin action and insulin receptor binding in, 706–714
gastric parietal
autoantibodies to, in diabetic rats, 313–317
gastric parietal cell autoimmunity
as marker for gastric and hematologic abnormalities associated with diabetes, 1051–1054
insulinoma hybrids
proinsulin-like material produced by, 1035–1040
pancreas endocrine
quantitation in nondiabetics and diabetics, 694–699
porcine thoracic aortic endothelial
in vitro injury by very-low-density lipoproteins from diabetic rat serum, 593–598
rat adipose
insulin resistance in, and high-fat/low-carbohydrate feeding, 589–591
replication
insulin and multiplication stimulating activity on islet B-cells, 160–164
sorting by light scattering with fluorescence-activated cell sorter, 299–305

CELLULAR IMMUNE REACTIONS
against pancreatic islet cells, 80–81‡

CENTRAL NERVOUS SYSTEM
benign tumor of
as cause of death in UGDP study, patient baseline characteristics and, 42–51§

CEREBRAL VASCULAR ACCIDENT
as cause of death in UGDP study
patient baseline characteristics and, 42–51§

CHEMICAL AGENTS
hyperglycemia producing in animals, 47–48*

CHILDREN. *See also* Juvenile diabetics
insulin-dependent diabetics
prognosis of impaired glucose tolerance in siblings of, 385–387
insulin-dependent diabetics without vascular disease
elevated factor VIII activity and factor VIII-related antigen in, 1006–1008

CHINESE HAMSTER
diabetic
diet and, 51–52*
and diabetic neuropathy research, 66*
islets
for islet studies, 52*
and macrovascular disease, 55*
spontaneously diabetic, 14–21*, 48–49*
availability, 21*
biochemical studies in tissues of, 18–19*
genetic analysis of, 16*
history and colony development, 14–16*
and inbreeding, 15*
morphologic changes and complications, 19–20*
nutrition and environmental effects on, 19*
and pathogenesis of diabetes in, 20–21*
physiological studies of, 16–18*

CHLORAMINE T
and separation of A_{14}-^{125}I-insulin from heterogeneously labeled insulin molecules, 1128–1130

CHLORPROPAMIDE
and insulin binding and glycemic control in insulin-dependent diabetics, 890–895
therapy
and hyperglycemia-induced islet changes in rats, 319–324

CHOLCYSTITIS
as cause of death in UGDP study, patient baseline characteristics and, 42–51§

CHOLECYSTOKININ
and insulin regulation of sugar transport in pancreatic acini from streptozotocin-diabetic mice, 679–681

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

CHOLESTEROL
dietary
in alloxan diabetic nonhuman primates, 40*
feeding
and atherosclerosis in animal models, 55*, 57*
in diabetic rabbits, 58*
high-density-lipoprotein
in non-insulin-dependent diabetics, 126–131
levels
in diabetic nonhuman primates, 38*
levels in diabetics
and increased low density and very-low-density lipoproteins, 217–224
levels in UGDP
and cause of death, 42–43§, 46–47§, 50–51§
and mortality, 12§
of surviving patients, 54–56§, 60–62§, 66–68§
metabolism
in nonketotic diabetes mellitus, 903–909

CHROMATOGRAPHY
affinity and cation exchange
and assays for Amadori compounds, 58†
aminophenylboronic acid affinity
and glycosylated hemoglobin measurement in man and animals, 701–705
carboxymethylcellulose column
and measurement of nonenzymatically glycosylated serum albumin, 52–53†
cation exchange
and acetaldehyde hemoglobin adduct, 18†
and glycosylated hemoglobin measurement, 702, 704
DEAE and HPLC
and separation of A_{14}-^{125}I-insulin from heterogeneously labeled insulin molecules, 1128–1131
and glycosylated hemoglobin measurements, 71–72†
high-pressure liquid
and measurement of available and total lysine, 30†
and quantification of glycosylated hemoglobin, 630–632
lectin affinity
and photoaffinity labeling of insulin receptors in cultured human lymphocytes, 411
lectin-sepharose affinity column
of fetal bovine pancreas, 1002–1005
of rat fetal liver
in insulin metabolism study, 62
Sephadex G-50
of ^{35}S-labeled glomeruli material from streptozoticin diabetic rats, 422, 423
Sepaharose 6B
and collection of erythrocyte sectrin, 65†

CHROMIUM
supplementation
and glucose clearance in nonhuman primates, 39*
urinary excretion
and exercise-induced glucose utilization, 212–215

CHROMOSOMES
composition of human insulinoma hybrid cells, 1036–1040
and mutant mice, 3*

CHYLOMICRON
metabolism
in diabetics, 905–906

CLONES
of cells from rat islet cell tumor
insulin, glucagon, and somatostatin receptors on, 521–530
of rat proinsulin cDNA
and quantification of proinsulin mRNA, 625

COBALAMIN
deficiency
risk of, and parietal cell autoantibodies screening in diabetics, 1051–1054

COLLAGEN
cross-linking and glucosylation
and age and diabetes, 47–51†
skin metabolism
in streptozotocin-diabetic rats, 426–430

COLLAGENASE
age-related decrease in
and diabetes, 47–51†
and H-2 antigen studies, 9‡
for isolation of islets, 109‡

COLLOID CLEARANCE TEST
in diabetics with severe microangiopathy, 7–11

COLLOIDAL CARBON
reticuloendothelial system hyperphagocytosis of, in streptozotocin-diabetic rats, 110–117

COLOR FUNDUS PHOTOGRAPHS
and retinal vascular system reactivity to norepinephrine and angiotensin, II
in diabetics and nondiabetics, 1056–1060

COLORIMETRY
and glycosylated hemoglobin measurements, 72–73†

COMPLEMENT
and 1a antiserum treatment in islet cell transplanted mice, 15‡

COMPLEMENT-MEDIATED CYTOTOXICITY ASSAYS
and detection of H-2 antigens on pancreatic B-cells, 1–2

COMPUTERS
LIPED program
and linkage analysis between insulin-dependent diabetes and Kidd red blood cell marker locus, 991–992
microdensitometry studies
of retinal vascular reactivity to norepinephrine and angiotensin II in diabetics and nondiabetics, 1056–1060
and minimal mathematical model of glucose kinetics
glucose clamp studies based on, 432–440

CONCANAVALIN-A
interaction with extracts of fetal bovine pancreas, 1002–1005

CONGENITAL MALFORMATIONS
in infants of diabetic mothers, 89–90*
in offspring of diabetic rats
maternal insulin therapy and, 1–6

CONTINUOUS SUBCUTANEOUS INSULIN INFUSION
and diabetes management risks and benefits, 479–483
in type 1 diabetics
effectiveness of human and porcine regular insulins in, 600–602

COPROPHAGY
in diabetic dogs, 28*

CORTISOL
fasting levels
and hypoglycemia, 773
levels
and hypothalamic lesions in nonhuman primates, 40*

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

normal responses to in rats
transplanted with neonatal islets, 856–861
response to hypoglycemia
in diabetics with autonomic neuropathy, 734

COX REGRESSION ANALYSIS
in UGDP study, 13§, 77§

COXSACKIE B VIRUS
and diabetes pathogenesis, 46–47*
glucose abnormalities produced in mice by, 496–499

CRYOPRESERVATION
of human fetal pancreas
functional studies of, 238–240

CYCLIC AMP
and calcium ion interactions in pancreatic islets
mathematical modeling of, 170–176

CYCLOHEXAMIDE
and insulin regulation of sugar transport, 679

CYCLOSPORIN A
complications and side effects, in kidney transplantation patients, 99‡
in human pancreas transplantation patients, 100–106‡
and immunosuppression, 92–106‡, 108‡
and islet cell allografts in rats, 95–97‡, 98‡
and kidney transplantation, 98–100‡
mechanism of action, 92‡

CYNOMOLGUS MACAQUES. *See* Macaca fascicularis

CYTOPHOSPHAMIDE
pretreatment of transplant donors with, 11†
and renal transplantation, 38‡

D

D600
inhibition of insulin release by
compared with diazoxide, 776–782

DEGU
streptozotocin diabetic
and cataracts, 83–84*

DEHYDROEPIANDROSTERONE
therapeutic effects in diabetic mice, 830–833

DEHYDROREDUCTONES
physiologic effects, 27†

DELAYED HYPERSENSITIVITY REACTIONS
and pancreatic islets transplantation in "BB" rats, 90–91‡

2-DEOXY-D-GLUCOSE
transport in isolated pancreatic acini from streptozotocin diabetic mice
insulin and, 674–681

DEXTRANS
and blood hyperviscosity
and retinal capillary aneurysms in animals, 86*

DIABETES MELLITUS
acute-onset insulin-dependent
trapping of peripheral blood lymphocytes in pancreases of, 463–465
adult-onset
insulin therapy and vascular complications in, 1–25‡
ε-amino-lysine-bound glucose in tissues and, 1123–1126
animal models of, *see* Animal models of diabetes
autoimmune with lymphocytic thyroiditis in BB/W rats
autoantibody studies in, 816–819
and autonomic neuropathy
and quantitative evaluation of cardiac parasympathetic activity in normal and diabetic subjects, 339–344
in BioBreeding (BB) rat, 7–12*
and serum autoantibodies, 313–317
and cardiovascular complications
animal models of, 54–62*
and cataract formation
and nonenzymatic glycosylation and browning, 57–62†
complications
and mouse models, 3*, 5*
and nonenzymatic glycosylation of serum and plasma proteins, 55–56†
and continuous subcutaneous insulin infusion
and hypoglycemia risks, 480–482
control
and animal research on cardiovascular disease, 62*
and Coxsackie B virus in mice, 496–499
diagnosis
criteria in UGDP study, 4–6§
and diet
in animal studies, 51–52*
duration
and glycosylated hemoglobin, 74†
duration and control
and pupil size measurements, 442–447
effect on glycosaminoglycan component of human glomerular basement membrane, 735–740
estimation of insulin secretion rate from urinary C-peptide excretion rate in, 449–453
etiology
animal models of, 45–52*
exercise and blood sugar levels and, 215
and glucose modulation of insulin and glucagon secretion, 489–494
and glucosylation of collagen, 47–51†
and glycemic control
and nonenzymatic glycosylated serum and plasma proteins, 53–55†
and glycosylated hemoglobin measurements, 70–78†
by aminophenylboronic acid affinity chromatography, 701–705
and glycosylated low-density lipoproteins in plasma, 288–289
and glycosylation of hemoglobin and other proteins, 15†
and growth
and somatomedins and circulating peptides, 97–103
and impaired insulin secretion
and effect of naloxone-induced opiate receptor blockade, 367–370
induced in monkeys, 60*
insulin-dependent
and beta-cell dysfunction in nondiabetic HLA identical siblings, 149–153
characteristics of, 45*
chemical agents and animal studies of pathogenesis, 47–48*
comparison between continuous subcutaneous insulin infusion and multiple insulin injections in, 255–263
and detection of potentially reversible albuminuria, 973–975
and diabetes risk among relatives, 136–143
and gastric parietal cell autoantibodies in diabetic BB rats, 313
genetic aspects for animal research, 46*
and genetic susceptibility to development of retinopathy, 226–230
glucose control and recovery from hypoglycemia in, 771–774
and HLA antigen distribution among Nigerian black diabetics, 1119–1122
and immune response to insulin HLA alloantigens and, 716–722
insulin action in fat cells from, 706–714

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

insulin resistance frequency in, 795–800
islet cell antibodies and histocompatibility antigens in first-degree relatives and, 585–588
linkage analysis between Kidd red blood cell marker locus and, 991–992
metabolic control and reversal of abnormalities in ocular fluorophotometry, 80–84
and potential of pancreatic islets of Langerhans transplantation, 39–46‡
predictive value of gastric parietal cell autoantibodies as marker for gastric and hematologic abnormalities associated with, 1051–1054
preferential lysis of pancreas B-cells by islet cell surface antibodies in, 459–462
pupil size in, 442–447
risk to siblings, 1115–1117
role of adrenergic mechanisms in acute glucose counterregulation after insulin-induced hypoglycemia in, 641–646
with severe microvascular disease, genetic and immunologic factors in, 70–73
and subcutaneous peritoneal access device, 470–473
and sulfonylureas and insulin binding and glycemic control, 890–895
in U.S. vs. African blacks, evidence for genetic admixture as determinant of occurrence of, 532–536
viral aspects for animal research, 46–47*
insulin-dependent in children
elevated factor VIII activity and factor VIII-related antigen without vascular disease, 1006–1008
and family studies of HLA antigens cytoplasmic islet cell antibodies, and carbohydrate tolerance, 292–297
and prognosis of impaired glucose tolerance in siblings of, 385–387
juvenile onset
and HLA-DR antigens in Japanese diabetics and nondiabetics, 105–106
and ketoacidosis, *see* Ketoacidosis, diabetic
and kidney complications
animal models and, 71–78*
lesions common to
compared with lesions in alcoholic patients, 17†
and liver perisinusoidal space ultrastructural studies
microangiopathy and, 1061–1066
and Maillard reaction, 27†
management
and use of glycosylated hemoglobin measurement, 75–78†
maturity-onset
characteristics of, 45*
etiology, 45*, 46*
maturity onset insulin dependent
HLA-A, -B, and -DR studies in, 122–125
meticulous management of, 479–483
potential risks of, 480
and prevention of diabetic complications, 479
and reversal of complications, 479–480
short-term benefits, 479
in mice
and acarbose inhibition of aglycosidase and amelioration of nephropathy in, 249–253
and alterations in basement membrane proteoglycan, 185–188
metabolic control and 2-tetradecylglycidate and prevention of nephropathy in, 12–17
with microangiopathy
impaired phagocytic function and increased immune complexes in, 7–11
in monkeys
and correlations of hemoglobin A_{1c} with metabolic status, 1105–1107
and neuropathy, *see* Neuropathy, diabetic
and nonenzymatic glucosylation of erythrocyte spectrin, 64–68†
non-insulin-dependent
abnormal high density lipoproteins in, 126–131
effect of chronic sulfonylurea therapy on hepatic glucose production in, 333–337
insulin clamp studies of basal plasma glucose concentration variations and glucose utilization and metabolic clearance rates, 396–399
insulin responses to nonglucose stimuli during tolbutamide infusion in, 154–158
and insulin secretion and action in nonobese and moderately obese subjects with, 382–387
integrated regulation of kinetics of very low density lipoprotein triglyceride and apolipoprotein B in, 217–224
and restriction fragment length polymorphism of insulin gene, 275–277
role of glucose transport in postreceptor defect of, 1016–1021
sulfonylurea treatment and insulin secretion and action in, 307–311
nonketotic
cholesterol and plasma triglycerides metabolism and, 903–909
in nonobese mice with insulitis
effects of large-dose nicotinamide injections, 749–753
normoinsulinemic, non-insulin-dependent
insulin resistance caused by postreceptor defects in, 911–916
in obese mouse, 3*
and obesity
autoimmunity and, 24–25*
and glucose-induced thermogenesis, 1023–1028
and ocular complications, 82–83*
animal research and, 83–87*
onset
in nonobese diabetic (NOD) mouse, 24*
and pancreas allografts, 84‡
and pancreas endocrine cell content compared with nondiabetics, 694–699
and pancreatic islets transplantation, 88‡
pancreatogenic and type I insulin-dependent
insulin sensitivity, binding, and kinetics in, 346–354
pathogenesis
animal research recommendations, 51–52*
after pentamidine-induced hypoglycemia, 40–45
and physical training
peripheral insulin sensitivity, muscle mitochondrial enzymes, and blood glucose control and, 1044–1049
and prostacyclin production, 454
and proteinuria
nephropathy and, 72–74*
in rats
and islet cell surface antibodies and lymphocyte antibodies in, 278–280
oxytetracycline treatment and insulin response in, 53–59
and plasma prostaglandin levels, 994–1000
and sterol synthesis, 388–395
and red cell deformability, 62*
research
mouse models for, 2–6*
and reticuloendothelial system phagocytosis, 110
with and without retinopathy
and retinal vascular reactivity to norepinephrine and angiotensin II, 1056–1060
screening
and Macaca fascicularis, 60*

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

severity
and effects of inbred background on mutant mice, 4–5*
spontaneous, in animal models
in BB rat, 7–12*
and nonobese models, 48–50*
and obese models, 50–51*
and target-cell insulin resistance
insulin clearance in vivo and, 132–135
type 1
and effectiveness of human and porcine regular insulins in continuous subcutaneous insulin infusion, 600–602
type I in children
and diabetes risk in HLA-identical and nonidentical siblings, 862–865
and urinary pyrroles, 27†

DIARRHEA
and Maillard browned foods, 39†

DIAZOXIDE
inhibition of insulin release by
compared with D 600, 776–782

DIET. *See also* Nutritional animal models

DIET
adherence to
and causes of death in UGDP study, 44–45§, 48–49§, 52§
atherogenic
and cardiomyopathy in alloxan-diabetic monkeys, 61*
in diabetic rats, 57*
and atherosclerosis in Macaca nigra, 58*
and availability of lysine, 5–6†
cholesterol feeding
and atherosclerosis in animal models, 55*, 57*
and cholesterol and plasma triglycerides metabolism in nonketotic diabetes, 904
and diabetes
animal studies of, 51–52*
and glucose tolerance in Yucatan miniature swine, 31, 33
high fat
in rats, and soleus muscle insulin binding, glucose transport, and glucose metabolism, 232–237
high-fat/low-carbohydrate in rats
and insulin resistance in adipose cells, 589–591
high-galactose
and ocular lesions in animal models, 85*
and insulin therapy in diabetic dogs, 28*
and Maillard browning of foods, 38–40†
and Maillard products formed between free amino acids and sugars
effects in rats, 24–25†
mixed meal
and artificial B-cell therapy in insulin-dependent diabetics, 49–52
and non-insulin-dependent diabetes
and blood glucose control, 7–8‡
and obesity in New Zealand obese (NZO) mouse, 24*
and ocular disease in animal models, 85–86*
and spontaneously diabetic Chinese hamster, 49*
after total pancreatectomy in dogs, 27*
in UGDP
and weight change, 14§
vitamin E in
and restoration of prostacyclin/thromboxane A_2 balance in streptozotocin-diabetic rats, 947–950

DIGITALIS
use for heart disease in UGDP, 16§
and cause of death, 42–43§, 46–47§, 50–51§
mortality and, 12§
by surviving patients, 54–56§, 60–62§, 66–68§

DIHYDROCYTOCHALASIN B
and inhibition of insulin regulation of sugar transport in pancreatic acini from diabetic mice, 681

DIIODOINSULINS
binding affinities, biologic potencies, and properties of decay products of, 634–639

DIISOPROPYLFLUOROPHOSPHATE
and insulin action, 976–983

DISACCHARIDASE
in rat gut
effects of glucose-amino acid browning products, 24†

DNA
assay in human fetal islets of Langerhans, 898, 899
cloned rat proinsulin
quantification of proinsulin mRNA with, 625
and gene mapping, nonpancreatic insulin synthesis studies and, 183–184
and streptozotocin action, 47*, 48*
synthesis
in fetal pancreatic B-cells, 755, 756–757, 758–759
variant sequences flanking human insulin gene
in diabetics, 275–277

DOGS
alloxan diabetic
and cardiomyopathy, 61*
comparison of peripheral and portal venous insulin administration on postprandial metabolic responses in, 579–583
alloxan diabetic and normal
effects of chronic administration of sodium chloropropionate in, 484–488
alloxan and streptozotocin diabetic
and prolonged hypoglycemic effect of subcutaneous administration of insulin in liposomes, 506–510
early-onset insulin-requiring diabetes in, 27*, 28*
estrus-induced temporary diabetes in, 27*, 28*
glucose production in
and intrahepatic contribution to glucagon effect on, 917–921
glucagon and glucose turnover in
and relative importance of first- and second-phase insulin secretion, 964–971
hereditary diabetes in, 27–28*
hypoglycemic action of dichloroacetate in
contribution of liver and extrasplanchnic tissues to, 326–332
induced diabetes in, 26–27*
alloxan and streptozotocin and, 26–27*
intraportal glucose infusion matched to oral glucose absorption in, 27–34
isolated perfused pancreas
inhibition of glucagon secretion by exogenous glucagon in, 512–514
pancreatectomy and induced diabetes in, 27*
plasma somatostatin, 28
evidence for presence of, 474–476
spontaneously diabetic, 27*
treatment of, 28*
streptozotocin-diabetic and normal
beta-hydroxybutyrate and somatostatin release from isolated pancreas of, 270–274
vascular disease research in, 60*

DR-ANTIGENS
positive cells
in human fetal pancreas tissue, 23–27‡, 29‡

DRUGS
use for heart disease in UGDP, 16§

DYE BINDING
and assays of chemically and nutritionally available lysine, 11†

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

E

EDEMA
and diabetic neuropathy, 358

EDTA
and very-low-density lipoproteins from diabetic rat serum
in vitro injury of porcine aortic endothelial cells by, 597

ELECTRICAL ACTIVITY
of extensor muscles from alloxan diabetic rats, 194–201
glucose-induced in islet B-cells
anion transport and, 653–655
of mouse islet electrical pacemaker response to alpha-adrenergic stimulation, 985–989

ELECTROCARDIOGRAM
abnormalities in UGDP study
and cause of death, 42–43§, 46–47§, 50–51§
in surviving patients, 54–56§, 60–62§, 66–68§

ELECTRON SPECTROSCOPY FOR CHEMICAL ANALYSIS (ESCA)
and assays of chemically and nutritionally available lysine, 8†, 9

ELECTROPHORESIS
detection of insulin in tissue extracts after, 648–651
SDS gel
of proteins from tissues of inbred nondiabetic and diabetic Chinese hamsters, 18*
SDS-polyacrylamide gel
and cell-free synthesis of rat insulin-like growth factor II, 656–658
sodium dodecyl sulfate-polyacrylamide gel
and photoaffinity labeling of insulin receptors in cultured human lymphocytes, 411

ELECTROPHYSIOLOGIC STUDIES
of insulin regulation of sugar transport in pancreatic acini from streptozotocin-diabetic mice, 676

EMBRYOGENESIS
of human fetal islets of Langerhans, 897–901

ENCEPHALOMYOCARDITIS VIRUS
and diabetes onset in mice, 46*

ENCEPHALOPATHY, HYPOGLYCEMIC
and continuous subcutaneous insulin infusion, 480

ENDONEURIAL FLUID PRESSURE
and diabetic neuropathy, 358

ENDOTHELIAL CELLS
antigens on, 38‡
cultured bovine
insulin metabolism in, 1077–1082
of human islet-enriched fractions
localization of HLA-DR antigen in, 20–22‡
porcine thoracic aortic
in vitro injury by very-low-density lipoproteins from diabetic rat serum, 593–598

ENVIRONMENTAL AGENTS
damage by
and increased beta-cell activity in HLA-identical nondiabetic siblings of insulin-dependent diabetics, 152

ENZYMES
abnormalities
and diabetes-obesity syndrome in mice, 3*
activity
in obese mice, 3*
bovine pancreatic ribonuclease and *E. coli* asparaginase
effects of reductive alkylation on biologic properties of, 3†
fructose-2,6-biphosphate in rat pancreatic islets
glucose-induced accumulation of, 90–92
muscle mitochondrial
and physical training of diabetics, 1044–1049
pancreatectomy
supplementation of diet after pancreatectomy with, 27*

EPIDERMAL LANGERHANS CELLS
and skin allograft rejection, 23‡

EPINEPHRINE
and electrical activity of mouse perifused islets, 985–989
-induced insulin release inhibition
and adrenergic blocking agents, 779
interaction of glucose with
and regulation of insulin secretion, 802–807
normal responses to in rats transplanted with neonatal islets, 856–861
secretion
during insulin-induced hypoglycemia, cellular uptake of potassium and, 615–617
and suppression of endogenous insulin secretion
in insulin removal rate and age study, 670–673

ERYTHROCYTES
aggregation
in diabetic dogs, 26*
H-2 antigens on, 6‡
insulin binding to
and chlorpropamide in insulin-dependent diabetics, 890–895
membrane
glucose-containing fraction from, and transferrence of glucose to hemoglobin in vitro, 371–374
mouse
and complement-mediated cytotoxicity assays of H-2 antigens, 1–2
spectrin
nonenzymatic glycosylation in diabetics, 64–68†

ESCHERICHIA COLI
and bactericidal properties of insulin, 36–38

ESTROGENS
and inhibition of streptozotocin-diabetes in mice, 724–729

ETHANOL
metabolism
and reactions of biologic aldehydes with proteins in alcoholics, 15–20†

ETHYL VINYL SULFONE METHOD
and assays of chemically and nutritionally available lysine, 9–10†

EUGLYCEMIC GLUCOSE CLAMP TECHNIQUE
and comparison of insulin secretion and action in nonobese and moderately obese non-insulin-dependent diabetics, 383–387
and effect of graded doses of insulin on total glucose uptake, oxidation, and storage in man, 957–962
on influence of plasma glucose and insulin concentration on plasma glucose clearance, 683–687
and insulin clearance and age study, 851–854
and insulin infusion studies in pancreatogenic and type I diabetics, 349–350
and insulin resistance and clearance study, 132–135
and in vivo deactivation of peripheral, hepatic, and pancreatic insulin action in man, 929–935
and insulin resistance in insulin-dependent diabetes, 795–800
minimal mathematical model-based, 432–440

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

in non-insulin-dependent diabetics
on effect of variations in basal plasma glucose concentration on glucose utilization and metabolic clearance rates, 396–399
and physical training in diabetics, 1044–1049
and plasma insulin changes in elderly subjects, 209

EXERCISE
and autonomic neuropathy, 730–733
effects on serum glucose, insulin and glucagon
and chromium excretion, 212–215
moderate, in man
and effect of hyperinsulinemia on glucose homeostasis during, 603–607
physical training in insulin-dependent diabetics
peripheral insulin sensitivity, muscle mitochondrial enzymes, and blood glucose control and, 1044–1049
physical training in mildly streptozotocin diabetic rats, 406–409
tests
and albumin excretion in diabetics, 72*

EYES
examination results
in UGDP follow-up studies, 17–18‡
lens
and nonenzymatic glycosylation and Maillard browning reaction, 57–62†
pupil size
in insulin-dependent diabetics, 442–447
rat lens capsule basement membrane synthesis in vitro
glucose stimulation of, 1084–1086

F

FACTOR VIII COMPLEX
alterations
in diabetic children without vascular disease, 1006–1008

FAMILY STUDIES
beta-cell dysfunction in nondiabetic HLA-identical siblings of insulin-dependent diabetics, 149–153
of diabetes risk among relatives of insulin-dependent diabetics, 136–143, 1115–1117
of diabetes risk in siblings of insulin-dependent children
and HLA genotyping, 862–865
HLA antigens, cytoplasmic islet cell antibodies, and carbohydrate tolerance
in families of children with insulin-dependent diabetes, 292–297
islet cell antibodies and histocompatibility antigens in insulin-dependent diabetics and first-degree relatives, 585–588
linkage analysis between Kidd red blood cell marker locus and insulin-dependent diabetes, 991–992
of pancreatogenic and type I diabetics
in insulin metabolism study, 348
prognosis of impaired glucose tolerance in siblings of children with insulin-dependent diabetes, 385–387

FASTING
and fructose metabolism
kidneys and, 516–520
pancreatic content of insulins I and II
in mice, 843

FATS
interference with fluorodinitrobenzene procedure for determination of chemically and nutritionally available lysine, 8†

FATTY ACIDS
nonesterified
levels in diabetic nonhuman primates, 38*

FEET
gangrene
in obese KK mice, 56*

FERTILITY
and glucose-glycine premelanoidin in rats, 25†

FETUS
bovine pancreas
glycoprotein-like large glucagon immunoreactive substances in extracts of, 1002–1005
and diabetic pregnancy, 89–90*
human and mouse pancreatic islets in organ culture
and allografting studies, 39–46‡
human pancreas
cryopreservation and function of, 238–240
human pancreas tissue in
HLA-DR antigens in, 23–27‡, 29‡
islets of Langerhans structural and biochemical development of in humans, 897–901
lung development
and diabetic pregnancy, 90–91*
mouse pancreas
insulin content in organ culture and after transplantation, 826–829
rat
and maternal diabetes, 1–6
maturation of liver insulin handling in, 60–68
rat pancreas transplants
and total lymphoid irradiation, 69–74‡
rat pancreatic B-cells
role of glucose in regulation of cell cycle kinetics and proliferation, 754–759

^{125}I-FIBRIN
monomers
reticuloendothelial system phagocytosis of, in streptozotocin-diabetic rats, 110–117

FIBROBLASTS
cultured human
rate of degradation of ^{125}I-labeled glucosylated low-density lipoprotein, 283–290

FISHER EXACT TEST
in University Group Diabetes Program study, 4§
and cancer hospitalizations and mortality, 20§
and hypertension, 17§
and kidney examination results, 19§
and mortality results, 10–11§
and peripheral vascular examination results, 19§
and use of medications for heart disease, 16§

FLOW CYTOMETRY
light-scatter
and rat islet B-cell-enriched fractions, 939–943

FLUORESCEIN ANGIOGRAPHY
and retinopathy in juvenile-onset type I diabetes of short duration, 874–882

FLUORODINITROBENZENE (FDNB) PROCEDURE
and estimates of chemically and nutritionally available lysine, 6–8†, 30†

FOODS
Maillard reaction in, 29–35†
measurement of, 30
nutritional and toxicologic effects, 37–45

FORMALDEHYDE
reaction with amines, 2†
reaction with proteins, 15–16†

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–[illegible]
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

FRUCTOSE
metabolism in fasted humans
kidney function and, 516–520

FRUCTOSE-2,6-BIPHOSPHATE
glucose-induced accumulation in pancreatic islets, 90–92

FRUCTOSE-6-P, 2-KINASE
in rat islets, 90–92

FUNDUS PHOTOGRAPHS
and follow-up eye examinations in UGDP, 17–18§

FUROSINE METHOD
and assays for Amadori products, 58†

G

GALACTOSE
excess feeding in animal models
and diabetic neuropathy research, 68–69*
and ocular lesions in animals, 85*

GALLBLADDER
biliary lipid metabolism
in diabetes, 906–907, 908–909

GANGRENE
and amputations in UGDP peripheral vascular follow-up examinations, 19§
and atherogenesis in diabetics, 54*
in obese KK mice, 56*

GASTRIC PARIETAL CELLS
autoimmunity
as marker for gastric and hematologic abnormalities associated with insulin-dependent diabetes, 1051–1054

GASTRITIS
and parietal cell autoantibodies screening in diabetics, 1051–1054

GASTROINTESTINAL SYSTEM
abnormalities associated
with insulin-dependent diabetes, predictive value of gastric parietal cell autoantibodies as marker for, 1051–1054
amino acid transport
and Amadori compounds, 26†
duodenal calcium absorption
and body growth in streptozotocin diabetic rats, 401–405
gastric parietal cell autoantibodies
in spontaneously diabetic rats, 313–317
and hepatic glucose storage, 27–34
and Maillard browned foods, 39†
rat gut
effects of glucose-amino acid browning products, 24†
sterol synthesis
and diabetes, 388–395
subcutaneous peritoneal access device
in diabetics, 470–473
tolbutamide-stimulated gastric somatostatin release
from isolated perfused rat stomach, 119–121

GEL FILTRATION
of fetal bovine pancreas studies, 1002–1005

GENES
and admixture of U.S. black and white populations
increased incidence of insulin-dependent diabetes in blacks and, 532–536
and effects of inbred background on mutant mice, 4–5*
and hereditary diabetes in dogs, 27–28*
and identification of mutant mice, 5*
and immune response to insulin, 716–722
and inbred spontaneously diabetic Chinese hamsters, 14–16*
insulin
and restriction fragment length polymorphism in diabetics, 275–277
and mutant mice, 1–2*, 3–4*, 51*
and obese mice, 3*
and spontaneously diabetic BB rats, 7–8*
and spontaneously diabetic Chinese hamsters, 16*, 20–21*

GERBILS
diabetic
cataracts in, 83*

GLAUCOMA
neovascular
and diabetes, 82*
in UGDP follow-up eye examinations, 18§

GLICLAZIDE
-induced calcium^{2+} influx into rat pancreatic B-cells, 1010–1015

GLIPIZIDE
and insulin secretion and action
and non-insulin-dependent diabetics, 307–311

GLOMERULAR FILTRATION RATE
and proteinuria in diabetic nephropathy, 74–75*

GLOMERULOSCLEROSIS
and induced diabetes in dogs, 26*

GLUCAGON
fasting levels
in diabetic nonhuman primates, 38*
and glucose production in dogs, evidence for intrahepatic contribution to waning effect of, 917–921
and glucose turnover in dogs
relative importance of first- and second-phase insulin secretion on, 964–971
glycoprotein-like large immunoreactive substances
in fetal bovine pancreas extracts, 1002–1005
in human fetal islets of Langerhans, 898–901
and hypoglycemia, 773
levels
during glucose infusion in pancreatogenic and type I diabetics, 350–351
pancreatic secretion in rats
effects of synthetic human and bovine pancreatic polypeptides and C-terminal hexapeptide on, 178–180
plasma and pancreatic
in diabetic Chinese hamsters, 17–18*
release
from cultured neonatal pancreatic islets from lean and preobese Zucker rats, 944–946
in superfusion medium of dissociated pancreatic cells attached to cytodex beads, 190–192
response to arginine infusion
in spontaneously diabetic dogs, 28*
response to glucose and arginine
in diabetic Chinese hamsters, 17*
-rich pancreas endocrine cells
in nondiabetics and diabetics, 695–699
secretion
glucose modulation of, in nondiabetic and diabetic man, 489–494
inhibition by exogenous glucagon in isolated perfused dog pancreas, 512–514
pulsatile, synchronous basal insulin secretion and, 22–26
secretion from neonatal rat cultured islet B-cells
and insulin and multiplication stimulating activity stimulation of cell replication, 160–164

GLUCAGON RECEPTORS
on cloned and cultured cells from rat islet cell tumor, 521–530

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

GLUCONEOGENESIS
alloxan-induced, 47*
and diabetes-obesity syndrome in mice, 3*
in diabetic Chinese hamsters, 18*
in obese mouse, 3*
in spontaneously diabetic obese mice, 50*

GLUCOREGULATION
and meticulous control of diabetes, 479–483

GLUCOSE
alanine and lactate conversion into
and sodium dichloroacetate in dogs, 328
ε-amino-lysine bound
in human tissues from diabetics, 1123–1126
and calcium efflux and insulin release from rat islet B-cells, 1011
and casein or soy protein lysine losses, 6†
control
and recovery from hypoglycemia in insulin-dependent diabetics, 771–774
counterregulation
after insulin-induced hypoglycemia in insulin-dependent diabetes, role of adrenergic mechanisms in, 641–646
disposal rate
and in vivo insulin action deactivation in man, 931
effects on proinsulin messenger RNA in rats, 624–628
endogenous production
during glucose infusion in pancreatogenic and type I diabetics, 350–351
fasting levels in UGDP study
and cause of death, 44–45§, 48–49§, 52–53§
of surviving patients, 57–59§, 63–65§, 69–71§
and glucosylated hemoglobin measurement, 702, 704
and glucosylation of low-density lipoprotein
and rate of degradation by cultured human fibroblasts, 283–290
hepatic production of
effect of chronic sulfonylurea therapy in non-insulin-dependent diabetes on, 333–337
homeostasis
in insulin-treated diabetics with and without artificial B-cell therapy, 46–52
during moderate exercise in man, effect of hyperinsulinemia on, 603–607
and physical training in rats with mild streptozotocin diabetes, 406–409
-induced accumulation of fructose-2,6-biphosphate in pancreatic islets, 90–92
-induced electrical activity in islet B cells
anion transport and, 653–655
-induced insulin release
vincristine inhibition of, glucose and arginine and prevention of, 834–836
-induced thermogenesis
in nondiabetic and diabetic obese subjects, 1023–1028
injection in mice
and pancreatic content of insulins I and II, 843
and insulin and glucagon secretion
in nondiabetic and diabetic man, 489–494
interaction of epinephrine and
and regulation of insulin secretion, 802–807
intraportal infusion and oral absorption study, 27–34
levels
and pyrroles, 27†
load in UGDP
and standards for diabetes diagnosis, 5–6§
in mathematical models of cyclic AMP and calcium^{2+} interactions in pancreatic islets, 170–176
and nonenzymatic glycosylation of proteins, 3†
perfusion
and tolbutamide-stimulated gastric somatostatin release from isolated perfused rat stomachs from streptozotocin-diabetic and normal rats, 119–121
permeability
and nonenzymatic glycosylation of hemoglobin in human and animal red cells, 743–747
postprandial rates of appearance and disappearance in alloxan-diabetic dogs
portal and peripheral venous insulin infusions and, 581
production in dogs
and intrahepatic contribution to glucagon effect on, 917–921
production and metabolism
quantitative study in healthy young and elderly subjects, 203–210
production and utilization
insulin dose-response kinetics for, 664, 665
and rat fetal pancreatic B-cells kinetics and proliferation, 754–759
reactivity with hemoglobin
compared with glucose-6-phosphate, 2†
and serum insulin and glucose response
in cultured neonatal pancreatic islets from lean and preobese Zucker rats, 944–946
-stimulated insulin release
and diazoxide and D600, 776–782
-stimulated insulin release from isolated rat islets
phenytoin and calcium^{2+} and, 265–269
stimulation
and pancreas islets somatostatin receptor migration kinetics, 467–469
stimulation of rat lens capsule basement membrane in vitro, 1084–1086
in superfusion medium of dissociated pancreatic cells attached to cytodex beads
and insulin, somatostatin, and glucagon release, 190–192
total uptake, oxidation, and storage
effect of graded doses of insulin on, 957–962
transferrence to hemoglobin
in glucose-containing fraction of young erythrocyte membranes, 371–374
transport
in fat cells from insulin-dependent diabetics, 708, 710
and postreceptor defect of non-insulin-dependent diabetes, 1016–1021
transport and metabolism in rat soleus muscle
effects of high fat diet on, 232–237
transport systems
and high-fat/low-carbohydrate diet, insulin resistance in rat adipose cell and, 589–591
turnover in dogs
relative importance of first- and second-phase insulin secretion on action of glucagon on, 964–971
utilization
effect of variations in basal plasma glucose concentration in non-insulin-dependent diabetics, 396–399

GLUCOSE CLAMP TECHNIQUE. *See* Euglycemic glucose clamp technique

GLUCOSE INTOLERANCE
and exercise-induced blood glucose increases, 215
and high hepatic extraction of insulin in Yucatan miniature swine, 30–31*
in nonhuman primates, 38*, 39*
and pregnancy, 89–90*
of spontaneously diabetic Chinese hamsters, 16–17*

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

GLUCOSE METABOLISM
and glucose clearance, 685
and hemoglobin A_{1c}
in diabetic monkeys, 1105–1107
and sodium dichloroacetate in dogs, 328–329

GLUCOSE OXIDASE METHOD
and oxytetracycline treatment and insulin response in diabetic rats, 54–59

GLUCOSE-6-PHOSPHATE
and nonenzymatic glycosylation of proteins, 3†
reactivity with hemoglobin compared with glucose, 2†

GLUCOSE TOLERANCE
and dietary changes in Yucatan miniature swine, 31*, 33*
and exercise
insulin sensitivity and, 406
and glucose-induced thermogenesis
in nondiabetic and diabetic obese subjects, 1023–1028
impaired
in siblings of children with insulin-dependent diabetes, 385–387
and spontaneous hyperglycemia in athymic nude BALB/c mice, 821–824
and insulin secretion and action
and sulfonylurea treatment in non-insulin-dependent diabetics, 307–311
and oxytetracycline treatment in diabetic rats, 56–57
in pregnancy, streptozotocin diabetic rats, 75–78
and spontaneous remission of streptozotocin diabetes in neonatal rats, 167

GLUCOSE TOLERANCE TESTS
in athymic nude BALB/c mice, 822, 823
and Coxsackie B virus infection in mice, 496–499
intravenous
in HLA-identical nondiabetic siblings of insulin-dependent diabetics, 149–153
and islet cell transplantation in rats after total lymphoid irradiation and bone marrow cells infusion, 66‡
in nonhuman primates, 37*, 38*, 39*
oral
in siblings of insulin-dependent diabetic children, 385–387
in UGDP
and blood glucose levels, 7–10§
and cause of death, 42–43§, 46–47§, 50–51§
and definitions of blood glucose control, 7§
and diabetes diagnostic criteria, 4–6§
and mean blood glucose levels, 8–9§
mean values and standard errors, 36§
of surviving patients, 54–56§, 60–62§, 66–68§

D-U-^{14}C-GLUCOSE
conversion to carbon dioxide
in fat cells from insulin-dependent diabetics, 708

GLYCERALDEHYDE
reactions with proteins, 15–16†

GLYCOGEN
hepatic storage during oral glucose ingestion, 27–34

GLYCOHEMOGLOBIN
labile, elimination of
and quantitation of glycosylated hemoglobin, 630–632

^{35}S-GLYCOPEPTIDE
metabolism
by glomeruli and aorta isolated from streptozotocin-diabetic rats, 418–424

GLYCOPROTEINS
fluoresceinated-avidin
selective binding to A-cells of sectioned rat and human pancreas, 107–109
-like large glucagon immunoreactive substances
in fetal bovine pancreas extracts, 1002–1005

^{35}S-GLYCOSAMINOGLYCAN
metabolism
by glomeruli and aorta isolated from streptozotocin-diabetic rats, 418–424

GLYCOSURIA
and nicotinamide injections in nonobese diabetic mice with insulitis, 749–753
in nonobese diabetic mouse (NOD), 24*

GLYCOSYLATED HEMOGLOBIN
in alcoholics, 15–20†
and blood glucose control and diabetic vascular complications study, 70–71†
chromatographic methods, 71–72†
clinical application of, 73–76†
colorimetric methods, 72–73†
and diabetes management
case histories, 76–78†
and duration of diabetes, 74†
goals for diabetes care, 75†
in human and animal red cells, 743–747
in insulin-dependent diabetics
and continuous subcutaneous insulin infusion vs. multiple insulin injections, 255–263
levels in diabetics
and nonenzymatic glycosylation, 57†
measurement by aminophenylboronic acid affinity chromatography
in man and animals, 701–705
and metabolic status
in nondiabetic, borderline diabetic, and diabetic monkeys, 1105–1107
in pancreatectomized baboons, 40*
and plasma glucose, 75†
quantitation method, 630–632
and risk of symptomatic hypoglycemia, 74–75†

GLYCOSYLATION. *See* Glycosylated hemoglobin measurements; Nonenzymatic glycosylation

GNOTOBIOTIC STUDIES
of spontaneously diabetic BB rats, 9*

GOLGI APPARATUS
and insulin biosynthesis and release, 539–553
morphology of, 542–549

GRAFT-VERSUS-HOST DISEASE
and use of total lymphoid irradiation in transplantation of rat fetal pancreases, 69–74‡, 75‡

GRANULOCYTES
of normal and diabetic children
phagocytic and bactericidal activity of, 1041–1043

GROWTH
and diabetic neuropathy in rats, 357
inhibition in untreated diabetic dogs, 28*

GROWTH HORMONE
fasting levels
and hypoglycemia, 773
-induced insulin resistance in man
mechanisms of, 663–668
release
and hypothalamic lesions in nonhuman primates, 40*
response to hypoglycemia
in diabetics with autonomic neuropathy, 734

GUANIDINIUM-HYDROCHLORIDE
and gel filtration of fetal bovine pancreas, 1002–1005

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

GUINEA PIGS
nonenzymatic glucosylation of high-density lipoproteins in, 1029–1032
spontaneous diabetes in, 50*

H

H-2 ANTIGENS
and islet B-cell transplants, 16‡
and mouse islet cells, 12‡
on surface of mouse pancreatic B-cells
islet cell transplantation and, 1–8, 9–10

HAMSTERS. *See also* Chinese hamsters
Djungarian
spontaneous diabetes in, 51*
South African
spontaneous diabetes in, 50*

HEAD
injuries
and diabetes development in nonhuman primates, 40*

HEART
aorta
of spontaneously diabetic Chinese hamster, 20*
aortic atherosclerosis
in diabetic nonhuman primates, 38*
cardiomyopathy in diabetics, 54*
in animal models, 60–61*
examination in UGDP, 14–17§
and mean values and standard errors of heart rate at baseline and follow-up examinations, 38§
failure, independent of coronary artery disease
in diabetics, 60*
microangiopathy of
in animal models, 61–62*
myocardial glycogen levels
and hyperglycemia and ketoacidosis in rats, 61*
output
and exercise in diabetics with autonomic neuropathy, 731
parasympathetic activity
in diabetics and normal subjects, 339–344
protein synthesis
and hyperglycemia, 61*
rate
and exercise in diabetics with autonomic neuropathy, 731

HEART ALLOGRAFTS
in rats
and cyclosporin A immunosuppression, 93–95‡, 98‡

HEART DISEASE
in UGDP
atherosclerotic, as cause of death, patient baseline characteristics and, 42–51§
as cause of death in phenformin treatment group, 29§
as cause of death in tolbutamide treatment group, 30§
rheumatic, as cause of death, patient baseline characteristics and, 42–51§
use of medications for, 16§

HEAT. *See* Temperature

HEATING TIME
and browning product formation between free amino acids and sugars
effects of, 24†

HEMOGLOBIN. *See also* Glycosylated hemoglobin
measurements and glyceraldehyde, 16†
reactivity of glucose-6-phosphate and glucose with, 2†
sickle cell
glyceraldehyde and, 16†
transferrence of glucose to
by glucose-containing fraction from young erythrocyte membrane, 371–374

HEPATOCYTES
H-2 antigens and, 9–10†
isolated rodent
insulin receptor internalization in, 659–662

HEREDITY. *See also* Family studies
and diabetes in dogs, 27–28*
and diabetes risk in siblings of insulin-dependent diabetic children
and HLA genotyping, 862–865
and diabetic retinopathy in twins, 19–21
and expression of major histocompatibility determinants on islets of Langerhans, 12‡
and genetic admixture as determinant of insulin-dependent diabetes occurrence
in U.S. blacks vs. African blacks, 532–536
and HLA antigen studies in maturity-onset insulin-dependent diabetics, 122–125
and HLA antigens, cytoplasmic islet cell antibodies, and carbohydrate tolerance
in families of children with insulin-dependent diabetes, 292–297
and HLA-DR antigens in Japanese juvenile-onset diabetics and nondiabetics, 105–106
HLA factors in insulin-dependent diabetics with severe microvascular disease, 70–73
and immune response to insulin
HLA alloantigens and, 716–722
and inbreeding of spontaneously diabetic Chinese hamster, 49*
and insulin-dependent diabetes research, 46*
and KK mouse, 25*
and linkage analysis between Kidd red blood cell marker locus and insulin-dependent diabetes, 991–992
and New Zealand obese (NZO) mouse, 24*
and nonobese diabetic (NOD) mouse, 24*
and obese animal models, 3*, 50–51*
and restriction endonucleases in diabetics, 275–277
and risk of diabetes in siblings of insulin-dependent diabetics
age at diagnosis and, 1115–1117
and susceptibility of pancreas beta cells to viruses, chemical toxins, or autoimmune mechanisms, 45*
and susceptibility to retinopathy of insulin-dependent diabetics, 226–230

HEXURONIC ACID
analyses of diabetic basement membranes, 735–740

HISTOCOMPATIBILITY ANTIGENS. *See* HLA antigens

HLA ANTIGENS
cytoplasmic islet cell antibodies carbohydrate tolerance and
in families of children with insulin-dependent diabetes, 292–297
and diabetes risk in siblings of insulin-dependent diabetic children, 862–865
distribution among Nigerian diabetics, 1119–1122
identical, in nondiabetic siblings of insulin-dependent diabetics
beta-cell dysfunction and, 149–153
and immune response to insulin, 716–722
in insulin-dependent diabetics and first-degree relatives, 585–588
in Japanese juvenile-onset diabetics and nondiabetics, 105–106
in maturity-onset, insulin-dependent diabetics, 122–125
and retinopathy in insulin-dependent diabetics

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

and blood glucose control, 226–230
and severe microvascular disease in insulin-dependent diabetics, 70–73

HLA-D HISTOCOMPATIBILITY LOCUS
in mice, 46*

HLA-DR ANTIGENS
in human fetal pancreas tissues, 23–27‡, 29‡
and organ culture of fetal pancreatic islets, 45‡

HORMONES
assays
and islets of Langerhans cell sorting study, 300
in rat islet B-cells sorted by flow cytometry, 940–943
cholecystokinin
in insulin regulation of sugar transport studies, 679–681
and continuous subcutaneous insulin infusion
and hypoglycemia risk, 481–482
counterregulatory
and recovery from hypoglycemia by insulin-dependent diabetics, 773
estrogens and androgens
effects on induction of streptozotocin diabetes in mice, 724–729
-induced diabetes in dogs, 26*
pancreatic
and hypoglycemia in diabetics with autonomic neuropathy, 734
response to exercise
in diabetics with autonomic neuropathy, 732
steroid
and severity of virus-induced diabetes in mice, 46*

HUMECTANTS
and Maillard reaction in foods, 32†

β-HYDROXYBUTYRATE
and somatostatin release from isolated pancreas from streptozotocin-diabetic and normal dogs, 270–274

5-HYDROXYMETHYLFURALDEHYDE
and erythrocyte spectrin glucosylation in diabetes, 64–68†

5-HYDROXY-METHYLFURFURALDEHYDE
and assays of glycosylated serum proteins, 53†
physiologic effects, 27†

^{3}H-HYDROXYPROLINE
skin content
in streptozotocin diabetic rats, skin collagen metabolism and, 426–430

HYPERCARBIA
ventilatory responses of diabetics to autonomic neuropathy and, 609–613

HYPERCHOLESTEROLEMIA
and diabetes
and sterol synthesis, 388–395
in nonhuman primates, 38*
in spontaneously diabetic dogs, 28*

HYPERGLUCAGONEMIA
in alloxan diabetic dogs
sodium 2 chlorpropionate and reduction of, 487

HYPERGLYCEMIA
in alloxan diabetic nonhuman primates, 40*
and cardiac protein synthesis, 61*
and cardiovascular disease, 54*
and congenital malformations in offspring of diabetic rats, 1–6
and Coxsackie B virus infection in mice, 496–499
defined for nonhuman primate studies, 37*
and dehydroepiandrosterone in diabetic mice, 831–833
in diabetes (db) mouse, 3*
and diabetes-obesity syndromes in mice, 3*
effects on low-density lipoproteins, 283, 290
experimental in mice
and intrasplenic islet cell transplantation, 55–59‡, 78–82‡, 83‡
and hyperglucagonemia in alloxan diabetic dogs
and sodium 2 chlorpropionate, 487
and insulitis in spontaneously diabetic BB rat, 9*
and islet changes in rats
insulin or chlorpropamide therapy and, 319–324
in KK mouse, 25*
and nonenzymatic glycosylation of plasma and serum proteins, 53–55†
in obese mouse, 3*
in pancreatectomized dogs, 27*
and plasma glucose clearance, 683–687
and pregnancy, 89–90*
spontaneous
in Yucatan miniature swine, 33*
spontaneous, and impaired glucose tolerance
in athymic nude BALB/c mice, 821–824
in spontaneously diabetic BB Wistar rat, 49–50*
in spontaneously diabetic dogs, 28*
and streptozotocin, 48*
streptozotocin and susceptibility of mice to
and androgen-estrogen ratios, 724–729
during stress
and epinephrine inhibition of B-cell function, 802–807
virus-induced, 46–47*

HYPERINSULINEMIA
and diabetes-obesity syndromes in mice, 2–3*
in diabetic nonhuman primates, 38*
in fatty Zucker rat, 25*
and glucose homeostasis during moderate exercise in man, 603–607
and hypothalamic lesions in nonhuman primates, 40*
in KK mouse, 25*
in nonhuman primates, 37–38*
in nonhyperphagic prediabetic Chinese hamsters, 19*
in Pima Indians
and insulin resistance, 952–956
and plasma glucose clearance, 683–687
in spontaneously diabetic obese mice, 50*, 51*

HYPERLIPIDEMIA
in fatty Zucker rat, 25*

HYPERLIPOPROTEINEMIA
in nonhuman primates, 38*

HYPEROSMOLARITY
in diabetic nonhuman primate, 38*

HYPERPHAGIA
and diabetes-obesity syndromes in mice, 2*
and hypothalamic lesions
and induced diabetes in nonhuman primates, 40*
in fatty Zucker rat, 25*
in KK mouse, 25*
in obese mouse, 3*
in prediabetic Chinese hamsters, 19*

HYPERPHAGOCYTOSIS
reticuloendothelial
in streptozotocin-diabetic rats, 110–117

HYPERTENSION
in alloxan-diabetic rats, 57*
and diabetic nephropathy, 72*

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

and macrovascular research in obese spontaneously hypertensive rat, 56–57*
in UGDP, 16§
and mortality, 12§

HYPERTRIGLYCERIDEMIA
pregnancy-associated
in normal and diabetic women, 1092–1096

HYPERTROPHY
of rat cecum
and glucose-amino acid browning products, 24†

HYPOGLYCEMIA
in autonomic diabetic neuropathy, 734–735
and continuous subcutaneous insulin infusion, 480–482
control of
and measurement of capillary blood glucose, 257, 258
in diabetic dogs, 28*
and diazoxide and D600 studies, 776–782
and encephalopathy
and continuous subcutaneous insulin infusion, 480
frequency of
in pancreatogenic and type I diabetics in insulin metabolism study, 348
in insulin-dependent diabetics
glucose control and recovery from, 771–774
insulin-induced
regulation of serum potassium during, 615–617
insulin-induced in diabetics
role of adrenergic mechanisms in acute glucose counterregulation after, 641–646
pentamidine-induced
diabetes mellitus following, 40–45
prolonged in diabetic dogs
after subcutaneous administration of insulin in liposomes, 506–510
as response to insulin
diminished in non-insulin-dependent diabetics, postreceptor defects and, 911–916
risk of
and glycosylated hemoglobin measurements, 74–75†
sodium dichloroacetate-induced in dogs
contribution of liver and extrasplanchnic tissues to, 326–332
and spontaneous diabetes in obese mice, 50*
in UGDP final report, 9–10§

HYPOGLYCEMIC UNAWARENESS
and diabetics with autonomic neuropathy, 735

HYPOGONADISM
and diabetes-obesity syndrome in mice, 3*

HYPOINSULINEMIA
in alloxan diabetic nonhuman primates, 40*
in nonhuman primates, 38*
in spontaneously diabetic dogs, 28*

HYPOTENSION
orthostatic
in diabetics with autonomic neuropathy, 733–734

HYPOTHALAMUS
defects
in diabetes (db) mouse, 4*
function
in fatty Zucker rat, 25*
lesions
and diabetes induction in nonhuman primates, 40*, 60*
of obese mice, 3*

HYPOXEMIA
ventilatory responses of diabetics to autonomic neuropathy and, 609–613

I

IMMUNE COMPLEXES
increased
in diabetics with severe microangiopathy, 7–11
in insulin-dependent diabetics with microvascular disease, 70–73

IMMUNE DEFICIENCY
in obese and diabetes mice, 4*

IMMUNE RESPONSES
to insulin
HLA alloantigens and, 716–722
theory of, 30–32‡

IMMUNE SYSTEM
and pancreatic islet transplantation, 30–37‡
specific and nonspecific stimulation of
and susceptibility of established allografts to rejection, 36‡
and spontaneous hyperglycemia and impaired glucose tolerance in athymic nude BALB/c mice, 821–824

IMMUNOCYTOCHEMISTRY
and localization of antigen-bearing cells in rat islets, 52–53‡
and localization of HLA-DR antigens in human islets of Langerhans, 17–22‡

IMMUNOELECTROPHORESIS
analysis of pancreatic content of insulins I and II
in mice and rats, 841–845

IMMUNOFERRITIN-LABELING TECHNIQUE
and H-2 antigens on mouse pancreatic B-cells, 1–8‡, 12‡

IMMUNOFLUORESCENCE STUDIES
and endocrine cell content in pancreas of nondiabetics and diabetics, 694–699
of renal cortex from diabetic mice
acarbose inhibition of a-glycosidase and, 250, 252

IMMUNOFLUORESCENT STUDIES
and autoantibodies in BB/W rats, 817–819

IMMUNOGENICITY
and fetal pancreas allografts, 35–37‡
of tissue allografts organ culture and, 36‡

IMMUNOGLOBULIN
and proteinuria and nephrosis in diabetics, 73*

IMMUNOGLOBULIN G
-transferrin clearance index and proteinuria in diabetic nephropathy, 73*

IMMUNOLOGIC DISORDERS
animal research on, 51*

IMMUNOLOGY
antibody to glomerular basement membrane in diabetic animal models, 77–78*
and pathogenesis of insulin-dependent diabetes, 46*
and virus-induced diabetes in mice, 46*

IMMUNOPEROXIDASE STAINING
and HLA-DR antigens in human fetal pancreas tissue, 24–27‡, 29‡

IMMUNOSUPPRESSION
conventional
in human kidney transplantation, compared with cyclosporin A immunosuppression, 99‡

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

in human pancreas transplantation, compared with cyclosporin A immunosuppression, 100–101‡
and cyclosporin A, 92–106‡, 108‡
elimination in islet cell transplantation and pretreatment of islet cells, 11–13‡, 15–16‡
elimination by total lymphoid irradiation, 75–77‡
research in, 93‡
side effects of and organ culture of pancreatic islets of Langerhans, 39‡

IMPOTENCE
and autonomic neuropathy, 65*

INFANTS
of diabetic mothers
clinical problems of, 89–90*
and prevention of congenital malformations in offspring of diabetic rats, 1–6

INFECTION
with Coxsackie B virus
and glucose abnormalities in mice, 496–499
and diabetes control, 479
and diabetes development in nonhuman primates, 40*
and gnotobiotic studies in BB rats, 9*
and phagocytic and bactericidal activity of granulocytes in diabetic children, 1041–1043
viral
and increased beta-cell activity in HLA-identical nondiabetic siblings of insulin-dependent diabetics, 152

INFERTILITY
in diabetes (db) mouse, 3*
of diabetic male dogs, 28*
in obese-diabetic syndrome in mice, 5*
in obese mice, 3*
in spontaneously diabetic Chinese hamsters, 20*, 48*

INSULIN
action
in fat cells from insulin-dependent diabetics, insulin receptor binding to fat and blood cells and, 706–714
inhibition by small molecular weight trypsin inhibitors, 976–983
in vivo deactivation in man, 929–935
administration
after pancreatectomy in dogs, 27*
binding
in insulin-dependent diabetics, sulfonylureas and, 890–895
in rat soleus muscle, effects of high fat diet on, 232–237
binding, internalization, and degradation in bovine aortic endothelial cells, 1077–1082
binding capacity and microvascular diseases, 70–73
binding and degradation by isolated renal brush border membranes, 618–623
binding by liver plasma membranes from fatty Zucker rats, 867–872
biosynthesis
and effects of glucose on proinsulin mRNA in rats, 624–628
biosynthesis and release
by cryopreserved human fetal pancreas, 238–240
and pancreas B-cells subcellular organization, 539–553
clearance
age and, 851–854
commercial U.S.P.
bactericidal properties of, 36–38
comparison of peripheral and portal venous administration on postprandial metabolic responses in alloxan-diabetic dogs, 579–583
content of fetal mouse pancreas
in organ culture and after transplantation, 826–829
continuous subcutaneous infusion
risks and benefits, 479–483
-dependent diabetes
beta-cell dysfunction in nondiabetic HLA identical siblings of, 149–153
continuous subcutaneous insulin infusion compared with multiple injections of insulin, blood glucose control and, 255–263
and detection of potentially reversible albuminuria, 973–975
following pentamidine-induced hypoglycemia, 40–45
and genetic susceptibility to development of retinopathy, 226–230
glucose control and recovery from hypoglycemia in, 771–774
and HLA antigen distribution among Nigerian diabetics, 1119–1122
immune response to insulin and HLA alloantigens, 716–722
insulin resistance in, 795–800
islet cell antibodies and histocompatibility antigens in first-degree relatives and, 585–588
linkage analysis between Kidd red blood cell marker locus and, 991–992
metabolic control and reversal of abnormalities in ocular fluorophotometry in, 80–84
physical training and, peripheral insulin sensitivity, muscle mitochondrial enzymes, and blood glucose control and, 1044–1049
predictive value of gastric parietal cell autoantibodies as marker for gastric and hematologic abnormalities associated with, 1051–1054
risk to siblings, 1115–1117
role of adrenergic mechanisms in acute glucose counterregulation after insulin-induced hypoglycemia in, 641–646
with severe microvascular disease, genetic and immunologic factors in, 70–73
streptozotocin induction in mice, estrogens and androgens and, 724–729
and subcutaneous peritoneal access device, 470–473
and sulfonylureas, 890–895
-dependent diabetes in children
and family studies of HLA antigens, cytoplasmic islet cell antibodies, and carbohydrate tolerance, 292–297
and prognosis of impaired glucose tolerance in siblings, 385–387
without vascular disease elevated factor VIII activity and factor VIII-related antigen in, 1006–1008
-dependent diabetes in U.S. blacks vs. African blacks
genetic admixture as determinant of occurrence of, 532–536
-dependent maturity onset diabetics
HLA-A, -B, and -DR antigen studies in, 122–125
-dependent and non-insulin-dependent diabetes
and pregnancy-associated hypertriglyceridemia, 1092–1096
-dependent and non-insulin-dependent diabetic twins
retinopathy study in, 19–21
-dependent serum factor in rats
and regulation of skeletal muscle ornithine decarboxylase, 500–504
diiodoinsulins
characterization of, 634–639
dosage in UGDP, 2§
means and standard errors of, 35§
and duodenal calcium absorption in diabetic rats, 401–405
entrapped in liposomes
subcutaneous administration in diabetic dogs, prolonged hypoglycemia and, 506–510
first- and second-stage secretion in dogs

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

and glucagon action on glucose turnover, 964–971
graded doses of
and total glucose uptake, oxidation, and storage in man, 957–962
and growth of diabetic dogs, 28*
in human fetal islets of Langerhans, 898–901
human and porcine regular
effectiveness in continuous subcutaneous insulin infusion, 600–602
immune response to in man, 716–722
immunodetection of nanogram quantities in tissue extracts, 648–651
-induced alterations in insulin binding and action
in primary cultures of rat hepatocytes, 145–148
-induced hypoglycemia
regulation of serum potassium during, 615–617
-induced loss of insulin-like growth factor-1 receptors on IM-9 lymphocytes, 375–380
levels
and effect of chronic sulfonylurea therapy on hepatic glucose production in non-insulin-dependent diabetes, 333–337
and moderate exercise in man, 603–607
and plasma glucose levels, influence on plasma glucose clearance, 683–687
and pyrroles, 27†
-like activity in diabetic rat serum
blunting by inhibitor, 97–103
metabolism
in nonobese spontaneously diabetic animal models, 48–50*
in obese spontaneously diabetic animal models, 50–51*
in spontaneously diabetic nonobese Chinese hamster, 48–49*
metabolism in rat fetal liver
maturation of, 60–68
pancreatic content of I and II
in mice and rats, 841–845
peripheral sensitivity
and physical training in diabetics, 1044–1049
photoreactive derivatives
biologic activity and labeling properties in isolated rat adipocytes, 1068–1075
production
by cultured fetal mouse and human islets, 42‡
and prostacyclin production in rats, 454–457
quasi-electric laster light scattering examination of formulations of, 364–366
release
from cultured neonatal pancreatic islets from lean and preobese Zucker rats, 944–946
diazoxide and D600 inhibition of, mechanisms of, 776–782
glucose-induced, vincristine inhibition of, glucose and arginine and, 834–836
phenytoin and, 265–269
from rat islet B cells, gliclazide and, 1010–1015
of single rat islet B-cells sorted by flow cytometry, 940–943
in superfusion medium of dissociated pancreatic cells attached to cytodex beads, 190–192
removal rate from plasma in rats and man
aging and, 670–673
-requiring spontaneous idiopathic diabetes in dogs, 27*
requirements
of BB rats, 7*
resistance
and diabetes-obesity syndromes in mice, 3*
in diabetic ketoacidosis, 923–927
in fatty Zucker rat, 25*
frequency in insulin-dependent diabetes, 795–800
growth-hormone-induced, 663–668
and impaired in vivo insulin clearance, 132–135
increased in vivo, in nondiabetic Pima Indians compared with Caucasians, 952–956
in normoinsulinemic non-insulin-dependent diabetes, postreceptor defects and, 911–916
in rat adipose cell with high-fat/low-carbohydrate feeding, and depletion of intracellular glucose transport systems, 589–591
in spontaneously diabetic Chinese hamsters, 17*
in Yucatan miniature swine, 31*
response
in pregnant, streptozotocin-diabetic rats, 75–78
response in diabetic rats
oxytetracycline treatment and, 53–59
responses to nonglucose stimuli
during tolbutamide infusion in non-insulin-dependent diabetics, 154–158
and reticuloendothelial system hyperphagocytosis in streptozotocin-diabetic rats, 112, 117
rich pancreas endocrine cells in nondiabetics and diabetics, 695–699
secretion
in diabetes, and effect of naloxone-induced opiate receptor blockade, 367–370
and exogenous glucagon in isolated perfused dog pancreas, 514
glucose and epinephrine interactions and regulation of, 802–807
and glucose-induced fructose-2,6-biphosphate accumulation in rat islets, 90–92
glucose modulation of, in nondiabetic and diabetic man, 489–494
and hemoglobin A_{1c} in monkeys, 1105–1107
in HLA-identical nondiabetic siblings of insulin-dependent diabetics, 149–153
and physical training in rats with mild streptozotocin diabetes, 406–409
synchronous pulsatile glucagon secretion and, 22–26
secretion
in Yucatan miniature swine, 33*
secretion and action
in nonobese and moderately obese non-insulin-dependent diabetics, 382–387
and sulfonylurea treatment in non-insulin-dependent diabetics, 307–311
secretion and content
of cultured mouse islets, 56–57‡
secretion rate
estimation from urinary C-peptide excretion rate in obese and diabetic subjects, 449–453
secretion and synthesis
in fatty Zucker rat, 25*
sensitivity
and minimal-model-based glucose clamp studies 432–440
physical training and, 408
sensitivity, binding, and kinetics
in pancreatogenic and type I diabetes, 346–354
and slow axonal transport velocity of sciatic nerve in streptozotocin-diabetic rats, 689–693
and spontaneous remission of streptozotocin diabetes
in neonatal rats, 165–169
-stimulated sugar transport by rat soleus muscle
and Ca^{2+}-dependent ionophore A23187, 846–849
and stimulation of islet B-cell replication
in neonatal rat pancreatic monolayer cultures, 160–164
subcutaneous nonresponsiveness
and implantation of peritoneal access device in diabetics, 470–473
and sugar transport in isolated pancreatic acini from streptozotocin-diabetic mice, 674–681

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

synthesis by IM-9 lymphocytes
evidence against, 182–184
therapy
continuous subcutaneous vs. multiple injections, blood glucose control and, 255–263
conventional and directed by artificial B-cell, glucose homeostasis in diabetics and, 46–52
in diabetic dogs, 28*
and estrus-induced temporary diabetes in dogs, 27*
and hyperglycemia-induced islet changes in rats, 319–324
in insulin-dependent diabetes, and chlorpropamide, 890–895
in nonhuman primates, 38*
and plasma triglycerides and cholesterol metabolism in diabetics, 904
in spontaneously diabetic Chinese hamsters, 17*
therapy in adult-onset diabetics, UGDP final report on vascular complications and, 1–25§
therapy in diabetic pregnant rats
and prevention of congenital malformations in offspring, 1–6
therapy in non-insulin-dependent diabetics
blood glucose control and, 7–8‡
therapy in UGDP
and adherence of surviving patients, 6–7§, 57–59§, 63–65§, 69–71§
determination of adherence levels, 3–4§
and discontinuation of phenformin and tolbutamide treatment groups, 28§
mortality by high adherence levels, 13–14§
tolerance
and oxytetracycline treatment in diabetic rats, 57

INSULIN GENE
restriction fragment length polymorphism in diabetes, 275–277

INSULIN INFUSION SYSTEMS
continuous subcutaneous
vs. multiple injections of insulin in diabetics, blood glucose control and, 255–263
in spontaneously diabetic Chinese hamsters, 17*
mortality from
and reporting to Centers for Disease Control, 572
peripheral and portal venous routes
and postprandial metabolic responses in alloxan-diabetic dogs, 579–583
and reversal of abnormalities of ocular fluorophotometry in diabetics, 80–84

INSULIN-LIKE GROWTH FACTOR-1 RECEPTORS
on IM-9 lymphocytes
insulin-induced loss of, 375–380

INSULIN-LIKE GROWTH FACTOR II
rat
cell-free synthesis of, 656–658

INSULIN RECEPTORS
in adipose tissue
aging and, 210
binding to fat and blood cells
and insulin action in fat cells from insulin-dependent diabetics, 706–714
on cloned and cultured cells from rat islet cell tumor, 521–530
in cultured human lymphocytes
photoaffinity labeling of, 410–416
development in rat fetal liver, 60–68
function
growth hormone infusion and, 664, 665
hepatic
in fatty Zucker rats, 867–872
and insulin resistance and clearance, 132–135
internalization in rodent hepatocytes, 659–662
in isolated rat adipocytes
and photoreactive insulin derivatives study, 1068–1075
in obese mouse, 3*
in primary cultures of rat hepatocytes
and insulin-induced alterations in insulin binding and action, 145–148
on renal brush border membranes, 618–623

^{125}I-INSULIN
binding to erythrocytes
in pancreatogenic and type I diabetes, 349
binding to isolated rodent hepatocytes, 659–662
binding to red cells
in pancreatogenic and type I diabetics, 351–352

A_{14}-^{125}I-INSULIN
separation from heterogeneously labeled insulin molecules, 1128–1131

INSULINOMAS
human somatic cell hybrids
proinsulin-like material produced by, 1035–1040

INSULINOPENIA
alloxan induced, 47*
in nonobese diabetic (NOD) mouse, 24*

INSULITIS
and damage to transplanted pancreatic islets, 84–88‡
experimental in mice
and intrasplenic islet cell transplantation, 78–82‡, 83‡
in nonobese diabetic mice
and large-dose nicotinamide injections, 749–753
spontaneous immune in rats
and islet cell transplantation and neonatal bone marrow cell inoculation, 84–88‡, 90–91‡
in spontaneously diabetic BB rat, 9*, 49–50*
thymectomy and, 11*

INTERFERON, 51*

INTERMITTENT CLAUDICATION
in UGDP peripheral vascular follow-up examinations, 19§

INTERNATIONAL HUMAN PANCREAS AND ISLET TRANSPLANTATION REGISTRY
report through 1981, 112–115‡

IONOPHORE A23187
Ca^{2+}-dependent
and basal and insulin-stimulated sugar transport by rat soleus muscle, 846–849

IRON
availability in diabetic ketoacidosis
susceptibility to mucormycosis and, 1109–1113
levels in BB rats, 316

IRRADIATION. *See also* Total lymphoid irradiation
in streptozotocin-diabetic mice, 809, 810–811, 812–814

ISLET CELL TRANSPLANTATION
and allogenic reactivity theory, 31–32‡
of cultured adult mouse islets, 32–35‡
of cultured allogeneic mouse islets
reversal of hyperglycemia by, 55–59‡
of cultured fetal islet cells
and reversal of diabetes, 35–37‡
of cultured islet cells
prolongation of allograft survival and, 48–54‡
of fetal islets
and HLA-DR antigens, 23–27‡, 29‡
and H-2 antigens on mouse pancreatic B-cells, 1–8, 9–10

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

intrasplenic
in mice with experimental insulitis and hyperglycemia, 78–82‡, 83‡
in mice
and elimination of immunosuppression with pretreatment of islets, 11–13‡, 15–16‡
and reversal of diabetes, 32–37‡
and organ culture of fetal mouse and human islets, 39–46‡
in rats
across major histocompatibility barriers, total lymphoid irradiation and allogeneic bone marrow cells infusion and, 63–67‡
and cyclosporin A immunosuppression, 96–97‡, 98‡
in rats with immune insulitis
and bone marrow cell neonatal inoculation, 84–88‡, 90–91
report of International Human Pancreas and Islet Transplantation Registry through 1981 on, 112–115‡
strain-specific maintenance and rejection in mice, 13‡
and susceptibility of established allografts to rejection, 36–37‡
and theory of allogeneic reactivity, 30–32
and tolerance compared with enhancement, 15–16‡
xenogeneic
and reversal of diabetes, 35‡

ISLETS OF LANGERHANS
B-cells
light and electron microscopy of, 538, 539
and effects of inbred background on obese and diabetes mice, 4–5*
endocrine cell types within
and sorting with fluorescence-activated cell sorter, 299–305
human
immunocytochemical localization of HLA-DR in, 17–22‡
human fetal
structural and biochemical development of, 897–901
hydropic degeneration
and hypothalamic lesions in nonhuman primates, 40*
hyperplasia
and diabetes in dogs, 27–28*
hyperplasia and hypertrophy
in diabetes (db) mouse, 3*
and diabetes-obesity syndrome in mice, 3*
in fatty Zucker rat, 25*
isolation from beef and pig pancreas
new method for, 109–111‡
lesions
and spontaneous diabetes in non-human primates, 38*
mouse
isolation of, 2‡
of nonobese diabetic (NOD) mouse, 24*
perifused mouse
membrane potentials in response to alpha adrenergic stimulation, 985–989
in rat
microvasculature studies of, 883–888

ISOPROTERENOL
and assessment of sympathetic and parasympathetic nervous systems
in respiration cardiac reflex in diabetic and non-diabetic subjects, 341–344
insulin responses to
in non-insulin-dependent diabetics, 155–156

J

JAPANESE
juvenile-onset diabetics and nondiabetics
HLA-DR antigens in, 105–106

JUVENILE DIABETES
and early insulin therapy
endogenous insulin release and, 169
insulin dependent of short duration
retinopathy in, 874–882
phagocytic and bactericidal activity of granulocytes in, 1041–1043
spontaneous remission in, 165, 169

K

KETOACIDOSIS, DIABETIC
acetone metabolism in, 242–248
and animal models research, v*
in dogs, 28*
insulin resistance in, 923–927
in rats
and myocardial glycogen levels, 61*
and plasma prostaglandin levels, 994–1000
in spontaneously diabetic dogs, 28*
susceptibility to mucormycosis in, 1109–1113

KETONES
urinary excretion
and monitoring of diabetic control in dogs, 28*

KETONURIA
in spontaneously diabetic Chinese hamsters, 16–17*, 19*

KETOSIS
proneness
and HLA antigens in insulin-dependent, maturity-onset diabetics, 122–125

KIDD RED BLOOD CELL MARKER LOCUS
linkage analysis between insulin-dependent diabetes and, 991–992

KIDNEY TRANSPLANTATION
and cyclosporin A immunosuppression, 98–100‡
mechanism of long-term survival, 15‡
in rats
and prevention of rejection, 38‡
results of pancreas transplants and, 114‡
and total lymphoid irradiation and bone marrow conditioning, 67‡

KIDNEYS
a and B galactosidase and N-Ac-B-D-hexosaminidase
in inbred Chinese hamsters, 15*
AC galactosidases
in diabetic Chinese hamsters, 18*
antibodies to tubular basement membrane in diabetic animal models, 78*
capillary basement membrane thickening
in pancreatectomized baboons, 40*
cytomegaly of tubular cells
and Amadori compound of lysine, 26†
of diabetes (db) mouse, 4*
and diabetic glomerulosclerosis in animal models, 71–78*
and proteinuria, 72–74*
disease
in obese Zucker rat, 56*
examination in UGDP, 18–19§
failure in UGDP
as cause of death, patient baseline characteristics and, 42–51§
and fructose metabolism in fasted humans, 516–520
function
of diabetics with microangiopathy in immune complexes study, 8, 9
exercise and, 212–215
glomerular basement membranes
biochemistry in animal models, 76–77*
glomerular basement membrane glycosaminoglycan components
diabetes and, 735–740
glomerular basement membrane thickening
in spontaneously diabetic Chinese hamsters, 20*

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

glomerular nephritis
in New Zealand obese (NZO) mouse, 24–25*
in spontaneously diabetic New Zealand obese mouse, 51*
glomeruli from streptozotocin-diabetic rats
^{35}S-glycosaminoglycan and ^{35}S-glycopeptide metabolism in, 418–424
glomerulopathy in diabetes
and renal pathology research, 71–72*
immune glomerular and tubular injuries
in diabetic animal models, 77–78*
islet cell transplantation under capsule of, 32–37‡
isolated brush border membranes
binding and degradation of insulin by, 618–623
nephropathy
and acarbose inhibition of a-glycosidase in genetically diabetic mice, 249–253
and idiopathic diabetes in dogs, 27*
2-tetradecylglycidate and metabolic control and prevention in diabetic mice, 12–17
of spontaneously diabetic dogs, 28*
weight
and Maillard browned diets in animals, 40†, 42†

L

LACTIC ACIDOSIS
as cause of death in UGDP phenformin treatment group, 29§

LACTOBACILLUS CASEI
maltol and inhibition of growth and lactic acid synthesis, 27†

LAMB
neonatal
alloxan and myocardial function in, 61*

LESIONS
cardiovascular
in pigs, 34*
in diabetics and alcoholics, 17†
hypothalamic
and induced diabetes in monkeys, 60*
and induced diabetes in nonhuman primates, 40*
microvascular
in diabetes mouse, 4*

LEUCINE
as source of alanine nitrogen in man, 86–89

^{3}H-LEUCINE
incorporation into acinar protein
and insulin regulation of sugar transport, 676

LEUKOCYTES
passenger
and tissue rejection, 2

LEUPEPTIN
and insulin action, 976–983

LIFE EXPECTANCY
and maturity-onset non-insulin-dependent diabetes, 22–23§
of nonhuman primates, 37*, 40*

LIFE SPAN
of animal models
and diabetes etiology studies, 45–46*

LI-MANTEL ESTIMATOR
in family study of diabetes risk to relatives of insulin-dependent diabetics, 140–143

LIPASE
in diet supplementation after pancreatectomy in dogs, 27*

LIPEMIA
in spontaneously diabetic dogs, 28*

LIPIDS
synthesis
and pancreatectomy in nonhuman primates, 40*

LIPOGENESIS
in fat cells from insulin-dependent diabetics, 708

LIPOLYSIS
in fat cells from insulin-dependent diabetics, 708–709
and glucose oxidation in non-insulin-dependent diabetics
insulin resistance and, 911–916

LIPOPROTEINS
in chemically-induced diabetic rats, 57*
in diabetic baboons, 40*
high-density
abnormalities in composition of, in non-insulin-dependent diabetics, 126–131
nonenzymatic glucosylation in guinea pigs, 1029–1032
low density
and diet in alloxan diabetic nonhuman primates, 40*
nonenzymatic glucosylation of, alteration in biologic activity and, 283–290
very-low-density
and inhibition of in vitro lymphocyte response by streptozotocin diabetic rat serum, 1098–1103
very-low-density from diabetic rat serum
in vitro injury of porcine aortic endothelial cells by, 593–598

LIPOPROTEIN TRIGLYCERIDE
very-low-density, kinetics of apolipoprotein B and
in non-insulin-dependent diabetics, 217–224

LIPOSOMES
insulin entrapped in
subcutaneous administration in diabetic dogs, prolonged hypoglycemia and, 506–510

LIQUID SCINTILLATION COUNTING
in studies of fat cells from insulin-dependent diabetics, 708

LIVER
acid glycohydrolases
in diabetic Chinese hamsters, 18*
cultured rat hepatocytes
insulin-induced alterations in insulin binding and action in, 145–148
cytosolic aldehyde dehydrogenase
and alcoholics, 15†
fatty degeneration and necrosis
hydroxymethyl furfural-induced, 27†
and fructose infusion after fasting, 518
gluconeogenesis
in diabetic Chinese hamsters, 18*
gluconeogenesis and glycogenelysis
in spontaneously diabetic BB Wistar rats, 50*
glucose production
and glucose clearance, 685
effect of chronic sulfonylurea therapy in non-insulin-dependent diabetes on, 333–337
and moderate exercise in man, 603–607
glucose production, glucose infusion and
in healthy young and elderly subjects, 204–205, 207–208
glycogen
in diabetic Chinese hamsters, 18*
glycogen storage during oral glucose ingestion
gastrointestinal glucose uptake and, 27–34
insulin action
in vivo deactivation in man, 929–935
Kupffer cell activity
and reticuloendothelial hyperphagocytosis in streptozotocin-diabetic rats, 111–117

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

lipogenesis
in obese mouse, 3*
perisinusoidal space ultrastructural studies
in diabetics with and without microangiopathy, 1061–1066
plasma membranes from Zucker fatty rats
insulin binding by, 867–872
rat
and synthesis of rat insulin-like growth factor II, 656–658
rat fetal
maturation of insulin handling by, 60–68
and sodium dichloroacetate-induced hypoglycemia in dogs, 326–332
and waning effect of glucagon on glucose production in dogs, 917–921
weight
and Maillard browned diets in animals, 40†

LUNGS
fetal
and diabetes, 90–91

LYMPHOCYTES
antibodies
in spontaneously diabetic rats, 278–280
cultured human
photoaffinity labeling of insulin receptors in, 410–416
H-2 antigens on, 9†
IM-9
insulin-induced loss of insulin-like growth factor-1 receptors on, 375–380
IM-9, acid-ethanol extracts of
evidence against insulin synthesis by, 182–184
infiltration into islets of diabetic Chinese hamsters, 19*
infiltration into pancreatic islets of streptozotocin-diabetic mice, 80–81‡
peripheral blood
trapping in pancreas of acute onset insulin-dependent diabetics, 463–465
response by streptozotocin-induced diabetic rat serum
very-low-density lipoproteins and inhibition of, 1098–1103
splenic
and diabetes susceptibility of genetically susceptible mice treated with streptozotocin, 808–814

LYMPHOID CELLS
1a-bearing
and rejection phenomena, 12–13‡

LYSINE
Amadori product of
physiologic effects, 26†
assays of chemical and nutritional availability
dye binding method, 11†
fluorodinitrobenzene procedure, 6–8†
as index of browning, 5–12†
Ninhydrin and, 11†, 12†
reductive alkylation and, 10–11†
trifluoroacetylation, 11†
vinyl compounds and, 8–10†
chemically available
defined, 5–6†
loss
and measurement of Maillard reaction, 30
nonenzymatic glycosylation of, 1†
and reversal of diazoxide and D600 inhibition of insulin release, 778–779

LYSIS
of pancreas B-cells by islet cell surface antibodies
in insulin-dependent diabetics, 459–462

M

MACACA FASCICULARIS
atherosclerosis research in, 59–60*
screening program for diabetes in, 60*
spontaneous diabetes in, 38*

MACACA MULATTA
alloxan diabetes in, 40*
atherosclerosis research in, 60*
and diabetic pregnancy studies, 92*
hypothalamic lesions and induced diabetes in, 40*
spontaneous diabetes in, 38–39*
streptozotocin diabetes in, 39–40*

MACACA NIGRA
and atherosclerosis research, 58–59*
spontaneous diabetes in, 37–38*

MACACA RADIATA
spontaneous diabetes in, 38*

MACAQUES. *See Macaca nigra; Macaca fascicularis; Macaca mulatta; Macaca radiata*

MACROPHAGES
infiltration of pancreatic islets after streptozotocin, 48*

MAILLARD NONENZYMATIC BROWNING REACTION, 37–45†
and acetaldehyde hemoglobin reaction in alcoholics, 20†
and Amadori compounds
physiological effects, 26
bioassays, 30
and carbohydrate and protein structure, 1–3†
and cataract formation in aging and diabetes, 57–62†
chemical steps and pathways in, 22–23†
chemically reactive and unreactive lysine as index of, 5–12†
of egg albumin-glucose mixture
nutritional and physiologic effects, 38–40†
in foods, 29–35†
and bisulfites, 32–33†
effects of atmospheric oxygen, 34†
effects of humectants, 32†
effects of initial reactant species, 30†
effects of packaging, 34–35†
effect of pH, 30–31†
effect of temperature, 33–34†
effects of water, 31–32†
nutritional and physiologic effects of, 38–40†
research on, 29†
between free amino acids and sugars
effects on rats, 24–25†
and hydroxymethyl furfural
physiologic effects, 27
in vivo as aging process, 27†
kinetics, 23†
maltol
physiologic effects, 27†
measurement methods, 30†
mutagenicity studies of, 43–45†
physiologic effects, 26–27†
between proteins and sugars, 25†
effects in rats, 25–26†
pyrazines
physiologic effects, 27†
pyrroles
physiologic effects, 27†
reductones and dehydroreductones
physiologic effects, 27†
stages of, 22–23†, 29†, 37–38†
terminology, 23†
toxicologic and antinutritional effects, 40†, 42–43†
toxicologic studies, 24†

MAJOR HISTOCOMPATIBILITY COMPLEX, *See also* Antigens
and influence of passenger cell removal from skin and parathyroid allografts, 60–61‡
islet cell transplantation across
and total lymphoid irradiation, 63–67‡
rat fetal pancreas transplantation across
and total lymphoid irradiation, 69–74‡, 75–77
specific markers of
and genetic admixture as determinant of increased insulin-dependent

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

diabetes, incidence in U.S. blacks, 532–536

MALTOL
physiologic effects, 27†

MATHEMATICAL MODELS
of cyclic AMP and calcium ion interactions in pancreatic islets, 170–176

MELANOIDINS. *See also* Premelanoidins
defined, 23†

MENSTRUAL CYCLE
and estrus-induced temporary diabetes in dogs, 27*
of Macaque species, 37*

METABOLIC CLEARANCE RATES
effect of variations in basal plasma glucose concentration in non-insulin-dependent diabetics, 396–399
and estimation of insulin secretion rate from urinary C-peptide excretion rates, 449–453

METABOLISM
acetone
in diabetic keotacidosis, 242–248
adaptation to exercise
in diabetics with autonomic neuropathy, 732–733
and alloxan, 47*
branched chain amino acids as source of alanine nitrogen in man, 86–89
carbohydrate, *see* Carbohydrate metabolism
cholesterol and plasma triglycerides
in nonketotic diabetes mellitus, 903–909
chylomicron
in diabetics, 905–906
of cyclosporin and conventionally treated pancreas transplantation patients, 102–105‡
of diabetes (db) mouse, 4*
and effects of browning products on rats, 24–26†
and effects of hypoglycemia on brain function, 482
fructose
in fasted humans, kidneys and, 516–520
glucose
in diabetic Chinese hamsters, 18*
glucose homeostasis in insulin-dependent diabetics with artificial B-cell therapy, 46–52
^{35}S-glycosaminoglycan and ^{35}S-glycopeptide
by glomeruli and aorta isolated from streptozotocin-diabetic rats, 418–424
of glycosylated low-density lipoproteins, 283–290
insulin
in cultured bovine aortic endothelial cells, 1077–1082
and insulin-dependent diabetes development, 45*
insulin and glucose
correlations with glycosylated hemoglobin A_{1c} in nondiabetic, borderline diabetic, and diabetic monkeys, 1105–1107
*myo*inositol
and diabetic neuropathy, 358
of New Zealand obese (NZO) mouse, 24*
prostaglandin
and diabetic nephropathy in animal models, 75–76*
of protein-bound premelanoidins, 25†
of pure Maillard substances, 26–27†
response to hypoglycemia
in diabetics with autonomic neuropathy, 734–735
skin collagen
in streptozotocin-diabetic rats, 426–430
and spontaneously diabetic nonobese animal models, 48–50*
and spontaneously diabetic obese animal models, 50–51*
and weight maintenance in obese mouse, 3*

METHACRYLATE CORROSION CASTS
and microvasculature of islets of Langerhans in rat, 883–888

3-O-METHYL-D-GLUCOSE
transport in isolated pancreatic acini from streptozotocin diabetic mice
insulin and, 674–681

3-O-METHYL GLUCOSE
uptake
in non-insulin-dependent diabetics and role of glucose transport in postreceptor defect of, 1016–1021

METHYL-PREDNISOLONE
and cyclosporin A in kidney transplantation patients, 99‡

MICE
adult and fetal cultured islet cell transplantation in
and reversal of diabetes, 32–37‡
allografted
establishment and induction of tolerance in, 36–37‡
athymic nude BALB/c
spontaneous hyperglycemia and impaired glucose tolerance in, 821–824
Coxsackie B virus-induced glucose abnormalities in, 496–499
diabetes-obesity syndromes in
and mutations, 1–2*
diabetic
2-tetradecylglycidate and prevention of nephropathy in, 12–17
with experimental insulitis and hyperglycemia
and intrasplenic islet cell transplantation, 78–82‡, 83‡
fetal pancreas
insulin content in organ culture and after transplantation, 826–829
fetal pancreatic islets for allotransplantation, 39–46‡
gene mutations in breeding experiments, 1–2
genetic mapping in, 46*
genetically diabetic
acarbose inhibition of α-glycosidase and nephropathy in, 249–253
alterations in basement membrane proteoglycan in, 185–188
dehydroepiandrosterone effects in, 830–833
genetically susceptible to diabetes
streptozotocin treatment in, and lethal irradiation and splenic lymphocytes, 808–814
glucosylated low-density lipoprotein metabolism in peritoneal macrophages, 286–287
H-2 antigens and pancreatic B-cells islet cell transplantation, 1–8
induction of streptozotocin diabetes in
estrogens and androgens and, 724–729
islet cell transplantation of cultured allogeneic islets
reversal of hyperglycemia by, 55–59‡
islet cell transplantation without immunosuppression
and pretreatment of islets, 11–13‡, 15–16‡
KK, 25*
models for diabetes-obesity research, 2–6*
advantages and disadvantages of, 5–6*
diabetes (db) mouse, 3–4*
differences in symptoms, 2–3*
effects of inbred background, 4–5*
identification and maintenance of specific mutations in, 6*
obese (ob) mouse, 3*
New Zealand obese (NZO), 24–25*
autoimmune disorders in, 24–25*
spontaneous diabetes, 51*
nonobese diabetic (NOD), 24*, 50*

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

effects of large-dose nicotinamide injections on, 749–753
obese
and diabetic neuropathy research, 66–67*
obese db/db
macrovascular disease research in, 56*
obese hyperglycemic
pancreatic content of insulins I and II in, 843
obese KK
macrovascular disease research in, 56*
obese ob/ob
islet beta-cells, 52*
macrovascular disease research in, 55–56*
obese ob/ob and db/db
spontaneous diabetes in, 50–51*
organ cultured fetal pancreas
islet cell transplantation with, 35–37†
pancreatic content of insulins I and II, 841–845
perifused islets of Langerhans
membrane potentials in response to alpha-adrenergic stimulation, 985–989
skin allografting in
effects of passenger cell removal, 60–61‡
spiny
spontaneous diabetes in, 51*
streptozotocin diabetic
insulin regulation of sugar transport in isolated pancreatic acini from, 674–681
and virus-induced diabetes, 46*

MICROANGIOPATHY
and blood glucose control in maturity-onset diabetics, 3‡
end-stage
and meticulous diabetic management, 479–480
and impaired phagocytic function and increased immune complexes, 7–11
and liver perisinusoidal space ultrastructural studies
in diabetics, 1061–1066

MICRODENSITOMETRY
and retinal vascular system reactivity to norepinephrine and angiotensin II
in diabetics and nondiabetics, 1056–1060

MICROSCOPY
and axonal dystrophy in autonomic neuropathy in rats, 762–768
of cultured mouse islet tissue, 33‡
development of, 538
and effect of insulin or chlorpropamide on hyperglycemia-induced islet changes in rats, 320–324
electron
and atherosclerosis in animal models, 55–60*
of covalently bound ^{125}I-photoreactive insulin incubated with isolated rat hapatocytes, 659–662
and DR localization in human islets of Langerhans, 20–21‡
freeze-fracture vs. thin section, 542, 544–545
of freshly isolated and cultured rat pancreatic islets, 49–52‡
and H-2 antigens on pancreatic B-cells, 3‡
of pancreatic islets of diabetic and normal BB rats, 9*
of pancreatic islets of spontaneously diabetic Chinese hamsters, 19–20*
of rat islet B-cells sorted by cytometry, 940–943
of sciatic nerves from alloxan diabetic rats, 68*
of sorted islets of Langerhans endocrine cells, 304
electron immunocytochemistry
and localization of DR antigen in human islets of Langerhans, 19–20‡
of endocrine pancreas, 538–563
of human fetal cryopreserved pancreas sections
insulin secretion studies and, 240
of human fetal pancreas tissue
and HLA-DR antigens, 24–26‡
of infarcted spinal ventral roots of spontaneously diabetic rats with proximal motor neuropathy, 785–788
of intrasplenic transplants of allogenic islets, 58‡
of islets isolated by new method, 110‡, 111‡
light
and DR localization in human islets of Langerhans, 20‡
of fetal pancreatic islets, 40–45‡
of intrasplenic syngeneic islets implanted into streptozotocin-diabetic mice, 81‡
of kidneys of diabetic mice after acarbose inhibition of α-glycosidase, 250, 252–253
of pancreatic islets of streptozotocin-diabetic mice, 80‡
of liver perisinusoidal space
in diabetics with and without microangiopathy, 1061–1066
of normal and streptozotocin diabetic rat liver
colloidal carbon administration and, 115
scanning electron
of methacrylate corrosion casts of islets of Langerhans microvasculature in rat, 885–888

MICROVASCULAR DISEASE
in insulin-dependent diabetics
genetic and immunologic factors in, 70–73

MINERALS
metabolism
and premelanoidins in rats, 25

MIXED LYMPHOCYTE REACTION
as delayed-type hypersensitivity reaction, 90–91‡
and epidermal Langerhans cells, 23‡
and immunosuppressive effect of total lymphoid irradiation, 77‡
and islet cell allografting, 45–46‡
and islet graft maintenance or rejection in mice, 13‡
and removal of passenger cells from skin and parathyroid allografts in rats and mice, 61‡

MONKEYS. *See also* Macaca; Non-human primates
alloxan diabetic
and cardiomyopathy, 61*
and atherosclerosis research, 58–60*
and diabetes etiology research, 45–46*
Macaca nigra
hemoglobin A_{1c} and metabolic status in nondiabetic, borderline diabetic and diabetic, 1105–1107
nonobese spontaneous diabetes in, 50*

MONOCYTES
insulin binding to
and chlorpropamide in insulin-dependent diabetics, 890–895
insulin receptor binding
and growth hormone infusion, 665
insulin receptor occupancy
and biologic response to insulin, 665–667

MORTALITY
and cardiovascular complications in diabetics, 54*
of diabetes (db) mouse, 3*
in diabetic Chinese hamsters, 55*
and diabetic ketoacidosis
and animal studies, *v**
and diabetic nonhuman primates, 39*
and hypoglycemia in diabetic dogs, 28*
and streptozotocin- or alloxan-induced diabetes in dogs, 27*
in study of diabetes risk among relatives of insulin-dependent diabetics, 138

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96	Supplement 1, 1–102	July, 573–662	October, 841–938
February, 97–188	May, 375–478	August, 663–742	November, 939–1033
March, 189–282	June, 479–572	Supplement 4, 1–120	Supplement 5, 1–81
April, 283–374	Supplement 3, 1–82	September, 743–840	December, 1035–1180

unexplained
and diabetic autonomic neuropathy, 609–613
in UGDP, 1–25§
by blood glucose control, 14§
by cause of death in phenformin treatment group, 29§
by cause of death in tolbutamide treatment group, 30§
at closeout and follow-up after closeout, 31§
and Cox regression analysis, 13§, 77§
cumulative annual death rates, 11§
after discontinuation of phenformin therapy, 28§
after discontinuation of tolbutamide therapy, 28§
and follow-up after closeout examinations, 28–29§
and high adherence, 13–14§
life tables, 72–76§
by number and percent dead by cause of death, 10–11§
percent dead by selected baseline characteristics, 11–13§
since closeout examination by patient characteristics, 42–43§, 46–47§, 50–51§
and untreated diabetes in dogs, 28*

MOTOR NERVE CONDUCTION VELOCITY
in diabetic rats
effect of aldose reductase inhibition on, 789–793

MUCORMYCOSIS
susceptibility to in diabetic ketoacidosis
transferrin and iron availability and, 1109–1113

MULTIPLE SCLEROSIS
in families of children with insulin-dependent diabetes, 294

MULTIPLICATION STIMULATING ACTIVITY
and stimulation of islet B-cell replication in neonatal rat pancreatic cultures, 160–164

MUSCLE
capillary basement membrane thickening
in Yucatan miniature swine, 32*, 33*
diaphragm palmitate oxidation in diabetic mice
2-tetradecylglycidate and, 13, 14
extensor, from alloxan diabetic rats
contractile and electrical characteristics of, 194–201
glucose uptake and exercise
and chromium excretion, 212–215
insulin-like activity
and inhibitor in diabetic rat serum, 99–100, 101–103
mitochondrial enzymes
and physical training of diabetics, 1044–1049
rat skeletal
ornithine decarboxylase regulation by insulin-dependent serum factor in, 500–504
rat soleus
and effects of high fat diet on insulin binding, glucose transport, and glucose metabolism in, 232–237
insulin-stimulated sugar transport by, and Ca^{2+}-dependent ionophore A23187, 846–849

MUTAGENIC EFFECTS
of glucose-amino acid browning products in rats, 25†
of Maillard browned proteins, 43–45†
of maltol, 27†
and protein-sugar browning products, 26†
of triose reductone, 27†

MUTAGENS. *See also* Mutagenic effects
and diabetes obesity syndromes in mice, 2*

MUTATIONS
and diabetes (db) mouse, 3–4*
and diabetes-obesity syndromes in mice, 5*
fatty Zucker rat, 25*
in mice
and effects of inbred background, 4–5*
identification and maintenance of in mice, 6*
and obese (ob) mouse, 3*
spontaneous and mutagen-induced in mice, 1–2

MYOCARDIAL DISEASE
in animal models, 60–61*

MYOCARDIAL INFARCTION
and atherogenesis in diabetics, 54*
as cause of death in UGDP
and patient baseline characteristics, 42–51§
in tolbutamide treatment group, 30§
in phenformin treatment group, 29§

MYOINOSITOL
metabolism
and diabetic neuropathy, 358
in nerve axons of diabetics, 66*
and sciatic and tibial motor nerve conduction parameters
in streptozotocin-diabetic rats, 573–578

MYOSIN
phosphorylation by pancreas islets
calcium and calmodulin and, 566–569

MYOSIN LIGHT CHAIN KINASE
and insulin secretion, 566–569

N

NALOXONE
-induced opiate receptor blockade
and impaired insulin secretion in diabetics, 367–370

NATIONAL INSTITUTE OF ARTHRITIS, METABOLISM, AND DIGESTIVE DISEASES
liaison officers to University Group Diabetes Program, vii§

NEPHROPATHY
and blood glucose control in maturity-onset diabetics, 3‡
and diabetes control, 480
and diabetes in humans and animal models, 71–78*
in diabetic mice
2-tetradecylglycidate prevention of, 12–17
in genetically diabetic mice
acarbose inhibition of α-glycosidase and, 249–253
and ^{35}S-glycosaminoglycan and ^{35}S-glycopeptide metabolism by glomeruli and aorta from streptozotocin diabetic rats, 418–424
physiology of, 74–76*

NEPHROTOXICITY
and cyclosporin A immunosuppression in kidney transplantation patients, 99‡

NERVES
"axonal dwindling," 68*
sciatic
in alloxan diabetic rats, 68*

NERVOUS SYSTEM. *See also* Animal models, and diabetic neuropathy research
autonomic
of spontaneously diabetic Chinese hamster, 20*
axonal dystrophy
and diabetic autonomic neuropathy in rats, 761–770
and diabetic neuropathy, 66*
motor nerve conduction velocity
in diabetic rats, effect of aldose reductase inhibition on, 789–793
and effects of *myo*-inositol on sciatic and tibial motor nerves, 573–578
in spontaneously diabetic BB rat, 12*

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

parasympathetic
and heart rate and RR variation in diabetics and normal su'jects, 339–344
pathology
and diabetic neuropathy, 65–66*
peripheral
in streptozotocin diabetic rats, 357
proximal motor neuropathy
in spontaneously diabetic rats, 784–788
slow axonal transport velocity in streptozotocin-diabetic rats
insulin treatment and, 689–693
sympathetic
in diabetes (db) mouse, 4*

NEUROPATHY, DIABETIC
and abnormal *myo*inositol metabolism, 358
in animal models, 66–70*
chemically and nutritionally induced diabetes, 67–69*
genetic, 66–67*
recommendations on, 69–70*
autonomic
in diabetic Chinese hamsters, 55*
and exercise, 730–733
cardiovascular, hormonal, and metabolic studies of, 730–736
and hypoglycemia, 734–735
and postural changes, 733–735
in streptozotocin-diabetic rats, axonal dystrophy in, 761–770
symptoms and signs, 65*
and ventilatory responses to progressive hypoxemia and hypercarbia, 609–613
and axonal transport abnormalities, 358–360
axonopathy of, 356–361
animal models and, 356–357
diagnosis, 65–66*
incidence of, 65*
and increased water content of nerves, 358
motor symptoms and signs, 65*
nerve cell body changes in, 360
pathogenesis of, 357–358
peripheral
classification of syndromes in, 65*, 66*
in rats
and proximal motor nerves, 784–788
and retrograde axonal transport abnormalities
protein synthesis and, 160–161
sensory symptoms and signs, 65*
and spontaneously diabetic BB rat as model for, 12*

NICOTINAMIDE
injections in nonobese diabetic mice, effects on diabetes associated with insulitis, 749–753

NIGERIA
HLA antigen distribution among black diabetics in, 1119–1122

NINHYDRIN
and assays of chemical and nutritionally available lysine, 11†, 12†

NITROGEN
digestibility in rats
and protein-sugar Maillard products, 25–26†
utilization by rats
and amino-acid glucose browning products, 24–25†

NONENZYMATIC GLYCOSYLATION
and browning products, *see* Maillard nonenzymatic browning reactions
and carbohydrate and protein structure, 1–3†
in diabetes, 15†
in diabetes and aging
and cataract formation, 57–62†
discovery of, 1†
effects of, 2–3
effects on biologic properties, 3†
of erythrocyte spectrin in diabetics, 64–68†
and formation of Amadori products, 58–60†
of high-density lipoprotein
in guinea pigs, 1029–1032
of human collagen
and diabetes, 47–51†
of low-density lipoprotein
biologic activity and, 283–290
lysine content as index of, 5–12†
and serum and plasma proteins, 52–56†
and diabetes complications, 55–56†
glycemic control and, 53–55†
inhibition of glycosylation with aspirin, 55†
measurement of, 52–53†

NONHUMAN PRIMATE MODELS OF HUMAN DIABETES
advantages and disadvantages of, 40*
and diabetes management problems, 41*
hyperglycemia defined in, 37*
and hypothalamic lesions and induced diabetes in, 40*
and induced diabetes, 39–40*
Macaca fascicularis, 38*
Mucaca mulatta, 38–39*
Macaca nigra, 37–38*
Macaca radiata, 38*
maintenance of, 40–41*
and pancreatectomy for diabetes induction in, 40*
Saimiri sciureus, 39*
sources and availability, 38*, 39–40*
species characteristics compared with humans, 37*
spontaneous diabetes in, 37–39*

NOREPINEPHRINE
retinal vascular reactivity to
in diabetics and nondiabetics with and without retinopathy, 1056–1060
transport
in diabetes (db) mouse, 4*

NUTRITION. *See also* Nutritional animal models
and diabetes prevention or delay in spontaneously diabetic Chinese hamsters, 21*
and effects of nonenzymatic Maillard browning, 25–26†, 37–45†
and effects of pure Maillard substances, 26–27†
and "reactive" lysine content of protein, 5–12†
and spontaneously diabetic Chinese hamsters, 19*
and streptozotocin effects in animals, 47*

NUTRITIONAL ANIMAL MODELS
and diabetic neuropathy research, 68–69*

O

OBESITY
in animal models, 25*
and animal models of spontaneous diabetes, 50–51*
and diabetes
and autoimmunity, 24–25*
and estimation of insulin secretion rate from urinary C-peptide excretion rate, 449–453
and glucose-induced thermogenesis in diabetics and nondiabetics, 1023–1028
and HLA antigens
in insulin-dependent, maturity-onset diabetics, 122–125
and hypothalamic lesions
diabetes induction in nonhuman primates and, 40*
and insulin and glucagon release from cultured neonatal pancreatic islets from rats, 944–946

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

and insulin resistance in Pima Indians and Caucasians compared, 952–956
and insulin secretion
in Yucatan miniature swine, 33*
and insulin secretion in non-insulin-dependent diabetics, 382–387
in mouse models for diabetes-obesity research, 2–6*, 24*, 25*
and spontaneous diabetes in nonhuman primates, 38–39*
and spontaneous idiopathic diabetes in dogs, 27*
in Yucatan miniature swine, 34*

OCTODON DEGUS. *See* Degu

OCULAR FLUOROPHOTOMETRY
in insulin-dependent diabetics
metabolic control and reversal of abnormalities in, 80–84

OPIATE RECEPTORS
and impaired insulin secretion in diabetics, 367–370

ORAL HYPOGLYCEMIC AGENTS. *See also* Phenformin; Tolbutamide
in UGDP
discontinuation of, 24–25§

ORGAN CULTURE
and allograft survival, 11–12‡
of fetal islet cells
reversal of diabetes and, 35–37‡
of fetal mouse and human pancreatic islets
and allografting, 39–46‡
and immunogenicity of thyroid tissues, 31–32‡

ORNITHINE DECARBOXYLASE
in rat skeletal muscle
insulin-dependent serum factor and regulation of, 500–504

OXYGEN
atmospheric
and Maillard reaction in foods, 34–35†
and organ culture of fetal mouse and fetal human pancreatic islets for allografting, 39–46‡
and pretreatment of islet cells transplantation without immunosuppression and, 11–13‡, 15–16‡

OXYTETRACYCLINE
treatment
and insulin response in diabetic rats, 53–59

P

PALMITATE
oxidation in diaphragm muscle of diabetic mice
2-tetradecylglycidate and, 13, 14

PANCREAS. *See also* Artificial pancreas
acini from streptozotocin diabetic mice
insulin regulation of sugar transport in, 674–681
alpha, beta, and delta cells
in spontaneously diabetic BB Wistar rats, 50*
autoimmune destruction of beta cells
in BB rats, 9–12*
B-cell function
and development of hyperglycemia during stress, 802–807
beef and pig
new method for isolation of islets from, 109–111‡
beta-cell changes
in spontaneously diabetic Chinese hamsters, 21*
beta-cell dysfunction
in nondiabetic HLA identical siblings of insulin-dependent diabetics, 149–153
beta-cell proliferation and degeneration
diet and, 51–52*
beta cells
and chemical agents, 47–48*
communication with neighboring cells, 561–563
and Coxsackie B virus infection in mice, 496–499
and diabetes following pentamidine-induced hypoglycemia, 40–45
preferential lysis by islet cell surface antibodies, 459–462
subcellular organization and insulin biosynthesis and release, 539–553
susceptibility to viruses, toxins, and autoimmune mechanisms, 45*
and virus-induced diabetes in mice, 46*
cytoplasmic islet cell antibodies, HLA antigens, and carbohydrate tolerance
in families of children with insulin-dependent diabetes, 292–297
dissociated islet cell studies
and superfusion method of attachment to cytodex beads, 189–192
endocrine
structure and function correlations, 538–565
endocrine cell content
in diabetic and nondiabetic subjects, 694–699
fetal
changes in culture, 40–42‡
and culture in high concentrations of oxygen, 42‡
morphology of, 40‡
fetal bovine
glycoprotein-like large glucagon immunoreactive species in extracts of, 1002–1005
fetal mouse
insulin content in organ culture and after transplantation, 826–829
fetal rat B-cells
role of glucose in in vitro regulation of cell cycle kinetics and proliferation of, 754–759
hormonal and metabolic responses to chronic administration of sodium 2 chlorpropionate
in normal and alloxan diabetic dogs, 484–488
human endocrine
sampling and microscopy techniques, 558–560
human fetal
cryopreservation and preservation of morphology, insulin biosynthesis, and insulin release by, 238–240
HLA-DR antigens in, 23–27‡, 29‡
human and rat islets
selective binding of fluoresceinated-avidin to A-cells in, 107–109
hyperglycemia-induced islet changes in rats
insulin or chlorpropamide therapy and, 319–324
hypoplasia of islets or B-cells
in spontaneously idiopathic diabetes in dogs, 27*
insulin
and islet cell transplantation and H-2 antigens study in mice, 6‡
insulin action
in vivo deactivation in man, 929–935
insulin and glucagon
in inbred Chinese hamsters, 15–16*
insulins I and II
in mice and rats, 841–845
islet B-cell replication
stimulation by insulin and multiplication stimulating activity, in neonatal rat pancreatic cultures, 160–164
islet B-cells
glucose-induced electrical activity in, anion transport and, 653–655
islet-cell antibodies
in insulin-dependent diabetics and first-degree relatives, 585–588
islet-cell surface antibodies
in spontaneously diabetic rats, 278–280
islet cells

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

sorting of subpopulations by light scattering, 299–305
islet degranulation
in spontaneously diabetic Chinese hamsters, 21*
islet-enriched fractions, isolation of, 17‡
islet morphology
in BB spontaneously diabetic rat, 9*
islets
animal models as donors of, 52*
calcium-calmodulin-dependent myosin phosphorylation by, 566–569
cyclic AMP and calcium^{2+} interactions in, mathematical modeling of, 170–176
increases in number and size of, in KK mouse, 25*
somatostatin receptor migration kinetics in, 467–469
of spontaneously diabetic Chinese hamsters, 19–20*
and streptozotocin, 48*
and streptozotocin infusion in nonhuman primates, 39*
isolated perfused dog
inhibition of glucagon secretion by exogenous glucagon in, 512–514
isolated rat islets
diazoxide and D600 and insulin release inhibition studies in, 776–782
isolated rat islets
phenytoin-induced insulin release and calcium^{2+} fluxes in, 265–269
microscopy studies of, 538–563
mouse B-cell transplantation
and H-2 antigens, 1–8, 9–10
neonatal islets transplantation in rats
and normal responses to stress, epinephrine, and cortisol, 856–861
of prediabetic and diabetic Chinese hamsters, 17*
rat
insulin production, prostacyclin and, 454–457
rat B-cells
cellular environment of, 553–558
sorting by light-scatter flow cytometry, 939–943
gliclazide-induced calcium^{2+} influx into, 1010–1015
and vincristine inhibition of glucose-induced insulin release, 834–836
rat islet cell tumor
cultured and cloned cells from, insulin, glucagon, and somatostatin receptors on, 521–530
rat islets
glucose-induced accumulation of fructose-2,6-biphosphate in, 90–92
from lean and obese rats, insulin and glucagon release from, 944–946
somatostatin
in diabetic Chinese hamsters, 18*
somatostatin and glucagon secretion in rats
effects of synthetic human and bovine pancreatic polypeptides and C-terminal hexapeptide on, 178–180
from streptozotocin diabetic and normal dogs
β-hydroxybutyrate and somatostatin release from, 270–274

PANCREAS TRANSPLANTATION
in humans
and cyclosporin A immunosuppression, 100–106‡
rat fetal
and total lymphoid irradiation, 69–74‡
in rats
and cyclosporin A immuno-suppression, 95–96‡, 98‡
report of International Human Pancreas and Islet Transplantation Registry through 1981 on, 112–115‡
trapping peripheral blood lymphocytes in
in acute-onset insulin-dependent diabetics, 463–465

PANCREATECTOMY
-induced diabetes in dogs, 27*
-induced diabetes in monkeys, 60*
in nonhuman primates, 40*
pancreatogenic diabetes secondary to insulin sensitivity, binding, and kinetics in, 346–354
partial, in rats
and effect of insulin or chlorpropamide on hyperglycemia-induced islet changes, 319–324

PANCREATITIS
and pancreatogenic diabetes
insulin sensitivity, binding, and kinetics in, 346–354
and spontaneous idiopathic diabetes in dogs, 27*

PARATHYROID ALLOGRAFTS
in rats
and effects of passenger cell removal, 60–61‡

S⁻ PARENCHYMAL CELLS
antigen-bearing
and response to tissue allograft, 31–32‡

PASSENGER LEUKOCYTES
and rejection phenomena, 16‡, 17‡, 23‡, 31–32‡
removal from skin and parathyroid allografts in mice and rats, 60–61‡

PASSENGER LYMPHOCYTES
and rat models of renal transplantation, 38‡
and rejection phenomena in thyroid allograft model, 11‡

PEMPHIGUS
in families of children with insulin-dependent diabetes, 294–295

PENTAMIDINE
-induced hypoglycemia
diabetes mellitus following, 40–45

PEPSTATIN A
in skin collagen metabolism studies in streptozotocin-diabetic rats, 426–430

C-PEPTIDE
urinary excretion rate in obese and diabetic subjects
estimation of insulin secretion rate from, 449–453

PERITONEAL ACCESS DEVICE
and insulin infusion in diabetics nonresponsive to subcutaneous insulin, 470–473

PEROXIDASE-ANTIPEROXIDASE STAINING
and localization of HLA-DR antigens, 18–19‡

pH
and anion exchange
and regulation of electrical activity in pancreas islet B-cells, 653–655
effects on Maillard reaction in foods, 30–31†

PHAGOCYTES
impaired function
in diabetics with severe microangiopathy, 7–11

PHENFORMIN
in UGDP study, 23§
discontinuation of mortality results after, 28§
mortality by cause of death, 29§

PHENTOLAMINE
and assessment of sympathetic and parasympathetic nervous systems
in respiration cardiac reflex in diabetic and non-diabetic subjects, 341–344

PHENYLGUANIDINE
and insulin action, 976–983

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

PHENYLHYDRAZINE
and assays for Amadori compounds, 58†

PHENYTOIN
inhibition of insulin release, 265–269

PHOSPHOLIPIDS
in diabetic nerves, 66*

PHOSPHORYLATION
myosin, by pancreas islets
calcium and calmodulin and, 566–569

PHOTOAFFINITY LABELING
of insulin receptors in cultured human lymphocytes, 410–416

PHOTOCOAGULATION
and proliferative diabetic retinopathy, 83*
and retinopathy studies in animal models, 86–87*
in UGDP follow-up eye examinations, 18§

PIGS. *See also* Yucatan miniature swine
aortic endothelial cells
in vitro injury by very-low-density lipoproteins from diabetic rat serum, 593–598
development of cardiovascular lesions by, 34*

PIMA INDIANS
nondiabetic
insulin resistance in, compared with Caucasians, 952–956

PITTSBURGH, PA.
diabetes risk study among relatives of insulin-dependent diabetics, 136–143

pKa VALUES
of amino groups
rate of nonenzymatic glycosylation of proteins and, 2–3†

PLACENTA
insulin impermeability, 92*

PLASMA
alanine levels
and sodium dichloroacetate in dogs, 328
basal glucagon
in spontaneously diabetic dogs, 28*
catecholamine and growth hormone responses
during insulin-induced hypoglycemia in type 1 diabetics, 641–646
catecholamines
and exercise in diabetics with autonomic neuropathy, 731
epinephrine and glucagon
during insulin-induced hypoglycemia in type 1 diabetics, 641–646
epinephrine and norepinephrine
and sodium dichloroacetate in dogs, 329–330
free fatty acids
in 2-tetradecylglycidate-treated diabetic mice, 15
glucose
and diabetes onset in BB rat, 8–9*
in diabetic rats, oxytetracycline treatment and, 53–59
and glycosylated hemoglobin, 71†, 75†
response to test meal, in glipizide treated non-insulin-dependent diabetics, 307–311
glucose, fasting
and glucose production rate, in untreated non-insulin-dependent diabetes, 333
glucose, insulin, and glucagon
postprandial in alloxan-diabetic dogs, portal and peripheral venous insulin infusions and, 581
and streptozotocin administration in dogs, 271
glucose appearance, oxidation, and recycling
in healthy elderly and young subjects, 203–210
glucose clearance
influence of plasma glucose and insulin concentration on, 683–687
glucose concentration
effects of variations on glucose utilization and metabolic clearance rates in non-insulin-dependent diabetics, 396–399
glucose and glucagon
and pulsatile, synchronous basal insulin and glucagon secretion in man, 22–26
glucose and insulin levels
in athymic nude BALB/c mice, 822, 823
after glucose and insulin injection in HLA-identical nondiabetic siblings of insulin-dependent diabetics, 151–153
glucose levels
in anti-rat lymphocyte serum-treated spontaneously diabetic BB rats, 10*
and immunoreactive insulin and glucagon responses in diabetics and nondiabetics, 489–494
and insulin responses to nonglucose stimuli during tolbutamide infusion in non-insulin-dependent diabetics, 154–158
glucosylated low-density lipoproteins in diabetes mellitus and, 288–289
growth hormone, glucose and insulin and glucose infusion rates, 665
insulin
of Chinese hamsters, 17*
in diabetes (db) mouse, 3*
insulin, glucose, and ketone bodies
and insulin action in fat cells from insulin-dependent diabetics, 709
insulin, infusion of unlabeled glucose and
in healthy young and elderly subjects, 206–208
insulin clearance rates
in pancreatogenic and type I diabetics, 352, 353
insulin and glucagon
in inbred Chinese hamsters, 15–16*
insulin levels
normal in non-insulin-dependent diabetics, insulin resistance and, 911–916
insulin removal rate from
aging and, 670–673
ketone-body concentrations
in diabetic ketoacidosis, 244, 245
ketones
in ketoacidotic diabetic dogs and humans, 28*
lactate and alanine in alloxan diabetic dogs
portal and peripheral venous insulin infusions and, 581–582
lipids
in diabetic Chinese hamsters, 55*
in diabetic rats, 56*
in obese mice, 55–56*
progesterone
and estrus-induced temporary diabetes in dogs, 28*
prostaglandin levels
in rats with diabetes mellitus and diabetic ketoacidosis, 994–1000
proteins
nonenzymatic glycosylation of, 52–56†
renin activity
and diabetic nephropathy in animal models, 75*
and postural changes in diabetics with autonomic neuropathy, 734
somatostatin, glucagon and insulin levels
and chronic administration of sodium 2 chlorpropionate in alloxan diabetic and normal dogs, 486–487
somatostatin, 28
evidence for presence of, 474–476
triglycerides
metabolism in nonketotic diabetes, 903–909
volume

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

and exercise in diabetics with autonomic neuropathy, 732

PNEUMOCYSTIS CARINII PNEUMONITIS
and diabetes following pentamidine-induced hypoglycemia, 40–45

PNEUMONIA
as cause of death in UGDP
patient baseline characteristics and, 42–51§

POLY ADP-RIBOSE POLYMERASE
and streptozotocin, 47*

POLYMERIZATION
in Maillard reaction scheme, 23†, 29†
restriction fragment length, of insulin gene in diabetics, 275–277

POLYOL PATHWAY
and diabetic neuropathy, 66*
and excess galactose feeding model, 68*

POLYPEPTIDES, PANCREATIC
in endocrine cells of nondiabetics and diabetics, 695–699
synthetic human and bovine
effects on pancreatic somatostatin and glucagon secretion in rats, 178–180

POLYURIA
in nonobese diabetic mouse (NOD), 24*

PORTAL VEIN
glucose infusion and gut glucose absorption study, 27–34

POTASSIUM
and calcium efflux and insulin release from rat islet B-cells, 1011

PREBETALIPOPROTEINS
levels
hypothalamic lesions in nonhuman primates, 38*, 40*

PREDIABETES
in Chinese hamsters, 15*
and hyperphagia, 19*
in dogs, 28*
and spontaneously diabetic Chinese hamster, 49*

PREDNISONE
and cyclosporin A immunosuppression, 93‡
and heart allografts in rats, 94–95‡
in kidney transplantation patients, 99‡
in pancreas transplantation patients, 100–101‡

PREGNANCY
and diabetes development in nonhuman primates, 40*
and hypertriglyceridemia, 1092–1096
in nonhuman primates compared with humans, 37*
and pancreatic content of insulins I and II
in rats, 843–844
in Yucatan miniature swine, 31*

PREGNANCY, DIABETIC
and animal models, 90–94*
and fetal lung development, 90–91*
and hypertriglyceridemia
insulin-dependent, non-insulin-dependent, and gestational diabetes compared, 1092–1096
in rats
glucose tolerance and insulin response in, 75–78
and insulin therapy and prevention of congenital malformations in offspring, 1–6

PREMELANOIDINS
glucose-amino acid
metabolic transit in rats, 24†
and liver and kidney alterations in rats, 24–25†
protein-sugar
metabolic transit in rats, 25†

PROBAND EXCLUSION METHOD
in family study of diabetes risk to relatives of insulin-dependent diabetics, 140–143

PROGESTERONE
and estrus-induced temporary diabetes in dogs, 27*

PROINSULIN
-like material
produced by human insulinoma hybrids, 1035–1040
mRNA in rats
effects of glucose on, insulin biosynthesis and, 624–628

PROLINE
metabolism
in mutant mouse, 2*

^{3}H-PROLINE
and effect of insulin on slow axonal transport velocity of sciatic nerve in streptozotocin-diabetic rats, 689–693

PROPORTIONAL HAZARDS MODEL, 77‡

PROPRANOLOL
and assessment of sympathetic and parasympathetic nervous systems in respiration cardiac reflex in diabetic and nondiabetic subjects, 341–344
and regulation of serum potassium during insulin-induced hypoglycemia, 615–617
and role of beta adrenoreceptors in acute glucose counterregulation following insulin-induced hypoglycemia, 641–646
and suppression of endogenous insulin secretion
in insulin removal rate and age study, 670–673

PROSTACYCLIN
production
insulin and, in rats, 454–457
-thromboxane A_2 balance in streptozotocin diabetic rats
dietary vitamin E and, 947–950

PROSTAGLANDIN
-induced abortion
and cryopreservation of human fetal pancreas, 238–240
metabolism
and nephropathy in animal models, 75–76*
plasma levels
in rats with diabetes mellitus and diabetic ketoacidosis, 994–1000

PROTEASE
in diet supplementation after pancreatectomy in dogs, 27*
inhibitors
and insulin action, 976–983

PROTEIN
allergy to
and Maillard reaction, 26†
and axonal transport abnormalities in diabetic neuropathy, 359
in basement membrane of EHS tumors in normal and genetically diabetic mice, 185–188
browning products formation with sugars
effects in rats, 25–26†
cardiac synthesis of
and hyperglycemia, 61*
chemically available lysine content, as index of browning, 5–12†
cross-linking
and cataracts, 60–61†
nonenzymatic glycosylation of, *see* Nonenzymatic glycosylation
reactions with biologic aldehydes
in alcoholics, 15–20†
synthesis
and retrograde axonal transport in diabetes, 360–361

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

from tissues of spontaneously diabetic Chinese hamsters, 49*

PROTEIN EFFICIENCY RATIO
and Maillard browned foods, 39–40

^{125}I-PROTEIN A
and immunodetection of insulin in tissue extracts, 648–651

PROTEOGLYCAN
of basement membrane of EHS tumor in normal and genetically diabetic mice, 185–188
metabolism in diabetic kidneys, 424

PROTEOLYSIS
and catabolism of skin collagen in streptozotocin diabetic rats, 430
in rat gut
effects of glucose-amino acid browning products on, 24†

PUBERTY
and diabetes onset, 152
and diabetic retinopathy, 874–882

PULMONARY EMBOLISM
as cause of death in UGDP study patient baseline characteristics and, 42–51§

PULMONARY FUNCTION TESTS
and autonomic diabetic neuropathy, 609–613

PUPILLOGRAPHY
and diabetes duration, control, and long-term manifestations, 442–447

PUROMYCIN
and insulin regulation of sugar transport, 679

PYRAZINES
physiologic effects, 27†

Q

QUASI-ELECTRIC LASER LIGHT SCATTERING
and examination of insulin formulations, 364–366

R

RABBITS
alloxan diabetic
and fetal lung development, 91*
anti-human albumin antiserum
in agglutination test for urinary albumin in low concentration in diabetics, 973–975
diabetes and cardiomyopathy in, 61*
diabetic
and macrovascular disease research in, 58*

RACE
evidence for genetic admixture as determinant in occurrence of insulin-dependent diabetes in U.S. blacks vs. African blacks, 532–536
and HLA antigen distribution among Nigerian diabetics, 1119–1122
insulin resistance in nondiabetic Pima Indians and Caucasians, 952–956
and retinopathy in juvenile-onset type I diabetes of short duration, 874–882
in study of diabetes risk among relatives of insulin-dependent diabetics, 141
in UGDP
and cause of death, 42–43§, 46–47§, 50–51§
and mortality, 12§
of surviving patients, baseline characteristics and, 54–71§

RADIOCONTRAST STUDIES
of implanted subcutaneous peritoneal access device in diabetics, 472

RADIOIMMUNOBINDING ASSAYS
of cultured rat islets of Langerhans, 52‡

RATS
adipose cell
insulin resistance and high-fat low-carbohydrate feeding, intracellular glucose transport and, 589–591
alloxan diabetic
extensor muscle from, contractile and electrical characteristics of, 194–201
alloxan- and streptozotocin diabetic
macrovascular disease research in, 57*
and neuropathy research, 67–68*
BioBreeding (BB) model of spontaneous diabetes, 7–12*, 49–50*
anti-lymphocyte serum studies in, 9–10*
availability, 12*
compared with nonobese diabetic (NOD) mouse, 24*
diabetes complications in, 12*
diabetes onset in, 8–9*
as diabetic neuropathy model, 12*, 67*
diabetic symptoms, 8–9*
electron microscopic studies of pancreatic islets, 9*
epidemiology and genetics, 7–8*
gnotobiotic studies in, 9*
lymphocytic thyroiditis in, 11–12*
macrovascular disease research in, 56*
morphological studies, 9*
neonatal thymectomy studies in, 10–11*
and pancreatic islets transplantation, 84–88‡, 90–91
proximal motor neuropathy in, 784–788
Biobreeding/Worcester
autoantibodies in, 816–819
cultured hepatocytes
insulin-induced alterations in insulin binding and action in, 145–148
cultured islets of Langerhans allografts
and reduction of 1a antigen-bearing cells and prolongation of allograft survival, 48–54‡
with diabetes and diabetic ketoacidosis
plasma prostaglandin levels in, 994–1000
diabetic
cataracts in, 83*
oxytetracycline treatment and insulin response in, 53–59
diabetic and galactosemic
and cataract formation, 59–60†
and diabetic nephropathy
hypertension and, 72*
diabetic serum
inhibitor in, blunting of insulin-like activity by, 97–103
in vitro injury of porcine aortic endothelial cells by very-low-density lipoproteins from, 593–598
effect of diabetes mellitus on sterol synthesis, in 388–395
effects of browning products formed between free amino acids and sugars, 24–25†
fatty Zucker, 25*
and regulation of insulin binding by liver plasma membranes from, 867–872
fetal pancreas transplantation
and total lymphoid irradiation, 69–74‡
fetal pancreatic B-cells
role of glucose in in vitro regulation of cell cycle kinetics and proliferation of, 754–759
fetus
maturation of liver insulin metabolism in, 60–68
heart allografts in
and cyclosporin A immunosuppression, 93–95‡, 98‡

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

hepatocytes
internalization of insulin receptors in, 659–662
high fat diet in
and soleus muscle insulin binding, glucose transport, and glucose metabolism, 232–237
hyperglycemia and islet changes in insulin or chlorpropamide therapy and, 319–324
with immune insulitis
islet cell transplantation and neonatal bone marrow cell inoculation in, 84–88‡, 90–91
insulin-like growth factor II
cell-free synthesis of, 656–658
insulin and prostacyclin production interaction in, 454–457
insulin removal rate from plasma age and, 670–673
islet B-cells
gliclazide-induced calcium^{2+} influx into, 1010–1015
sorting by light-scatter flow cytometry, 939–943
islet cell allografts in
and cyclosporin A immunosuppression, 96–97‡, 98‡
islet cell transplantation across major histocompatibility barriers
and total lymphoid irradiation and allogeneic bone marrow cells infusion, 63–67‡
islet cell tumor cultured and cloned cells
insulin, glucagon, and somatostatin receptors on, 521–530
islets of Langerhans microvasculature study, 883–888
isolated adipocytes
biologic activity and labeling properties of photoreactive insulin derivatives in, 1068–1075
isolated perfused stomach
tolbutamide-stimulated gastric somatostatin release from, 119–121
lean and preobese Zucker
insulin and glucagon release from cultured neonatal pancreatic islets of, 944–946
lens capsule basement membrane synthesis
glucose stimulation in vitro of, 1084–1086
mild streptozotocin-diabetic
beneficial effects of physical training in, 406–409
neonatal, streptozotocin diabetes in
insulin treatment and spontaneous remission in, 165–169
neonatal dissociated pancreatic islet studies
and superfusion of dissociated A-, B-, and D-cells, 189–192
neonatal pancreatic monolayer cultures
insulin and multiplication stimulating activity stimulation of islet B-cell replication in, 160–164
obese spontaneously hypertensive
macrovascular disease research in, 56–57*
obese Zucker
macrovascular disease research in, 56*
pancreas allografts in
and cyclosporin A immunosuppression, 95–96‡, 98‡
pancreatic content of insulins I and II, 841–845
pancreatic islets
glucose-induced accumulation of fructose-2,6-biphosphate in, 90–92
phenytoin and calcium^{2+} and insulin release in, 265–269
selective binding of fluoresceinated-avidin to A-cells in, 107–109
somatostatin receptor migration kinetics in, 467–469
pancreatic somatostatin and glucagon secretion in
effects of synthetic human and bovine pancreatic polypeptides and C-terminal hexapeptide on, 178–180
parathyroid allografts in
effects of passenger cell removal, 60–61‡
plasma somatostatin, 28
evidence for presence of, 474–476
pregnant diabetic
insulin therapy and prevention of congenital malformations in offspring of, 1–6
skeletal muscle ornithine decarboxylase
insulin-dependent serum factor and regulation of, 500–504
soleus muscle
insulin-stimulated sugar transport by, and Ca^{2+}-dependent ionophore A23187, 846–849
spontaneously diabetic
and allogeneic islet transplantation, 34–35‡
autoantibody studies in, 313–317
islet cell surface antibodies and lymphocyte antibodies in, 278–280
neuropathy research in, 67*
streptozotocin diabetes and pregnancy in
glucose tolerance and insulin response and, 75–78
streptozotocin diabetic
autonomic neuropathy and axonal dystrophy in, 761–770
and calcium intake regulation of 1,25-dihydroxy-vitamin D formation, 401–405
and diabetic neuropathy studies, 357–359
and effect of aldose reductase inhibition on motor nerve conduction velocity, 789–793
and effect of insulin treatment on slow axonal transport velocity of sciatic nerve, 689–693
and fetal malformations, 91–92*
^{35}S-glycosaminoglycan and ^{35}S-glycopeptide metabolism by glomeruli and aorta from, 418–424
myo-inositol administration and sciatic and tibial motor nerve conduction parameters in, 573–578
and reticuloendothelial system hyperphagocytosis, 110–117
and serum lymphocyte response, very-low-density lipoproteins and inhibition of, 1098–1103
and skin collagen metabolism, 426–430
vitamin E and restoration of prostacyclin/thromboxane A_2 balance in, 947–950
with transplanted neonatal islets
normal responses to stress, epinephrine, and cortisol, 856–861
and vincristine inhibition of glucose induced insulin release in
and glucose and arginine effects on, 834–836
white-tailed
spontaneous diabetes in, 50*
Wistar BB
diabetic neuropathy research in, 67*
Zucker obese
spontaneous diabetes in, 51*

RED BLOOD CELLS. *See* Erythrocytes

REDUCTIVE ALKYLATION
and assays of chemically and nutritionally available lysine, 10–11†

REDUCTONES
physiologic effects, 27†

REGIONAL ILEITIS
in families of children with insulin-dependent diabetes, 294

REJECTION PHENOMENA. *See also* Allograft rejection; Survival
and 1a-like antigens, 17‡
and cytotoxic antibodies, 38‡
of islet allografts
tissue culture reduction of, 48–54‡
and passenger leukocytes, 2
susceptibility of established islet cell allografts to, 36–37‡

RESPIRATION
rates
and heart rate in diabetic and normal subjects, 341

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

ventilatory responses to progressive hypoxemia and hypercarbia
and autonomic neuropathy, 609–613

RESPIRATORY DISTRESS SYNDROME
and diabetic pregnancy, 90–91*

RETICULOENDOTHELIAL SYSTEM
hyperphagocytosis
in streptozotocin-diabetic rats, 110–117

RETINA
in UGDP
abnormalities, 17–18§

RETINOPATHY, DIABETIC
in animal models, 84–85*
background
experimental in animals, 86*
and blindness, 82–83*
and continuous subcutaneous insulin infusion, 480
future research on, 86–87*
genetic and immunologic factors and, 70–73
genetic susceptibility to
in insulin-dependent diabetics, 226–230
in identical twins, 19–21
and idiopathic diabetes in dogs, 27*
in immune complexes study, 7
incidence, 82*
and induced diabetes in dogs, 26*
in juvenile-onset type I diabetes of short duration, 874–882
and retinal vascular reactivity to norepinephrine and angiotensin II, 1056–1060
in UGDP
and blood glucose control, 3§

RHEUMATOID ARTHRITIS
in families of children with insulin-dependent diabetes, 294

RHIZOPUS ORYZAE
and susceptibility X_0 mucormycosis diabetic keotoacidosis and, 1109–1113

RIBONUCLEASE
bovine pancreatic
effects of reductive alkylation on biologic properties, 3†

RNA
from rat liver cell line
and cell-free synthesis of rat insulin-like growth factor II, 656–658
viruses
and diabetes pathogenesis research, 46*

mRNA
proinsulin
effects of glucose on, in rats, 624–628

RODENTS. *See also* Mice; Rats
as animal models of diabetes development, 45–46*
diabetic
and cardiomyopathy studies, 60–61*
and kidney complications, 71*
and diabetic neuropathy research, 66–67*
and macrovascular disease, 55–58*

RUBELLA VIRUS
and late-onset diabetes, 47*

S

SAIMIRI SCIUREUS
alloxan diabetes in, 40*
atherosclerosis research in, 59*
spontaneous diabetes in, 39*

SANAH-^{125}I-INSULIN
in photoaffinity labeling of insulin receptors in cultured human lymphocytes, 410–416

SATIETY CENTER
defective
in obese and diabetes mice, 4*

SCATCHARD ANALYSIS
and insulin action in fat cells from insulin-dependent diabetics, 709–712
and insulin-induced alterations in insulin binding and action study in cultured rat hepatocytes, 145–148
of insulin-induced loss of insulin-like growth factor-1 receptors on IM-9 lymphocytes, 375–380
of renal brush border membranes insulin binding and degradation, 618–623

SCHIFF'S BASE ADDUCTS
and acetaldehyde hemoglobin reactions, 16–20
and assays of chemically and nutritionally available lysine, 10–11†
and formation of Maillard browning products, 5–7†
in hemoglobin A_{1c}
Amadori rearrangement, 52†
physiologic effects, 26†

SCIATIC NERVE
conduction parameters
and myo-inositol administration in streptozotocin-diabetic rats, 573–578
slow axonal transport velocity in streptozotocin-diabetic rats
insulin treatment and, 689–693
sorbitol concentration
and sorbinil treatment in diabetic rats, motor nerve conduction velocity and, 789–793

SEROTONIN
Amadori compound of
physiologic effects, 26†

SERUM
albumin
measurement of nonenzymatic glycosylation of, 52–53†
anti-1a
and rejection phenomena, 12–13‡
and survival of islet cell transplants, 15‡
anti-lymphocyte
in spontaneously diabetic BB rats, 9–10*
cholesterol levels in UGDP mean values and standard errors at baseline and follow-up examinations, 39§
cholesterol and triglyceride
in obese spontaneously hypertensive rats, 57*
creatinine levels in UGDP follow-up kidney examinations, 18–19§, 33§
and cause of death, 44–45§, 48–49§, 52–53§
mean values and standard errors at baseline and follow-up examinations, 39§
mortality and, 12§
of surviving patients, 57–59§, 63–65§, 69–71§
from diabetic ketoacidosis patients
and susceptibility to mucormycosis, 1109–1113
from diabetic rats
in vitro injury of porcine aortic endothelial cells by very-low-density lipoproteins from, 593–598
lymphocyte response of, very-low-density lipoproteins and, 1098–1103
1,25-dihydroxyvitamin D
in diabetic rats, 401–405
glucose
and strenuous exercise, chromium excretion and, 212–215
glucose, insulin and glucagon and exercise
chromium excretion and, 212–215
GOT, alkaline phosphatase, and blood urea nitrogen
and protein-sugar Maillard reactions in rats, 26†
insulin values
in young and old subjects during eu-

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

glycemic insulin infusion, 851–854
lipid levels in UGDP follow-up studies, 19–20§
lipid peroxides
in diabetic rats, 948, 950
potassium regulation
during insulin-induced hypoglycemia, 615–617
proteins
nonenzymatic glycosylation of, 52–56†
rat
insulin-dependent factor in, and regulation of ornithine decarboxylase in skeletal muscle, 500–504
streptozotocin-diabetic rat
inhibitor in, blunting of insulin-like activity by, 97–103
vitamin B12 levels
in BB rats, 316

SEX
and development of obesity in Yucatan miniature swine, 34*
and diabetes incidence in nonobese diabetic mouse, 24*
of diabetics in comparative study of continuous subcutaneous insulin infusion vs. multiple insulin injections, 256
of diabetics with microangiopathy in immune complexes study, 8, 9
and glycosylated hemoglobin in diabetics, 74†
and implantation of peritoneal access device in diabetics, 471
of non-insulin-dependent diabetics in high-density lipoprotein composition study, 128, 129
in pancreas endocrine cell content study of nondiabetics and diabetics, 695, 696–699
of patients on chlorpropamide therapy in insulin-dependent diabetics study, 891
of Pima Indian and Caucasian subjects in insulin resistance study, 953
and retinopathy in juvenile-onset type I diabetes of short duration, 874–882
and spontaneous idiopathic diabetes in dogs, 27*
and streptozotocin effects in animals, 47–48*
in study of diabetes risk among relatives of insulin-dependent diabetics, 138
in UGDP
and cause of death, 42–43§, 46–47§, 50–51§
and mortality, 12§
of surviving patients, baseline characteristics of, 54–71§
and viral sensitivity of beta cells, 47*

SEXUAL DYSFUNCTION
and autonomic neuropathy, 65*

SHOCK
hemorrhagic
and diabetes development in nonhuman primates, 40*

SKIN
bacteria
and insulin bactericidal effects, 36–38
collagen
solubility properties and aging, 48–51†
collagen metabolism
in streptozotocin-diabetic rats, 426–430

SKIN ALLOGRAFTS
in mice
and effects of passenger cell removal, 60–61‡
rejection of, 2†, 16‡
and passenger cells, 23‡

SODIUM 2 CHLOROPROPIONATE
chronic administration in alloxan diabetic and normal dogs, 484–488

SODIUM CYANOBOROHYDRIDE
and reductive alkylation assays for available lysine, 10–11†

SODIUM DICHLOROACETATE
-induced hypoglycemia in dogs
contribution of liver and extrasplanchnic tissues to, 326–332

SOMATOMEDIN-C
receptors on IM-9 lymphocytes, 375

SOMATOMEDIN PEPTIDE INSULIN-LIKE GROWTH FACTOR-1. *See* Insulin-like growth factor-1

SOMATOSTATIN
-containing rat islet B-cells
sorting by light-scatter flow sytometry, 939–943
and fructose infusion after fasting, 518–520
in human fetal islets of Langerhans, 898–901
-like immunoreactivity
in dog and rat plasma, somatostatin 28 and, 474–476
-producing D cells
in diabetic Chinese hamsters, 19*
release
in superfusion medium of dissociated pancreatic cells attached to cytodex beads, 190–192
release from isolated pancreas from streptozotocin-diabetic and normal dogs
β-hydroxybutyrate and, 270–274
-rich pancreas endocrine cells
in nondiabetics and diabetics, 695–699
secretion
and exogenous glucagon in isolated perfused dog pancreas, 514
secretion from neonatal rat cultured islet B-cells
and insulin and multiplication stimulating activity stimulation of cell replication, 160–164
secretion in rats
effects of synthetic human and bovine pancreatic polypeptides and C-terminal hexapeptide on, 178–180
tolbutamide-stimulated release from isolated perfused rat stomach, 119–121

SOMATOSTATIN 28
evidence in dog and rat plasma of presence of, 474–476

SOMATOSTATIN RECEPTORS
on cloned and cultured cells from rat islet cell tumors, 521–530
migration kinetics in isolated pancreatic islets, 467–469

SORBINIL
and aldose reductase inhibition in diabetic rats
and motor nerve conduction velocity, 789–793

SPINE
lumbrosacral defects in offspring of diabetic rats, 82*
ventral roots
and proximal motor neuropathy in spontaneously diabetic rats, 784–788

SPLANCHNIC
glucose output
and fructose infusion after fasting, 518–520

SPLEEN
intrasplenic islet cell transplantation, 57‡
in mice with experimental insulitis and hyperglycemia, 78–82‡, 83‡
leukocytes
and localization of HLA-DR in human islets of Langerhans, 17–22‡
lymphocytes
and diabetes susceptibility in streptozotocin-treated mice, 809–810, 811–814
lymphocytes, antibodies to
in sponstaneously diabetic rats, 278–280
of obese and diabetes mice, 4*

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

SQUIRREL MONKEYS. *See* Saimiri sciureus

STAPHYLOCOCCAL PROTEIN A
radiolabeled
and detection of HLA-DR antigens, 18‡

STAPHYLOCOCCUS
and intercellular killing of bacteria by granulocytes of diabetic children, 1041–1043

STARVATION
and effects of glucose on proinsulin mRNA in rats, 624–628

STATHMOKINETIC STUDIES
of rat fetal pancreatic B-cells, 755, 757–758

STEREOSCOPIC FUNDUS PHOTOGRAPHY
and retinopathy in juvenile-onset type I diabetes of short duration, 874–882

STERILITY. *See also* Infertility
of diabetes (db) mouse, 3*, 4*
and diabetes-obesity syndromes in mice, 3*
of female fatty Zucker rat, 25*
in spontaneously diabetic Chinese hamsters, 14–15*

STEROIDS
and diabetes development in nonhuman primates, 40*

STEROL
synthesis
and diabetes in rats, 388–395

STREPTOZOTOCIN
metabolic events after administration in animal models, 47–48*
treatment in mice susceptible to diabetes, inhibition by lethal irradiation and restoration by splenic lymphocytes, 808–814

STREPTOZOTOCIN DIABETES
and albuminurea and nephropathy, 74*
and diabetic neuropathy in animal models, 67–68*
in dogs, 26–27*
and effects of beta-hydroxybutyrate on somatostatin release from isolated pancreas from, 270–274
and prolonged hypoglycemic effect of subcutaneous administration of insulin in liposomes, 506–510
induction in mice
inhibition by estrogens and potentiation by androgens, 724–729
in mice
and dehydroepiandrosterone, 830–833
and H-2 antigens in islet cell transplantation studies, 3–8
insulin regulation of sugar transport in isolated pancreatic acini from, 674–681
reversal by allogeneic islet transplantation, 33–34‡
and survival of intrasplenically implanted islets, 78–82‡, 83‡
in neonatal rats
insulin treatment and spontaneous remission in, 165–169
in nonhuman primates, 39–40*
in rats
and aminophenylboronic acid affinity chromatography glycosylated hemoglobin measurement in, 701–705
autonomic neuropathy and axonal dystrophy in, 761–770
beneficial effects of physical training in, 406–409
and calcium intake regulation of 1,25-dihydroxy-vitamin D formation, 401–405
and congenital malformations in offspring of, 1–6
and effect of aldose reductase inhibition on motor nerve conduction velocity, 789–793
and effect of inhibitor on serum insulin-like activity, 97–103
and effect of insulin treatment on slow axonal transport velocity of sciatic nerve, 689–693
and fetal malformations, 91–92*
^{35}S-glycosaminoglycan and ^{35}S-glycopeptide metabolism by glomeruli and aorta from, 418–424
in vitro injury of porcine aortic endothelial cells by very-low-density lipoproteins from serum of, 593–598
and islet cell transplantation after total lymphoid irradiation and bone marrow cells infusion, 63–67‡
and macrovascular research, 57*
and morphometric study of peripheral nerves, 357
myo-inositol administration and sciatic and tibial motor nerve conduction parameters in, 573–578
pregnancy and, glucose tolerance and insulin response and, 75–78
and reticuloendothelial system hyperphagocytosis, 110–117
and serum lymphocyte response, very-low-density lipoproteins and inhibition of, 1098–1103
and skin collagen metabolism, 426–430
and tolbutamide stimulated gastric somatostatin release from isolated perfused stomachs from, 119–121
and use of total lymphoid irradiation in transplantation of rat fetal pancreases, 69–74‡
vitamin E and restoration of prostacyclin/thromboxane A_2 balance in, 947–950
in rodents
and cardiomyopathy, 61*

STRESS
development of hyperglycemia during and inhibitory effect of epinephrine on B-cell function, 802–807
and diabetes onset in nonhuman primates, 39*, 40*
normal responses to, in rats transplanted with neonatal islets, 856–861

STROKES
and atherogenesis in diabetics, 54*

SUCROSE
intoxication model
diabetic neuropathy research and, 69*

SUGARS
aldehydic form
and nonenzymatic glycosylation of proteins, 1–2†
browning products formation with proteins
effects in rats, 25–26†
carbonyl groups
reactions with lysine, 5–12†
and free amino acids
effects of browning products of, 24–25†
reducing
availability of, and Maillard reaction rate, 30†
and nonenzymatic glycosylation of proteins, 1–3†
transport
in isolated pancreatic acini from streptozotocin-diabetic mice, insulin and, 674–681
transport by rat soleus muscle, insulin-stimulated
and Ca^{2+}-dependent ionophore A23187, 846–849

SUICIDE
as cause of death in UGDP study
patient baseline characteristics and, 42–51§

SULFONYLUREAS
chronic therapy in non-insulin-dependent diabetes
effect on hepatic glucose production, 333–337

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

gliclazide
and calcium^{2+} influx into pancreatic B cell in rat islets, 1010–1015
and insulin binding and glycemic control in insulin-dependent diabetics, 890–895
and insulin secretion and action in non-insulin-dependent diabetics, 307–311
in spontaneously diabetic Chinese hamsters, 17*

SUPERFUSION METHOD
and attachment of dissociated pancreatic islet cells to cytodex beads, 189–192

SURGERY
implantation of peritoneal access device in diabetics, 470–473
neonatal thymectomy
in spontaneously diabetic BB rats, 10–11*
ovariohysterectomy
and estrus-induced temporary diabetes in dogs, 27*
pancreatectomy
and induced diabetes in dogs, 27*
in nonhuman primates, 40*
partial pancreatectomy in rats
and hyperglycemia induced islet changes, 319–324
and size factors in selection of animal models, 46*
uninephrectomy in rats
and diabetic nephropathy, 72*
use of Yucatan miniature swine for, 34–35*
vitrectomy, 87*

SURVIVAL. *See also* Mortality
and immunosuppression with cyclosporin A, 92–106‡, 108‡
of intrasplenically implanted islets
in mice with insulitis and hyperglycemia, 78–82‡, 83‡
and pancreas transplantation patients
immunosuppression and, 102‡
of skin and parathyroid allografts in mice and rats
and removal of passenger cells, 60–61‡

SWINE. *See* Yucatan miniature swine

T

TEMPERATURE. *See also* Cryopreservation
and exposure of casein or soy protein to glucose
lysine losses and, 6†
glucose-induced thermogenesis in nondiabetic and diabetic obese subjects, 1023–1028
and Maillard browning effects on foods, 32†, 33–34†, 38–40†
regulation
and exercise in diabetics with autonomic neuropathy, 732
and hypoglycemia in diabetics with autonomic neuropathy, 735
and thermoregulation during cold stress in obese diabetic mice, 50–51*

TENDONS
collagen
glucosylation and diabetes and aging, 48†, 50–51†

THEOPHYLLINE
and reversal of diazoxide and D600 inhibition of insulin release, 778–779

THERMOGENESIS
glucose-induced
in nondiabetic and diabetic obese subjects, 1023–1028

THERMOREGULATION
and cold stress in obese diabetic mice, 50–51*
defects, and diabetes-obesity syndrome in mice, 3*

THIOBARBITURIC ACID TECHNIQUE
and assays for Amadori compounds, 58†
and assays of nonenzymatically glycosylated serum or plasma proteins, 53†
and glycosylated hemoglobin measurements, 72–73†
and measurement of erythrocyte spectrin glucosylation in diabetics, 64–68†

THREE-DROP ALBUTEST, 973–975

THROMBOXANE A_2
-prostacyclin balance in streptozotocin-diabetic rats
dietary vitamin E and, 947–950

THYMECTOMY
neonatal
in spontaneously diabetic BB rats, 10–11*

THYMOCYTES
antigens on, 9‡

THYMUS
and spontaneous hyperglycemia and impaired glucose tolerance
in athymic nude BALB/c mice, 821–824

THYROID ALLOGRAFTS
and in vitro culture prior to transplantation, 11‡
and passenger leukocytes, 17‡

THYROID GLAND
autoimmune disease
in spontaneously diabetic BB Wistar rats, 50*
dysfunction
in families of children with insulin-dependent diabetes, 294–295
function
in fatty Zucker rat, 25*
lymphocytic thyroiditis
and spontaneous autoimmune diabetes in BB/W rats, autoantibody study in, 816–819
and spontaneously diabetic BB rats, 11*

THYROID TISSUE TRANSPLANTATION
in mice, 6–7‡
and organ culture, 31–32‡

THYROIDITIS
lymphocytic
in spontaneously diabetic BB rats, 11–12*, 50*

TIBIAL MOTOR NERVE
conduction parameters
and myoinositol administration in streptozotocin-diabetic rats, 573–578

TISSUE CULTURE
of allogeneic mouse islets
reversal of hyperglycemia after transplantation of, 55–59‡
and islet allografts, 109‡
of rat pancreatic islets
and reduction of 1a antigen-bearing cells and prolongation of allograft survival, 48–54‡

TISSUES
biochemical studies
in diabetic and nondiabetic inbred Chinese hamsters, 18–19*
cultured rat hepatocytes
insulin-induced alterations in insulin binding and action in, 145–148
from diabetics
ε-amino-bound-lysine in, 1123–1126
distribution of 1a-like antigens in, 17‡
epididymal fat pad weight
and physical training in rats with mild streptozotocin diabetes, 407

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

extracts
immunodetection of nanogram quantities of insulin in, 648–651
extrasplanchnic
and sodium dichloroacetate-induced hypoglycemia in dogs, 326–332
glomeruli and abdominal aorta from streptozotocin-diabetic rats
^{35}S-glycosaminoglycan and ^{35}S-glycopeptide metabolism by, 418–424
insulin receptors
autoantibodies against, in New Zealand obese (NZO) mouse, 24*
muscle, from alloxan diabetic rats
contractile and electrical characteristics of, 194–201
nonpancreatic
insulin synthesis in, 183–184
rat epididymal fat pads
effects of somatomedins, insulin, and inhibitor from diabetic rat serum, 97–103
rat soleus muscle
basal and insulin-stimulated sugar transport by, Ca^{2+}-dependent ionophore A23187 and, 846–849
sensitivity to insulin
in insulin-dependent diabetics, 795–800

TOLBUTAMIDE
infusion in non-insulin-dependent diabetics
insulin responses to non-glucose stimuli during, 154–158
response to
in nonhuman primates, 39*
and somatostatin release
from isolated perfused rat stomach, 119–121
therapy in UGDP
discontinuation of, mortality results after, 28§
mortality by cause of death and, 30§

TOLERANCE
compared with enhancement, 15–16‡
establishment and induction in allografted animals, 36–37‡
induction with bone marrow cells, 84–88‡, 90–91‡

N-a-TOSYL-L-ARGININE METHYLESTER
and insulin action, 976–983

TOTAL LYMPH IRRADIATION
and heart allografts in rats
and cyclosporin A, 95‡
and rat fetal pancreas transplantation, 69–74‡
and survival of islet cell allografts in rats across major histocompatibility barriers, 63–67‡
and transplantation, 75–77‡

TRANSFERRIN
availability in diabetic ketoacidosis
susceptibility to mucormycosis and, 1109–1113

TRANSPLANTATION. *See also* Islet cell transplantation
of fetal mouse pancreas into syngeneic diabetic mice
insulin content in organ culture and after transplantation, 826–829
and immunosuppression with cyclosporin A, 92–106‡, 108†
of neonatal pancreatic tissue in rats
and responses to stress, epinephrine, and cortisol, 856–861
studies in pancreatectomized Macaca mulatta, 40*

TRICHLOROACETIC ACID
in skin collagen metabolism studies in streptozotocin-diabetic rats, 426–430

TRIFLUOROACETYLATION
and assays of chemically and nutritionally available lysine, 11†

TRIGLYCERIDES
fasting levels
in nonhuman primates, 38*
levels
and hypothalamic lesions in nonhuman primates, 38*, 40*
in non-insulin-dependent diabetics, 126–131

2,4,6-TRINITROBENZENESULFONIC ACID
and measurement of available lysine, 30†

TRIOSE REDUCTONE
mutagenic properties, 27†

TRITIUM
incorporation into hemoglobin of alcoholics and controls, 18†

TRYPSIN
inhibitors, small molecular weight
inhibition of insulin action by, 976–983
isolation of H-2 antigens, 9‡

TUBERCULOSIS
and etiology of pancreatogenic diabetes and insulin metabolism, 348

TUMORS
EHS in normal and genetically diabetic mice
basement membrane proteoglycan studies in, 185–188
insulinoma human somatic cell hybrids from proinsulin-like material produced by, 1035–1040
rat islet cell
cultured and cloned cells from, insulin, glucagon, and somatostatin receptors on, 521–530

TWINS
identical
diabetic retinopathy in, 19–21

TWITCH:TETANUS RATIO
of extensor muscle from alloxan diabetic rats, 197

U

UNIVERSITY GROUP DIABETES PROGRAM FINAL REPORT, 1–25§
adherence to treatment, 6–7§, 24§
analytic procedures, 3–4§
blood glucose control results, 7–8§
blood pressure levels during follow-up, 17§
cancer incidence in, 20§
and changed standards for evaluation and treatment of diabetes, ii§
characteristics of surviving patients, 54–71§
chronology of legal actions concerning, 78§
closeout examinations and follow-up for mortality, 28–29§
completed follow-up examinations, 6§
controversy over, ii§, 23–25§
Cox regression analyses used in, 77§
definitions of blood glucose control, 7§
diagnostic criteria, 4–6§
and discontinuation of oral hypoglycemic agents, 24–25§
dropout rates, 6§
eye examination results, 17–18§
glucose control related to adherence, 10§
heart examination results, 14–17§
and blood pressure levels during follow-up, 17§
and cardiothoracic ratio, 17§
and heart rate, 17§
and hypertension, 16§
and specified cardiovascular events, 14–15§
and use of medications for heart disease or heart-related problems, 16§
hypertension and treatment for hypertension in, 16§
hypoglycemic episodes, 9–10§
implications, 22–23§
kidney examination results, 18–19§
life tables, 72–76§
of cancer deaths only, 76§

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

of cardiovascular deaths only, 75§
reported deaths, 74§
mean blood glucose levels, 8–9§
means and standard errors for baseline variables in, 33–39§
for cardiothoracic ratio, 38§
for diastolic blood pressure, 38§
of fasting blood glucose, 34§, 36§
of heart rate, 38§
insulin dosage at baseline and each follow-up examination, 35§
of relative body weight, 37§
for serum cholesterol, 39§
serum creatinine levels, 39§
of sum glucose tolerance tests, 36§
of systolic blood pressure, 37§
mortality results, 10–11§
and baseline differences among treatment groups, 11–13§
by blood glucose control, 14§
by cause of death, 10–11§
cumulative annual death rates, 11§
by high adherence levels, 13–14§
patient characteristics related to mortality and non-mortality, 40–71§
peripheral vascular examinations, 19§
release of patient listings, ix§
results after protocol changes, 28–31§
mortality after discontinuation of phenformin therapy, 28§
mortality after discontinuation of tolbutamide therapy, 28§
serum lipid levels, 19–20§
status at closeout examination and follow-up after closeout, 31§
study design, 1–3§
study personnel and committees of, iv–viii§
administrative committees, v–vi§
clinical centers, lv–v§
liason officers from National Institute of Arthritis, Metabolism and Digestive Diseases, vii§
lipid laboratories, v§
participating consultants in, vi–vii§
past participating co-investigators and physicians, vii§
past participating personnel, viii§
past participating principal investigators, vii§
technical committees, vi§
and treatment changes, failures, and dropouts, 23§
and weight change, 14§

UREMIA
as cause of death, in UGDP study patient baseline characteristics and, 42–51§

URINE
acetone concentrations
in diabetic ketoacidosis, 244, 245–246, 247
albumin
agglutination test for low concentrations of, 973–975
chromium excretion
and exercise-induced glucose utilization, 212–215
output
and diabetes onset in BB rat, 8*
C-peptide excretion rate in obese and diabetic subjects
estimation of insulin secretion rate from, 449–453
protein in
and kidney examinations in UGDP, 19§
pyrroles
in diabetics, 27†
Testape examinations
and diabetes diagnosis in BB rats, 10*
volume and glucose and ketones excretion
and diabetes control monitoring in dogs, 28*

V

VASCULAR DISEASE. *See also* University Group Diabetes Program Final Report
atherosclerotic
and sterol synthesis in diabetes, 388–395
in KK mouse, 25*, 56*
prevention of
and meticulous diabetes control, 479

VASCULAR ENDOTHELIAL CELLS
and allograft rejection, 23–24‡, 32‡
and organ culture, 36‡

VASCULAR SYSTEM
bovine endothelial cells
insulin metabolism in, 1077–1082
peripheral, examination in UGDP follow-up studies, 19§
prostacyclin in streptozotocin-diabetic rats
dietary vitamin E and, 947–950
reticuloendothelial system intravascular phagocytosis in streptozotocin diabetic rats, 110–117
retinal
reactivity to norepinephrine and angiotensin II in diabetics and nondiabetics, 1056–1060

VEINS
portal
glucose infusion into, gut glucose absorption and, 27–34

VELCRO STRIPS
and new method for isolation of islets, 109–111‡

VENEZUELAN ENCEPHALITIS VIRUS
and hyperglycemia in rhesus monkeys, 47*

VERAPAMIL
and gliclazide-induced increase in calcium efflux and insulin release from rat perifused islets, 1011–1013

VINCRISTINE
and inhibition of glucose-induced insulin release
glucose and arginine and prevention of, 834–836

VIRUSES
Coxsackie B
and glucose abnormalities in mice, 496–499
and insulin-dependent diabetes, 45–47*
and streptozotocin-induced diabetes in mice, 48*

VISUAL ACUITY
in UGDP
and cause of death, 44–45§, 48–49§, 52–53§
in follow-up eye examinations, 18§
and mortality, 12§
of surviving patients, 57–59§, 63–65§, 69–71§

VITAMINS
B12
in BB diabetic rats, 316
D
and diabetes in animal models, 52*
1,25-dihydroxy-D formation in streptozotocin diabetic rats
calcium intake and regulation of, 401–405
E
and restoration of prostacyclin/thromboxane A_2 balance in streptozotocin diabetic rats, 947–950

VITRECTOMY
and retinopathy in animal models, 87*

W

WATER
content of nerves
and diabetic neuropathy, 358
intake
and diabetes onset in BB rat, 8*

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

WEIGHT
changes
in streptozotocin diabetic rats, and skin collagen metabolism, 428
of diabetic dogs
and outcome of insulin therapy, 28*
of diabetics in acetone metabolism and ketoacidosis study, 243
of diabetics with microangiopathy
in immune complexes study, 7
and motor nerve conduction velocity in diabetic rats, 792
in obese mouse, 3*
and physical training in rats with mild streptozotocin diabetes, 407, 408
in UGDP
and cause of death, 42–43§, 46–47§, 50–51§
changes in, 14§
means and standard errors at baseline and follow-up examinations, 37§
and mortality, 12§
of surviving patients, 54–56§, 60–62§, 66–68§

WHEAT-GERM-LECTIN-SEPHAROSES
interaction with extracts of fetal bovine pancreas, 1002–1005

WOUND HEALING
in spontaneously diabetic Chinese hamsters, 20*

X

X-IRRADIATION
-induced mutations in mice, 2*

X-RAYS
chest, and cardiothoracic ratio in UGDP, 17§

Y

YUCATAN MINIATURE SWINE
and atherosclerosis research, 58*
and diabetes etiology studies, 45–46*
as diabetes model, 30–35*
advantages and disadvantages, 34*
availability and maintenance, 34–35*
breeding, 30*
characterization and model status, 30–31*, 33*
development of diabetes in, 32*, 33*
further studies required, 33–34*
insulin secretion in, 33*
spontaneous hyperglycemia and diabetes in, 33*

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

Author Index

A

Abioye, A.A., 1119–1122
Abrams, Jeffrey J., 903–910
Acquaviva, Angela Maria, 656–658
Acton, Ronald T., 122–125, 532–537
Adams, Peter W., 217–225
Agostino, M., 30–37‡
Aquirre, Gustavo, 82–88*
Albers, John J., 126–131
Albisser, A.M., 366–368
Alejandro, Rodolfo, 17–22‡, 48–54‡
Alfarsi, Salman, 217–225
Amatruda, John M., 145–148
Anderson, Arthur, 84–89‡
Anderson, Carol E., 45–53*
Anderson, Richard A., 212–216
Anderson, V.E., 1115–1118
Andersson, Arne, 55–59‡, 78–82‡, 238–241
Andreani, D., 7–11
Andres, Giuseppe A., 71–81*
Angeletti, Gabriella, 641–647
Aoki, Thomas T., 46–52
Appel, Michael C., 7–13*, 816–820
Arbogast, Bradley W., 593–599, 1098–1104
Arner, Peter, 911–916
Arnold, J.H., 947–951
Arquilla, Edward R., 54–64*
Artis, William M., 1109–1114
Asplin, Christopher M., 149–153, 489–495
Assan, R., 40–45
Axelrod, Lloyd, 994–1001

B

Baekkeskov, Steinunn, 278–281
Bailey, Anne C., 674–682
Barbosa, Jose, 585–588, 991–993, 1115–1118
Barger, Bruce O., 122–125, 532–537
Barker, Clyde F., 60–62‡, 84–89‡
Barrett, Eugene J., 923–928
Bassett, Martin L., 126–131
Bauman, William A., 182–184
Beard, James C., 154–159, 333–338, 802–807
Bégin-Heick, Nicole, 53–59
Beir, Jeffrey R., 27–35
Bell, David S., 122–125
Beligrau, Donald, 84–89‡
Belmonte, M.M., 255–264
Bennett, Peter H., 952–956
Berelowitz, Michael, 299–306
Berger, M., 600–602
Berger, Willi, 630–633
Bergman, Richard M., 27–35, 432–441
Bergstrom, Richard W., 976–984
Berhanu, Paulos, 410–417
Bernuau, Dominique, 1061–1067
Berry, Dianne, 1098–1104
Best, James D., 333–338, 802–807
Bevilacqua, Stefano, 923–928
Bhathena, Sam J., 521–531
Bier, D.M., 203–211
Bierman, Edwin L., 126–131
Biesbroeck, Robert C., 126–131
Bissé, Emanuel, 630–633
Björkén, C., 238–241
Björkman, Ola, 516–520
Blohmé, Göran, 771–775
Bloom, Gunnar D., 299–306
Blue, Marie L., 808–815
Bodansky, H.J., 70–74
Boden, G., 242–248
Bolinder, Jan, 911–916
Bolli, Geremia, 641–647
Bolton, W.E., 1035–1040
Bonner-Weir, S., 883–889
Borel, Jacques Paul, 371–374
Borkenstein, Martin H., 1006–1009
Bottazzo, G.F., 70–74, 862–866
Bouchard, Ph., 40–45
Bowen, K.M., 30–37‡
Bowles, Charles R., 964–972
Bown, E., 319–325
Boyd, A.E., III, 1035–1040
Brandenburg, Dietrich, 1068–1076
Branks, Michael J., 283–291
Bressler, Rubin, 12–18
Breyfogle, Russell P., 70–78†
Brink, J., 463–466
Britt, Lunzy D., 63–68‡
Brodsky, Joel, 339–345
Brooks, Susan M., 64–69†
Brown, David M., 71–81*, 418–425
Brown, Josiah, 23–28‡
Brown, Mark J., 573–578
Brown, Marvin R., 65–70*
Brunetti, Paolo, 641–647
Bruni, Carmelo Bruno, 656–658
Brunschwig, Jean-Pierre, 48–54‡
Bryden, Noella A., 212–216
Budowle, Bruce, 532–537
Bunn, H. Franklin, 743–748
Burnett, M., 22–26
Butler, Leonard, 7–13*

C

Canalese, J., 7–11
Cantraine, Francis, 170–177
Cappiapuoti, Federico, 367–370
Carpentier, Jean-Louis, 659–662
Cartechini, Maria G., 641–647
Carter, W.M., 39–47‡, 826–829
Caubarrère, I., 40–45
Cerami, Anthony, 57–63†
Cerasi, E., 1077–1083
Ceriello, Antonio, 367–370
Chang, Cecilia L., 145–148
Chang, Min Kun, 1–4†
Chantelau, E., 600–602
Charles, S., 776–783
Chavers, Blanche, 585–588
Chern, M.M., 1115–1118
Cherrington, Alan D., 326–332, 964–972
Chi, David S., 1098–1104
Chiba, Tsutomu, 119–121
Chichester, C.O., 37–46†
Chihara, Kazuo, 119–121
Chirgwin, John, 624–629
Chisholm, Donald J., 603–608
Chobanian, Aram V., 54–64*
Christlieb, A.R., 1056–1060
Christopherson, Kenneth W., 874–882
Church, D.B., 701–705
Ciaraldi, T.P., 1016–1022
Ciborowski, James, 1084–1087
Clark, A., 319–325
Clark, Charles M., Jr., 867–873
Clark, Julia B., 867–873
Clarkson, Thomas B., 54–64*
Clemens, A.H., 579–584
Clouse, M., 463–466
Cobelli, Claudio, 346–355
Cockburn, E., 1002–1005
Cohen, Margo Panush, 1084–1087
Coleman, Douglas L., 1–6*, 24–25*, 45–53*, 830–833
Collier, S., 39–47‡
Compagnucci, Pietro, 641–647
Conover, Cheryl, 500–505
Cook, Daniel L., 339–345, 985–990
Cooper, L.Z., 1088–1091
Cornell, Robert P., 110–118
Cornillot, Pierre, 371–374
Cornwell, D.G., 947–951
Craighead, John E., 45–53*
Cronin, Margaret A., 874–882
Cudworth, A.G., 70–74, 862–866
Cummins, J.C., 203–211
Cunningham, Lee N., 46–52

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

Curchod, B., 1023–1028
Cushman, Samuel W., 589–592

D

Dahlström, Elisabeth, 1–6
Dalpé-Scott, Marthe, 53–59
Danilovs, John A., 23–28‡
Davie, Joseph M., 11–14‡
Dean, Betty M., 70–74
De Feo, Pierpaolo, 641–647
DeFronzo, Ralph A., 683–688, 795–801, 923–928, 957–963, 1044–1050
De Haen, Christoph, 976–984
Delcher, Harry K., 1109–1114
D'Elia, J.A., 463–466
Del Prato, Stefano, 346–355
Denys, A., 1041–1043
De Vos, C.J., 60–69
Diamond, Michael P., 326–332, 917–922
Diddie, Kenneth R., 82–88*
Dillon, Karen A., 1098–1104
Di Mario, U., 7–11
Di Pinto, Paolo, 367–370
Doberne, Leonard, 307–312, 382–387, 396–400
Doberneck, Raymond C., 470–473
Dobersen, Michael J., 292–298, 459–462
Docherty, H., 474–477
Dollar, Laura A., 375–381
Dornan, T.L., 226–231
Draznin, Boris, 467–469
Duner, Elena, 346–355
Dunsworth, Tim, 585–588, 991–993
Durand, Anne-Marie, 1061–1067
Durkot, M., 203–211
Dyck, Peter J., 65–70*
Dyrberg, Thomas, 278–281
Dziatkowiak, H., 1041–1043

E

Eagleton, Lanie E., 609–614
Eaton, R. Philip, 36–39, 470–473
Eder, Howard A., 54–64*
Eisenbarth, G.S., 107–109
Elam, Richard L., 283–291, 1029–1032
Elder, Elizabeth, 52–56†
Elder, Melissa, 313–318
Engerman, Ronald L., 26–29*, 82–88*
England, Jack D., 70–78†
England, Jack E., Jr., 70–78*
Engle, Michael J., 89–94*
Eriksson, Ulf, 1–6
Evans, David J., 217–225

F

Famuyiwa, O.D., 1119–1122
Fantl, Wendy J., 15–21†
Faronato, Pier Paolo, 346–355
Farrell, Philip M., 89–94*
Faustman, Denise, 11–14‡
Fedun, B., 1088–1091
Feingold, Kenneth R., 388–394
Felber, Jean-Pierre, 957–963, 1023–1028
Feldmann, Gerard, 1061–1067
Felig, Philip, 516–520, 1044–1050
Ferguson, Ronald M., 92–107‡
Ferrannini, Eleuterio, 683–688, 923–928
Files, Nancye, 939–943
Finegood, Diane T., 432–441
Finke, Edward H., 109–111‡
Finkelstein, Daniel, 82–88*
Finot, P.A., 22–28†
Fischer, U., 579–584
Fisher, Milton, 283–291, 1029–1032
Fleischer, Norman, 808–815
Fleming, Hilari L., 60–62‡
Flier, J.S., 132–135
Flückiger, Rudolf, 630–633
Foss, Milton C., 46–52
Fountain, John A., 1109–1114
Fox, Richard R., 82–88*
Frank, Robert N., 82–88*, 874–882
Frantz, Ivan D., 89–94*
Friedman, Mendel, 5–14†
Fujita, Takuo, 119–121
Fuks, Z., 1077–1083

G

Gabreau, Thierry, 1061–1067
Galfo, C., 7–11
Galloway, John A., 716–723
Ganeval, D., 40–45
Garlick, Robert L., 743–748
Gattegno, Liliane, 371–374
Gazdar, Adi F., 521–531
Gentile, Salvatore, 367–370
Gerber, Pietro G., 178–181
Gerich, John E., 579–584, 663–669
Gerritsen, George C., 14–23*, 45–53*
Giddings, Stephen J., 624–629
Gillery, Philippe, 371–374
Ginsberg-Fellner, Fredda, 292–298, 1088–1091
Ginsberg, Henry, 903–910
Giugliano, Dario, 367–370
Gleason, R.E., 1056–1060
Gliemann, Jørgen, 634–640
Go, Rodney C.P., 122–125, 532–537
Goetz, Frederick C., 92–107‡
Golay, A., 1023–1028
Goldfine, Ira D., 674–682
Goldman, Allen S., 89–94*
Goldman, Hy, 897–902
Goldstein, David E., 70–78†
Golub, Lorne, 426–431
Gorden, Phillip, 659–662, 890–896
Gorsuch, A.N., 862–866
Gould, Michael K., 846–850
Gray, R.S., 929–936
Green, Donald R., 917–922
Greene, Douglas A., 573–578
Greenfield, Michael S., 307–312, 382–387, 396–400, 670–673
Gregory, Jay A., 470–473
Griffin, J., 929–936
Grodsky, Gerold M., 45–53*
Grossie, J., 194–202
Groth, C.-G., 238–241
Grunberger, George, 890–896
Grundleger, Melvin L., 232–237
Grundy, Scott M., 903–910, 1092–1097
Guillot, Raymonde, 1061–1067
Gunnarsson, R., 1044–1050

H

Hajek, Shirley Vaerewyck, 17–22‡
Hall, L.D., 579–584
Hall, Solveiga, 846–850
Hallett, F.R., 366–368
Halter, Jeffrey B., 154–159, 333–338, 339–345, 802–807
Hanafusa, Toshiaki, 749–753
Hansen, Carl T., 45–53*
Hansen, John A., 149–153
Hanwell, M.A., 789–794
Hassell, John R., 185–188
Hatcher, Victor B., 182–184
Hauff, C., 600–602
Hayek, Alberto, 944–946
Haymond, Morey W., 86–89, 579–584
Hedo, Jose A., 1068–1076
Heick, H.M.C., 53–59
Hellerström, Claes, 1–6, 238–241
Hendler, Rosa, 795–801
Henquin, J.C., 776–783
Henriksson, J., 1044–1050
Herberg, Lieselotte, 45–53*
Herchuelz, A., 1010–1015
Hermansen, K., 270–274
Hess, Randall, 70–78†
Higgins, Paul J., 743–748
Hill, T., 463–466
Hilsted, Jannik, 730–737
Hintz, Raymond L., 375–381
Hissin, Paul J., 589–592
Hjøllund, Elisabeth, 706–715
Hoeldtke, R.D., 242–248
Hoffman, L., 39–47‡, 826–829
Hoffman, William H., 874–882
Hofman, Florence M., 23–28‡
Hollander, Priscilla H., 149–153, 489–495
Hollingsworth, Dorothy R., 1092–1097
Horst, R.L., 401–405
Hostetter, Thomas H., 71–81*
Hourigan, Patrick M., 27–35
Howard, Charles F., Jr., 37–44*, 45–53*, 54–64*, 1105–1108

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

Hreidarsson, A.B., 442–448
Hunt, Sarah S., 385–387
Hurks, Charles, 834–837

I

Iavicoli, M., 7–11
Ingram, Marylou, 939–943
Iwaki, Yuichi, 105–106

J

Jacot, Eric, 957–963
Jakobsen, Johannes, 689–693
James, David E., 603–608
Janjic, Danilo, 265–269
Jaspan, J., 474–477
Jenkins, Arthur B., 603–608
Jéquier, Eric, 957–963, 1023–1028
Johnson, Armead H., 716–723
Johnson, Ginger C., 952–956
Jones, Henry E., 1109–1114
Joondeph, Howard C., 874–882
Jordan, George, 496–499
Judzewitsch, Roman G., 154–159, 333–338

K

Kadowaki, Seizo, 119–121
Kahn, C. Ronald, 716–723, 1068–1076
Kaiser, N., 1077–1083
Kakita, Keiji, 648–652, 841–845
Kaldany, A., 463–466
Kalkhoff, Ronald, 89–94*
Kao, M., 1016–1022
Karnieli, Eddy, 589–592
Karpen, C.W., 947–951
Kawai, K., 512–515
Keen, Stacey, 867–873
Kemnitz, Joseph W., 89–94*
Kennedy, Laurence, 52–56†
Keo, Lundy, 846–850
Kerp, Lothar, 615–617
Kim, Y.T., 724–729
King, Nick J.C., 1–8‡
King, T., 319–325
Kircher, Charles H., 12–18
Kissebah, Ahmed H., 217–225
Kitabchi, Abbas E., 1128–1131
Klein, David J., 418–425
Kleinman, Hynda K., 185–188
Kniaz, Daniel, 149–153
Knowler, William C., 952–956
Kohn, Robert R., 47–51†
Kohner, Eva M., 70–74
Kolterman, O.G., 929–936, 1016–1022
Koulmanda, M., 39–47‡
Kowalska, M., 1041–1043
Kowarski, A. Avinoam, 449–453
Kowluru, Anjaneyulu, 566–570
Kraegen, Edward W., 600–602, 603–608
Kramer, John W., 26–29*
Krupin, Theodore, 80–85
Kumar, Dinesh, 821–825
Kuno, Shotaro, 105–106
Kurtz, A.B., 70–74

L

Labuza, Theodore P., 29–36†
Lacy, Ellen T., 109–111‡
Lacy, Paul E., 11–14‡, 63–68‡, 109–111‡
Lacy, William W., 326–332
Lafferty, K.J., 30–37‡
Lager, Ibe, 771–775
Landsberg, L., 132–135
Lang, D.A., 22–26
LaPorte, Ronald E., 136–144
Larson, Ronald E., 454–458
Larsson, K. Sune, 1–6
Lasché, Eunice M., 454–458
Lattimer, Sarah A., 573–578
Lear, Steven R., 388–394
Lebrun, P., 1010–1015
Lee, Greta M., 593–599
Lee, Stanley M., 12–18, 249–254
Lee, Tung-Ching, 37–46†
Leiter, E.H., 830–833
Leitner, J. Wayne, 467–469
Lernmark, Åke, 45–53*, 278–281, 299–306
Leslie, R.D.G., 19–21
Levine, Lawrence, 994–1001
Levitt, Mindy A., 182–184
Lewis, Richard A., 573–578, 874–882
Like, Arthur A., 7–13*, 816–820
Linde, Susanne, 634–640
Lister, J., 862–866
Little, Randie R., 70–78†
Loubatieres-Mariani, M.M., 484–487

M

McClearn, Gerald E., 65–70*
McConnell, Thomas, 313–318
MacDonald, Michael J., 566–570
Maceda, Blanca Pérez, 634–640
MacGregor, Joan M., 136–144
Maclaren, Noel K., 313–318, 385–387, 1051–1055
McLennan, S., 701–705
McMillan, Donald E., 64–69†
McPherson, C.K., 226–231
MacRae, Gordon, 388–394
Maeder, Evelyne, 957–963, 1023–1028
Mahoney, Eileen M., 283–291
Malaisse, Willy J., 90–93, 170–177, 1010–1015
Malaisse-Lagae, Francine, 90–93, 694–700
Mamelok, Richard, 618–623
Mandarino, Lawrence J., 663–669
Mandel, T.E., 39–47‡, 826–829
Mann, Dean, 716–723
Mann, J.I., 226–231
Maquart, François-Xavier, 371–374
Margherio, Raymond R., 874–882
Margolis, Simeon, 449–453
Marliss, Errol B., 278–281
Marsh, J., 364–366
Martin, George R., 185–188
Martindale, H., 364–366
Mathot, F., 776–783
Matschinsky, Franz M., 45–53*
Matsukura, Shigeru, 119–121
Matthews, D.E., 203–211
Matthews, D.R., 22–26
Matthews, Judith A., 70–74
Mauer, S. Michael, 71–81*
Means, Gary E., 1–4†
Mehl, Thomas D., 52–56†
Meistas, Mary T., 449–453
Mendell, Nancy, 716–723
Merimee, Thomas J., 52–56†
Meyer, H.U., 1023–1028
Michael, Alfred F., 418–425, 585–588
Michelis, M.A., 724–729
Miles, John M., 86–89
Miller, Joshua, 17–22‡
Minaker, K.L., 132–135, 851–855
Mintz, Daniel H., 17–22‡, 160–164
Miyazaki, Atsushi, 749–753
Moghetti, Paolo, 346–355
Mondon, Carl E., 670–673
Monnier, Vincent M., 57–63†
Morris, P.J., 226–231
Morrow, Charles E., 92–107‡
Moser, Arthur H., 388–394
Moule, Margaret L., 659–662
Moulton, Stephanie M., 964–972
Mozzoli, M.A., 242–248
Muchmore, Douglas B., 976–984
Muggeo, Michele, 346–355
Mullen, Yoko, 69–74‡
Muntean, Wolfgang E., 1006–1009
Murphy, Catherine C., 122–125, 532–537

N

Nachazel, Delbert P., Jr., 874–882
Nadeau, André, 406–409
Nagaoka, Kengo, 105–106
Nagulesparan, Murugasu, 952–956
Najarian, John S., 92–107‡
Naji, Ali, 60–62‡, 84–89‡
Nakhooda, Azima F., 278–281
Nenquin, M., 776–783
Nerup, John, 275–277
Newmeyer, Holly W., 145–148
Nielsen, David A., 299–306
Nineham, Lynn J., 70–74
Nissley, S. Peter, 656–658
Noel, Jack, 48–54‡, 939–943
Nonaka, Kyohei, 749–753
Nosadini, Romano, 346–355

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

Notkins, Abner Louis, 292–298, 496–499
Nwabuebo, I.E., 1119–1122

O

O'Connell, Keith, 648–652, 841–845
Oegema, Theodore R., 418–425
Oie, Herbert K., 521–531
Olefsky, Jerrold M., 410–417, 929–936, 1016–1022
Oliver, John R., 1–8‡
Onodera, Takashi, 496–499
Orci, Lelio, 538–565, 659–662, 694–700, 883–889
Östman, Jan, 911–916, 1044–1050
Owen, Ann, 170–177
Owen, O.E., 242–248
Owerbach, David, 275–277

P

Pace, Caroline S., 653–655
Pacini, Giovanni, 432–441
Paik, Sang-Gi, 724–729, 808–815
Pallotta, J.A., 132–135, 851–855
Palmer, Jerry P., 149–153, 489–495
Panepinto, L.M., 30–36*
Panganamala, R.V., 947–951
Park, Min S., 105–106
Parker, John, 821–825
Parker, K. Michael, 70–78†
Parr, Earl L., 1–8‡
Parsons, John A., 506–511
Parthasarathy, Narayanan, 738–741
Passa, Philippe, 1061–1067
Patel, Harish M., 506–511
Patel, Yogesh C., 160–164, 694–700, 897–902, 939–943
Patterson, Kristine Y., 212–216
Peckar, C.O., 226–231
Pedersen, Oluf, 706–715
Perara, Eve, 985–990
Perelman, Robert, 89–94*
Permutt, M. Alan, 624–629, 648–652, 841–845
Perrelet, Alain, 694–700
Petersen, Jeffrey, 618–623
Petersen, Karl-Georg, 615–617
Peterson, Charles M., 15–21†
Petersson, B., 238–241
Pfeifer, Michael A., 154–159, 333–338, 339–345, 802–807
Phillips, Lawrence S., 97–104
Phillips, R.W., 30–36*
Picon, Luc, 75–79, 165–169
Pietro, Tiziana, 1029–1032
Pintauro, S.J., 37–46†
Pi-Sunyer, Xavier, 856–861
Pittman, William B., 122–125
Podgor, Marvin J., 874–882
Polansky, Marilyn M., 212–216
Polonsky, K., 474–477
Porte, Daniel, Jr., 65–70*, 154–159, 333–338, 339–345, 802–807
Portha, Bernard, 75–79, 165–169
Poussier, Philippe, 278–281
Powell, Henry C., 65–70*
Pozzilli, P., 7–11
Preissler, Margaret, 674–682
Price, Robert, 71–81*
Pritchard, K.A., Jr., 947–951
Prowse, S.J., 30–37‡
Pyke, D.A., 19–21

Q

Quigley, Carol, 160–164

R

Rabinovitch, Alexander, 48–54‡, 160–164, 939–943
Rabkin, Ralph, 618–623
Raess, Beat U., 976–984
Ramamurthy, Nangavaram, 426–431
Rand, L.I., 1056–1060
Randoux, Alain, 371–374
Raoux, Nadine, 1061–1067
Rawlings, Sharon S., 70–78†
Rayfield, Elliot, 45–53*, 292–298
Raymond, Thomas L., 593–599
Reach, G., 40–45
Rearner, Donald C., 212–216
Reaven, Eve P., 670–673
Reaven, Gerald, 307–312, 382–387, 396–400, 670–673
Recant, Lillian, 521–531
Rechler, Matthew M., 656–658
Reenan, A., 339–345
Regan, Timothy J., 54–64*
Reichard, G.A., Jr., 242–248
Reitnauer, Pamela J., 532–537
Rendell, Marc, 449–453
Renold, Albert E., 178–181
Rhie, F.H., 1056–1060
Ribes, G., 484–487
Rich, S.S., 991–993
Riley, William J., 45–53*, 313–318, 1051–1055
Riser, M.E., 1035–1040
Rizza, R.A., 579–584, 663–669
Robert, J.-J., 203–211
Roginski, Edward E., 212–216
Rohrbach, David H., 185–188
Roseman, Jeffrey M., 122–125, 532–537
Rosenbloom, Arlan L., 385–387
Rosenbloom, Edith K., 385–387
Rosenfeld, Ron G., 375–381
Rosenthal, Alan S., 716–723
Rosenthal, Mark, 307–312, 396–400, 670–673
Rosselin, Gabriel, 75–79
Rossini, Aldo A., 7–13*, 45–53*, 816–820
Rousseau-Migneron, Suzanne, 406–409
Rowe, J.W., 132–135, 851–855
Rowley, R.F., 107–109
Rozovski, Jaime, 500–505
Rubenstein, A., 474–477
Rubinstein, Pablo, 292–298
Rubinstein, P., 1088–1091
Ruderman, Neil B., 500–505
Russell, Thomas, 160–164, 939–943
Ryan, Janice, 890–896
Ryan, Una S., 17–22‡, 48–54‡
Ryman, Brenda E., 506–511
Rynasiewicz, John J., 92–107‡

S

Saccomanno, Franco, 367–370
Sacks, Jerome M., 136–144
Sai, P., 40–45
Sakurami, Takehiko, 105–106
Salans, Lester B., 589–592
Saltmarch, Miriam, 29–36†
Sandler, Stellan, 78–82‡, 238–241
Sandor, T., 1056–1060
Santeusanio, Fausto, 641–647
Santiago, Julio V., 80–85
Satchell, P.M., 789–794
Saunders, Derek T., 1068–1076
Savage, Peter J., 952–956
Scarlett, J.A., 929–936, 1016–1022
Schade, David S., 36–39, 470–473
Scharp, David W., 63–68‡, 761–770
Schedl, H.P., 401–405
Schenck, Henning v., 771–775
Schickler, Renee, 834–837
Schiffrin, A., 255–264
Schleicher, E.D., 1123–1127
Schlüter, Klaus Joachim, 615–617
Schmidt, Robert E., 761–770
Schneir, Michael, 426–431
Schnider, Stuart L., 47–51†
Scholz, Thomas D., 97–104
Schulz, Bernd, 307–312
Schutz, Y., 1023–1028
Schwizer, R.W., 830–833
Seino, Yutaka, 119–121
Sener, Abdullah, 90–93
Service, F.J., 579–584
Shah, Jayendra H., 834–837
Shah, S.T., 1056–1060
Shariff, Joshua E., 459–462
Shibukawa, Renee L., 69–74‡
Shienvold, Frances Litz, 17–22‡, 939–943
Shin, Seung-Il, 724–729, 808–815
Shoelson, S., 474–477
Siciliano, M.J., 1035–1040
Sidenius, Per, 356–363, 689–693
Siegel, Eberhard, 265–269
Silvers, Willys K., 60–62‡, 84–89‡
Silverstein, Janet H., 1051–1055
Sima, Anders A.F., 65–70*, 784–788

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180

Simeonovic, C.J., 30–37‡
Simonds, John F., 70–78†
Simonson, Donald, 795–801
Simpson, Ian A., 589–592
Siperstein, Marvin D., 388–394
Siu, K.P., 1002–1005
Skutches, C.L., 242–248
Slavin, Bernard, 821–825
Slavin, Shimon, 63–68‡
Smith, Mark A., 189–193
Smith, Ulf, 771–775
Sodoyez, J.C., 60–69
Sodoyez-Goffaux, F., 60–69
Soeldner, J.S., 463–466, 1056–1060
Soler, Norman G., 609–614
Sonne, Ole, 634–640
Sonnenberg, G.E., 600–602
Spangler, R., 30–36*
Spencer, K.M., 862–866
Spiess, Yuriko, 189–193
Spiro, Robert G., 738–741
Squifflet, Jean-Paul, 92–107‡
Steele, E.J., 30–37‡
Stefan, Yolande, 694–700
Steinberg, Daniel, 283–291
Steinbrecher, Uris P., 1029–1032
Steiner, Donald F., 299–306
Steiner, Kurt E., 964–972
Stentz, Frankie B., 1128–1131
Stern, Judy S., 89–94*
Stevens, Bernard, 834–837
Stevens, Victor J., 15–21†
Stevenson, Ralph W., 506–511
Suhrer, James H., Jr., 326–332
Sundermann, S., 600–602
Surma, Maria L., 1084–1087
Susa, John B., 89–94*
Sussman, Karl E., 467–469
Sutherland, David E.R., 92–107‡, 112–116‡
Swanson, J., 991–993
Swedine, Sally, 339–345
Swenne, Ingemar, 238–241, 754–760

T

Tamagawa, T., 776–783
Taminato, Tomohiko, 119–121
Tancrède, Gilles, 406–409
Tarui, Seiichiro, 749–753
Tarvin, John T., 653–655
Taylor, Clive R., 23–28‡
Terasaki, Paul I., 105–106
Thamm, Peter, 1068–1076
Theorn, Shirley W., 232–237
Thibert, Pierre, 784–788
Thiebaud, Daniel, 957–963, 1023–1028
Tice, David, 339–345
Tiengo, Antonio, 346–355
Ting, A., 226–231
Toffolo, Gianna, 346–355
Tonino, R., 851–855
Toniolo, Antonio, 496–499
Tosco, Clara, 821–825
Toskes, Phillip P., 1051–1055
Toyoshima, Hiroyuki, 749–753
Trapp, V.E., 242–248
Triadou, Nicole, 75–79
Trimble, Elisabeth R., 178–181
Tung, A.K., 1002–1005
Turner, R.C., 22–26, 226–231, 319–325
Tur-Sinai, A., 1077–1083
Turtle, J.R., 701–705, 789–794
Tutwiler, Gene, 12–18

U

Ueno, Yukio, 105–106
Unger, Roger H., 479–483, 512–515, 694–700

V

Vale, Wylie, 189–193
Valette, G., 484–487
Valette, J.F., 484–487
Valverde, Isabel, 170–177
Vanhegan, R.I., 319–325
Varghese, Matthew, 52–56†
Varma, Shambhu D., 82–88*
Venkatachalam, M.A., 71–81*
Vergani, D., 973–975
Verhulst, Dirk, 170–177
Vetriglia, L., 7–11
Viberti, G.C., 973–975
Vlachokosta, Fredericka V., 46–52
Viodavsky, I., 1077–1083
Vogt, B.W., 1123–1127
Voyles, Nancy R., 521–531

W

Wagener, Diane K., 136–144
Wahl, Patricia W., 126–131
Wahren, J., 1044–1050
Walker, M.E., 1088–1091
Wallberg-Henriksson, H., 1044–1050
Waltman, Stephen R., 80–85
Wang, Chih-Chen, 1068–1076
Ward, G.M., 22–26
Warhol, Richard M., 470–473
Weinberg, Clarice R., 126–131, 802–807
Weiss, Harold, 874–882
Wentworth, S., 463–466
Weringer, Elora J., 7–14*
Westland, R.E., 579–584
Westmoreland, N., 30–36*
Wiedmeyer, Hsiao-Mei, 70–78†
Wieland, O.H., 1123–1127
White, Neil H., 80–85
Widstrom, Anders, 307–312, 396–400
Wiley, Millie H., 388–394
Wilkins, Samuel D., 521–531
Williams, John A., 674–682
Williams, Philip E., 326–332, 917–922, 964–972
Williams, R. Michael, 7–13*
Williamson, Joseph R., 54–64*
Wilson, H.D., 401–405
Witt, Mary E., 292–298, 1088–1091
Witztum, Joseph L., 283–291, 1029–1032
Wolf, Eva, 70–74, 862–866
Wolfe, R.R., 203–211
Wollheim, Claes B., 265–269
Wong, Inés, 897–902
Woo, Rosy, 856–861
Wright, Diana, 670–673
Wright, Reba K., 1128–1131

Y

Yalow, Rosalyn S., 182–184
Yamada, Kentaro, 749–753
Yasunami, Yohichi, 109–111‡
Yip, Cecil C., 659–662
Yoon, Ji-Won, 496–499
Young, J.B., 132–135
Young, V.R., 203–211
Yu, Kin Tak, 846–850
Yue, D.K., 701–705, 789–794

Z

Zeidler, Adina, 821–825
Zhao, X.H., 203–211

DIABETES: VOLUME 31 (1982) PAGE NUMBERS BY ISSUE

January, 1–96
February, 97–188
March, 189–282
April, 283–374
Supplement 1, 1–102
May, 375–478
June, 479–572
Supplement 3, 1–82
July, 573–662
August, 663–742
Supplement 4, 1–120
September, 743–840
October, 841–938
November, 939–1033
Supplement 5, 1–81
December, 1035–1180